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The somatic isoform of angiotensin-converting enzyme (sACE), a key regulator of blood 
pressure and electrolyte fluid homeostasis, primarily cleaves the hypertension-associated 
angiotensin-I (AngI) and bradykinin peptides, as well as a number of other physiologically 
relevant peptides in vitro.  sACE consists of two homologous and catalytically active N- and 
C- domains which display marked differences in substrate specificities and chloride 
activation.  To investigate these potential mechanisms, a series of single amino acid 
substitution mutants (based on analysis of aligned C- and N-domain 3D structures) were 
generated in a soluble, minimally glycosylated C-domain construct.  Evaluation of these 
constructs was done using AngI and the short synthetic substrates hippuryl-L-histidyl-L-
leucine (HHL) and Z-phenylalanyl-L-histidyl-L-leucine (Z-FHL) under differing chloride 
concentrations. An isothermal titration calorimetry-based assay was developed to 
determine the effect of chloride concentration on enzyme thermodynamic and kinetic 
parameters.  Chloride binding in the chloride 1 pocket of tACE was found to affect 
positioning of K511 and potentially alter the conformation of the active site.   This would 
alter C-terminal substrate interactions, which were suggested to affect chloride 2 pocket ion 
affinity by coordinating Y520 and affect peptide bond rotation and hence substrate 
interactions.  The analysis of the chloride 2 pocket R522Q and R522K mutations revealed a 
key R522-Y523 Pi-cation interaction that is stabilized via chloride coordination of R522.  
Substrate interactions in the S2 sub-site were shown to affect positioning of this complex as 
well as chloride affinity in the chloride 2 pocket.  The E403-K118 salt bridge in tACE was 
shown to stabilize the hinge-bending region and reduce chloride affinity by constraining the 
chloride 2 pocket, an interaction which is destabilized via substrate interactions within the 
S2 pocket which results in tighter chloride binding. This work showed that substrate 
composition to the C-terminal side of the scissile bond, as well as interactions of larger 
substrates in the S2 sub-site, moderate chloride affinity in the chloride 2 pocket of the ACE 
C-domain, providing a rationale for the substrate selective nature of chloride dependence in 
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°C     degree Celsius  
ΔHapp  apparent molar enthalpy 
ΔHint  intrinsic molar enthalpy change of the reaction 
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ΔG  Gibbs free energy 
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ΔTΔS  change in temperature dependent entropy change on addition of chloride 
µcal  micro-calorie 
µl     micro-litre  
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Å   angstrom 
ACE    angiotensin-converting enzyme 
ACE2   angiotensin-converting enzyme 2 
ACN    acetonitrile 
AcSDKP   N-acetyl-Ser-Asp-Lys-Pro 
Ang I    angiotensin I 
Ang II  angiotensin II 
Ang III   angiotensin III 
Ang(1-7)  angiotensin(1-7) 
AT1    angiotensin II type I receptor 
AT2    angiotensin II type II receptor 
AT4    angiotensin type IV receptor 
B1    kinin type I receptor 
BK    bradykinin 
Bp  base-pair 
CHO-K1  Chinese hamster ovary K1 
CONH2  amidated C-termini 
CPA    carboxypeptidase A 
CPD    carboxypeptidase D 
dH2O    de-ionised H2O 
DMEM  Dulbecco’s modified eagle’s medium 
DMSO   dimethyl sulphoxide 
DNA     deoxyribonucleic acid 
E. coli    Escherichia coli 
EDTA    ethylenediaminetetraacetic acid 
FAPGG  furylacryloyl-Phe-Gly-Gly  
FCS    fetal calf serum 
FRET   fluorescence resonance energy transfer 
GnRH    gonadotropin-releasing hormone 
HEPES   N-2-hydroxyethylpiperazine-N’-2-ethanesulphonic Acid 
HHL   hippuryl-His-Leu 
HL    His-L-Leu-L 
HPLC    high-performance liquid chromatography 












KKS   kallikrein-kinin system 
kDa     kilo-dalton  
Ki      inhibition constant 
kcat    catalytic constant 
Kd,app   apparent dissociation constant for chloride binding 
Kd  dissociation constant for inhibitor binding 
Km      Michaelis constant 
LB     Luria-Bertani 
lis-W  lisinopril derivative with a P2’ Trp substituent 
mg   milli-gram  
min    minute  
ml     milli-litre  
mM   milli-molar 
n  stoichiometry of binding 
nH  proton transfer stoichiometry 
nM    nano-molar 
PBS    phosphate-buffered saline 
PCR    polymerase chain reaction 
PMSF    phenylmethylsulphonyl fluoride 
PDB    protein data bank (http://www.rcsb.org/pdb) 
RAS    renin-angiotensin system 
RE    restriction endonuclease site 
RXPA380  C-domain-specific phosphinic inhibitor 
RXP407  N-domain-specific phosphinic inhibitor 
FR1   the BamHI-Eco47III fragment of the tACEg13sol cDNA 
FR2   the Eco47III-SphI fragment of the tACEg13sol cDNA 
FR3   the SphI-NheI fragment of the tACEg13sol cDNA 
FR4   the NheI-NotI fragment of the tACEg13sol cDNA 
FR1,2,3 the BamHI-NheI fragment of the tACEg13sol cDNA 
sACE    somatic angiotensin-converting enzyme 
SAmin  specific activity at 0mM NaCl 
SAmax  specific activity at NaCl saturation 
SDS-PAGE  sodium dodecylsulphate polyacrylamide gel electrophoresis 
sec     second 
Si   initial substrate concentration prior to addition of enzyme 
S0   initial substrate concentration after addition of enzyme 
TΔS  temperature associated entropy 
tACE    testis angiotensin-converting enzyme 
TAPSO  3-[N-Tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid 
TBE   Tris-borate/EDTA buffer 
TES N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid 
TFA    trifluoroacetic acid 
TM    transmembrane region 
Tris  2-Amino-2-hydroxymethyl-propane-1,3-diol 
Vmax      maximum velocity 
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1.1  Biochemistry of ACE 
Angiotensin I-converting enzyme (ACE, EC 3.4.15.1) has been categorized as a member of 
the M2 gluzincin family of zinc metallopeptidases and functions primarily as a dipeptidyl 
carboxypeptidase, catalyzing the hydrolysis of carboxy-terminal dipeptides from a wide 
range of functional peptides (reviewed by Ehlers & Riordan, 1989; Eriksson et al., 2002; 
Turner & Hooper, 2002). 
1.1.1  Physical Properties 
ACE consists of two isoforms, somatic ACE (sACE) and testis ACE (tACE) (Figure 1.1) (Ehlers 
et al., 1989; Soubrier et al., 1988).  Somatic ACE is encoded by a single 21 kilobase gene on 
chromosome 17q23 consisting of 26 exons, with exon 13 spliced out, that is translated into 
a 1306 residue protein of 140-170 kDa in weight (Howard et al., 1990; Hubert et al., 1991; 
Wei et al., 1991a). Contained within this primary structure starting at the N-terminus is a 
1230-residue ectodomain; a 36-residue juxtamembrane region, a 17-residue hydrophobic 
transmembrane anchoring region and a C-terminal 30-residue long cytoplasmic region (Wei 
et al., 1991a; Soubrier et al., 1988).  The large ectodomain contains two domains of high 
homology (60% over two 357 residues stretches)(see Figure 1.2), the N-domain and the C-
domain, each of which contains the conserved HEXXH zinc-binding-motif indicative of the 
active sites of many Zn-metalloproteases, and are presumed to have come about as the 
result of a gene duplication event (Soubrier et al., 1988).  Somatic ACE is expressed in a wide 
variety of tissues, including vascular endothelium, renal proximal tubule epithelium, 
intestinal epithelium, macrophages and brain (Takada et al., 1984; Chai et al., 1987; Sibony 
et al., 1993; McKinley et al., 2003).   
tACE, the smaller isoform of ACE that is only expressed in the adult testis, arises from 
transcription of the same gene, but more specifically from a tissue-specific promoter within 
intron 12, with exons 13 through 26 transcribed (Hubert et al., 1991).  The mature tACE is a 
701-residue protein that is identical to the C-terminal domain of sACE, except for a unique 
leader peptide distinct from that used by sACE and a 36-residue serine and threonine rich N-
terminal region (Ehlers et al., 1989; Ehlers et al., 1992).  This 36-residue N-terminus region is 
heavily O-glycosylated and, in studies where this region has been removed, has been shown 

















Figure 1.1 Diagrammatic representation of ACE gene organisation and products. The ACE gene 
is composed of 26 exons, with two separate promoters (somatic & germinal) producing two 
isoforms: sACE contains an N-domain (red) and C-domain (dark blue), and tACE contains just the 
C-domain region as well the 36-amino acid region transcribed by exon 13 (light green) which is 
spliced out in sACE expression.  Both isoforms are anchored to the cell membrane by a 

















Figure 1.2 Protein sequence alignment of sACE N- and C-domains, and tACE.  (adapted from 
Acharya et al, 2003; Natesh et al, 2003; Corradi et al, 2006).   Residue numbering is according to 
that reported by Soubrier et al., (1988) and Ehlers et al., (1989).  Helices (α or 310) and strands 
are numbered sequentially, with α-helices highlighted in yellow, Β strands highlighted in blue and 
310 helices shown in red letters. The zinc-binding ligands and HEMGH motif are boxed in purple, 
chloride 1 pocket binding residues are boxed in black and chloride 2 pocket binding residues are 














The ectodomains of tACE and sACE are released from the cell surface (Ehlers et al., 1991; 
Wei et al., 1991a) by an as yet unidentified secretase that cleaves the Arg-Ser bond (Arg620 
– tACE and Arg1203 –sACE) in the juxtamembrane region  (Ehlers et al., 1996; Woodman et 
al., 2000).     
Human sACE contains 17 potential N-glycosylation sites, with 7 located in the C-domain 
(tACE) and 10 within the N-domain (Yu et al., 1997; O’Neill et al., 2008). Of the seven 
potential sites in tACE, six were found to be glycosylated, with 3 always glycosylated and 3 
partially glycosylated (Yu et al., 1997), with four of these sites clustered towards the N-
terminal region of tACE, and the unglycosylated site located close to the transmembrane 
region.  The N-domain was found to have a higher degree of glycosylation with 8 of the 10 
sites being found to be glycosylated (Yu et al., 1997; Anthony et al., 2010).  Glycosylation has 
been shown to be important for folding, localization and stability of glycoproteins 
(Hammond et al., 1994; Helenius & Aebi, 2004), which has been shown to be relevant to 
ACE as expression in bacteria, which lack eukaryote glycosylation machinery, or expression 
in the presence of the glycosylation inhibitor tunicamycin result in inactive protein 
(Sadhukan & Sen, 1996). Further, it has been shown that the N-domain is far more thermally 
stable than the C-domain (tACE) (Voronov et al., 2002; O’Neill et al., 2008), which can be 
attributed to their glycosylation patterns. 
The variation between the domains is not limited to glycosylation patterns.  Given that the 
C- and N- domains of ACE are the product of a gene duplication event, their 60% shared 
sequence identity (Figure 1.2) is expected, however they differ in a number of key ways.  
Firstly, they have different substrate specificities (Wei et al., 1991b).  Furthermore, the C-
domain has been found to have a higher chloride requirement for hydrolysis than the N-
domain, a trend which is dependent on the nature of substrate (Wei et al., 1991b; Wei et al., 
1992).  
1.1.2  Domain Structure  
The 3-dimensional structure of tACE has been determined in complex with a number of 
potent ACE inhibitors, including lisinopril (PDB code 1o36; Figure 1.3A) (Natesh et al., 2003), 
captopril and enalaprilat (Natesh et al., 2004), and the highly C-domain selective RXPA380 















yielded the data for the structural determination differed slightly from the wild-type form of 
tACE in that the unique 36 amino acids that constituted its N-terminus had been removed, 
essentially rendering it identical to the C-domain of sACE (Natesh et al., 2003). The overall 
shape that tACE (residues 37-625) assumes is ellipsoid, and can be divided into two 
subdomains with a central channel that descends for approximately 30Å into the molecule 
(Natesh et al., 2003).  The structure of tACE assumes a largely helical conformation, with 
helices α13, α14, α15, α17 and strand β4 forming the boundaries of the aforementioned 
central groove (Natesh et al., 2003).  There are three N-terminal α-helices (α1, α2, α3), all 
containing several charged residues, that cover this cavity containing the active site thereby 
accounting for tACE’s inability to hydrolyse large, folded polypeptides (Figure 1.3B) (Natesh 
et al., 2003). The N- and C-termini of the tACE ectodomain are defined by the Asp40 residue 
(α1) and the Gly615 residue, respectively, evidenced in the structure but further 
 
Figure 1.3 Three-dimensional N- and C- domain structures.  A) Aligned structures of tACE-
Lisinopril (PDB:1o86) in blue and N-domain-Lisinopril (PDB:2c6n) in red. Lisinopril is shown bound 
in the active site (yellow sticks), with the active site zinc (grey sphere) and chloride ions (green 
spheres) within either chloride 1 or chloride 2 pockets indicated. Chloride ion in Cl1 pocket not 
present in the N-domain structure.  Image was created using PyMOL 0.99 (DeLano Scientific, Palo 
Alto, CA, U.S.A).  B) Molecular surface representation (negative and positive potentials in red and 
blue, respectively) of tACE-Lisinopril (PDB:1o86) showing the active-site groove (taken from 
Natesh et al, 2003).  The molecular surface has been sliced for clarity and the buried lisinopril 














substantiated by mutagenic studies (Chubb et al., 2002; Natesh et al., 2003).   The structure 
also contains two internally bound chloride ions, each within a distinct binding pocket, 
which will be discussed later with regard to the main focus of this study (Natesh et al., 
2003). 
The crystal structure for the N-domain has been reported in complex with lisinopril (PDB 
code 2c6n; Figure 1.3A) (Corradi et al., 2006) and the highly N-domain selective inhibitor 
RXP407 (PDB code 3nxq) (Anthony et al., 2010).  The structures display a high degree of 
similarity in the overall topology and location of the zinc binding motif in the active site 
(Corradi et al., 2006).  A major point of variation when compared to the C-domain (tACE) is 
that only one chloride ion is bound to the N-domain to the two of tACE, a feature that will 
be discussed further. 
1.1.3  Active Site and catalytic mechanism 
The active site for both domains is contained within the large central groove, with the 
signature HEXXH zinc-binding motif residing on the α15 helix (Natesh et al., 2003; Corradi et 
al., 2006).  Access to this active site is severely limited, with a small pore in the N-terminal 
chamber or an occluded slot in the C-terminal chamber providing the only theoretical access 
and suggests that a degree of flexibility in the domain movements is required for 
admittance of substrate (Watermeyer et al., 2006; Corradi et al., 2006). H383, E411 and 
H387 in the C-domain (tACE numbering) and H361, E389 and H365 in N-domain, all part of 
the signature HEXXH motif for each domain, are seen to coordinate the highly ordered 
catalytic zinc ion (Natesh et al., 2003; Corradi et al., 2006).  The catalytic mechanism has 
been suggested based on comparison with work done on the structurally analogous zinc-
metalloprotease, thermolysin, and is proposed to occur via a general-base mechanism 
whereby a nucleophilic water molecule or hydroxide ion attacks the carbonyl carbon of the 
scissile bond (Figure 1.4) (Matthews, 1988; Sturrock et al., 2004). The nucleophilicity of the 
water molecule may be enhanced by polarization between the positive zinc and the 
negative carboxylate of E143 (which corresponds to E384 in tACE and E362 in N-domain), 
caused by substrate interactions displacing the zinc-bound watet al.,er toward E143, and 
may account for the different catalytic efficiencies for different substrates (Sturrock et al., 
2004).  The nucleophilic attack results in tetrahedral penta-co-ordinated carbonyl carbon 















confirmed the critical nature of the two zinc coordinating His residues (383 & 387 in tACE; 
361 & 365 in N-domain) and the Glu (E384 in tACE; 262 in N-domain), where substitution 
renders the domains inactive (Wei et al., 1991b; Wei et al., 1992)  Further mutagenic work 
by Fernandez et al (2001) has implicated H513 (tACE) as being involved in stabilizing the 
transition-state intermediate, supported by the fact that it’s identity is conserved in the N-
domain.  Additionally, K511 and Y520 in tACE (K489 and Y498 in N-domain) have been 
suggested to also play a role in stabilizing the transition-state intermediate by coordinating 
the C-terminal carboxylate of the substrate (Natesh et al., 2003). 
Lisinopril interacts with the active sites of both domains in an extended, highly-ordered, 
conformation that is shared when the two lisinopril-bound structures are superimposed, as 
well as retaining a number of conserved binding residues conformations (Natesh et al., 
2003; Corradi et al., 2006).  To describe interactions of substrates and inhibitors with the 
active sites of the ACE domains, the Schechter & Berger nomenclature model (Schechter 
and Berger, 1967) is routinely adopted.  Residues on the N-terminal side of the scissile bond 
(or zinc binding group for inhibitors) are designated P1-P2-P3-...-Pn, continuing outwards 
towards the N-terminus, while residues on the C-terminal side are assigned P1’-P2’-P3’-...-Pn’.  
The sidechains for each of the residues of the peptide/inhibitor interact with a series of sub-
site pockets lining the active site which are designated with the corresponding Sn-...-S2-S1-
S1’-S2’-...-Sn nomenclature.  Using a similar nomenclature, both ACE active sites can be 
described as having four sub-sites, S2, S1, S1’ and S2’, where the C-terminal dipeptide that is 
cleaved from the substrate (P1’ and P2’) interact with the S1’ and S2’ sub-pockets.   
 















1.1.4  Chloride binding sites 
Two chloride ions are found buried in the structure of tACE, separated by a distance of 
20.3Å (Natesh et al., 2003). The first chloride (Cl1) 20.7Å away from the zinc, is bound by 
four ligands, namely Arg186, Trp485, Arg489 and water, and is encapsulated by a 
hydrophobic shell of four tryptophans (Natesh et al., 2003).  The N-domain crystal structures 
show no chloride bound in this pocket, with the only difference in residue composition in 
the pocket being H164 which corresponds to R186 in tACE (Corradi et al., 2006).  The second 
chloride ion (Cl2) is located much closer to the zinc at 10.4Å and is coordinated by Arg522, 
Y224 (R500 and Y202 in N-domain) and a water molecule (Natesh et al., 2003).  Mutagenic 
work has highlighted Arg1098 (R522 in C-domain, R500 in N-domain) as having a crucial role 
in the chloride dependent activity of the C-domain (tACE) of ACE (Liu et al., 2001), which will 
be discussed further in section 1.3.  
1.2  Physiological importance of ACE 
1.2.1  Renin-Angiotensin and kallikrein-kinin systems 
The Renin-Angiotensin System (RAS) (Figure 1.5) is a complex enzymatic pathway that plays 
a critical role in blood pressure regulation and generates a number of bio-active peptides 
which control fluid and electrolyte homeostasis, hormone secretion as well as behavioural 
and cognitive responses (Inagami, 1994; Savaskan, 2005).  ACE has long been established as 
having an important role in the RAS, with ACE inhibitors being a major component of the 
medical treatment of hypertension.  Apart from ACE, the other key enzyme in controlling 
the RAS is renin, an enzyme produced from an inactive precursor in the liver in response to 
stress, decreased sodium levels or effective plasma volumes (Goldblatt et al., 1934; 
Houssay. and Fasciolo, 1937; Page and Helmer, 1940).  Active renin circulates in the blood 
where it releases the N-terminal decapeptide angiotensin I (Ang1) from the glycoprotein 
angiotensinogen, which is also produced in the liver (Inagama, 1994).   ACE primarily cleaves 
AngI to the potent vasoconstricting octapeptide angiotensin II (AngII) by removal of the C-
terminal His-Leu (Skeggs et al., 1954; Skeggs et al., 1956).  AngII mediates its effects via 
either the angiotensin II type I (AT1) receptor or the angiotensin II type II (AT2) receptor 
which exhibit opposing outcomes (Gasparo et al., 1995). Stimulation of the AT1 receptor 















sodium retention and water readsorption, sympathetic activation and cell growth 
proliferation (Timmermans et al., 1992; Timmermans et al., 1993).  Conversely, the effects 
of AT2 stimulation result in vasodilation, growth and proliferation inhibition, differentiation 
and apoptosis, although this receptor is only highly expressed during foetal development 
and is vastly reduced after birth (Horiuchi, 1996; Csikós et al., 1998; Lazard et al., 1994; 
Shanmugam & Sandberg, 1996).  
Whilst the central angiotensinogen-AngI-AngII pathway is core to the RAS, a number of 
other bioactive angiotensin peptide forms exist, which contribute to the complexity (Figure 
1.5).  The ACE homologue, ACE2, cleaves both AngI and AngII into angiotensin(1-9) and 
angiotensin(1-7) respectively, where ACE (as well as neural endopeptidase) also converts 
the inactive angiotensin(1-9) peptide into the vasodilatory angiotensin(1-7) although 
 
Figure 1.5 Role of ACE in the Renin-Angiotensin System. (adapted from Acharya et al., 2003; 
Fyhrquist and Saijonmaa, 2008). Solid lines indicate conversion of a peptide to a product, while 
broken arrows indicate action of a hormone on a receptor. Enzymes involved: Angiotensin 
converting enzyme (ACE); Angiotensin converting enzyme 2 (ACE2);Neutral endopeptidase (NEP); 














cleavage of AngII to Ang(1-9) is the predominant route (Donoghue et al., 2000; Turner et al., 
2002).  Angiotensin (1-7) mediates its effects via the Mas G-protein coupled receptor 
(Santos et al., 2003), which is interestingly increased in the context of an activated RAS 
(Nakamoto et al., 1995; Iyer et al., 2000; Nakamura et al., 2003).  Angiotensin III (AngII) is 
generated by the action of aminopeptidase A on AngII, and stimulates the AT1 and AT2 
receptors in a similar manner to AngII (Wright and Harding, 1997; Ardaillou and Chansel, 
1997). Of importance is the aminopetidase M-mediated conversion of AngIII to angiotensin 
IV, which binds to the AT4 receptor (Swanson et al., 1992; Albiston et al., 2001) and is linked 
to renal and cerebral blood flow, neuronal development and memory formation & retention 
(Wright and Harding, 1997).  The critical role of the RAS is demonstrated by transgenic mice 
models, where knockout of angiotensinogen (Kim et al., 1995), renin (Yanai et al., 2000), 
ACE (Krege et al., 1995; Esther et al., 1996) and AT1 receptor (Ito et al., 1995; Chen et al., 
1997; Tsuchida et al., 1998; Oliverio et al., 1998) all resulted in significant reductions in 
blood pressure when compared to wildtype controls. 
Additionally, there is significant interplay between the RAS and the kallikrein-kinin system 
(KKS).  The vasodilatory peptide bradykinin (BK) is produced by the action of plasma 
kallikrein on the high molecular weight glycoprotein precursor kininogen (Bhoola et al., 
1992).  Tissue kallikrein can also cleave this kininogen, as well as a second low molecular 
weight kininogen, into kallidin.  The kinin type II (B2) receptor is the primary target of these 
kinin peptides, which results in vasodilation, although the kinin type I (B1) receptor (which is 
upregulated during tissue damage) can also be triggered by products of kinin-
carboxypeptidase activity (des-Arg9-bradykinin and des-Arg10-kallidin) (Regoli et al., 1989).  
ACE has been shown to inactivate the vasodilatory BK into inactive products (Erdos & Yang, 
1967; Yang et al., 1970; Yang et al., 1971) via sequential C-terminal didpeptidyl degradation 
at the Pro7-Phe8 and Phe5-Ser6 scissile bonds (Baudin, 2002).  Further interaction between 
the systems is seen where kallikreins have been shown to activate pro-renin (Sealey et al., 
1979) and can generate AngII directly from angiotensinogen (Yamaguchi et al., 1991; 
Sasaguri et al., 1995).  The latter ability to generate non-renin-mediated AngII may be quite 
important as recent work by Guimaraes et al (2011) show that AngII interacts with ACE to 














1.2.2  Non-BP regulating roles for ACE hydrolysis activity 
A study by Shen et al (2007) generated transgenic mice that overexpressed ACE in 
macrophages by switching control of the ACE locus to the macrophage specific c-fms 
promoter.  Challenge of these mice using an aggressive mouse melanoma cell line showed 
that they were remarkably resistant to tumour growth and resulted in increased interleukin-
12 and nitric oxide.  The same transgenic mice were challenged with Listeria and methicillin-
resistant Staphylococcus aureus and shown to have 50-fold lower levels of bacterial load 
with similar increases in nitric oxide (Okwan-Duodu et al., 2010).  This enhanced 
inflammatory response with ACE overexpression is attributed to ACE being involved in 
processing the C-terminus of antigenic peptides for presentation by MHC Class I molecules 
thus enhancing the efficiency of antigen-specific CD8+ T cell priming (Shen et al., 2008). 
ACE was first linked to Alzheimer’s disease using genetic studies where the I allele of and 
insertion (I)/deletion(D) polymorphism in intron 16 of ACE, which leads to reduced ACE 
plasma levels, was associated with an increased risk for disease progression, whereas the D 
allele that produced increased ACE plasma levels was associated with protection (Rigat et 
al., 1990; Kehoe et al., 1999; Elkin et al., 2004; Lehmann et al., 2005).  ACE has been shown 
to degrade amyloid β peptides, which are responsible for plaque formation, both in vitro 
(Hemming & Selkoe, 2005; Oba et al., 2005) and in vivo where it has been suggested that 
ACE conversion of amyloid-β peptide 1-42 to amyloid-β peptide 1-40 preventing plaque 
formation (Zou et al., 2007).  ACE inhibitors have been shown to enhance cognitive function 
in mouse models (Yamada et al., 2010) suggesting ACE hydrolysis generates plaque forming 
products of amyloid-β peptide; however, there remains contention as to the exact cleavage 
sites and domain contributions (Hu et al., 2001; Oba et al., 2005; Zou et al., 2007).  Further 
complicating the picture is the fact that angiotensin receptor blockers (ARB’s) also prevent 
amyloid-β associated cognitive impairment (Takeda et al., 2009), which suggests that the 
brain RAS, of which ACE is a key part, is also playing a role.  The exact role of ACE in this 
remains contentious and is under active investigation in our laboratory. 
N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is a widely expressed peptide that is a natural 
inhibitor of pluripotent hematopoietic stem cell proliferation (Lenfant et al., 1989; Bonnet et 
al., 1993), elicits anti-fibrotic effects by suppressing the differentiation of human cardiac 














to promotion of angiogenesis in vivo and in vitro (Wang et al., 2004).  Critically, AcSDKP is 
hydrolysed almost exclusively by ACE (Hanesworth et al., 1993), with ACE inhibition in vivo 
showing reduced levels of peptide (Azizi et al., 1996; Azizi et al., 1997). This highlights the 
critical role ACE plays in modulating levels of this critical peptide.   
Testis ACE (tACE), an isoform of ACE which is expressed exclusively in the germinal sperm 
cells has been shown to be critical in fertility.  Male mice with tACE knocked out produce 
normal numbers of sperm with normal motility, yet reproduce poorly (Krege et al., 1995; 
Esther et al., 1996; Hagaman et al., 1998).  Fuchs et al (2005) showed work to indicate that 
dicarboxypeptidase activity, and not just the presence of tACE, is crucial for male fertility, 
although this remains an unconfirmed finding pending independent verification. 
ACE has also been shown to possess endopeptidase activity, hydrolyzing substrates that are 
amidated at the carboxyl terminus (reviewed by Eriksson et al., 2002).  Substrates 
implicated as targets of ACE endopeptidase activity include the neuropeptides substance P 
and cholecystokinin, as well as the gonadotropin releasing hormone (GnRH), which is 
blocked at both the N- and C- termini yet can be cleaved into several di-and tri-peptides 
(Skidgel & Erdos 1985; Skidgel et al., 1987; Jaspard et al., 1993).  The physiological roles for 
these peptides are unclear, however, substance P has been found to co-localise in specific 
areas of the brain (Defendini et al., 1983; Matsas et al., 1984; Strittmatter et al., 1984; Oblin 
et al., 1988; Barnes et al., 1988).   
1.2.3  Domain selective ACE hydrolysis 
As has been discussed, ACE is primarily involved in the RAS where it converts AngI to AngII, 
as well as hydrolysing angiotensin(1-9) and (1-7)  to angiotensin (1-7) and (1-5), respectively. 
It also hydrolyzes bradykinin, a component of the KKS, to the inactive bradykinin (1-7).  
Outside of this primary function though, ACE has also been implicated in a number of other 
physiological roles and shown to hydrolyze a number of highly diverse substrates (Figure 
1.6).  ACE also possesses endopeptidase activity, hydrolyzing substrates that are amidated 
at the carboxyl terminus (Eriksson et al., 2002).  Substrates implicated as targets of ACE 
endopeptidase activity include the neuropeptides substance P and cholecystokinin, as well 
















termini yet can be cleaved into several di-and tripeptides (Eriksson et al., 2002; Skidgel & 
Erdos 1985).   
Of great importance when looking at ACE substrates is the fact that there are two 
catalytically active domains in sACE, both highly homologous, yet different enough to 
display varying substrate specificities (discussed below) and chloride dependence (Wei et 
al., 1991b; Wei et al., 1992) for each of the large plethora of ACE substrates.   
Both the C and N domains have equal binding affinity for AngI, yet the C-domain hydrolyses 
this substrate more efficiently both in vitro (Wei et al., 1991b) and in vivo (Fuchs et al., 
2008).  Interestingly, when the domains are expressed separately, the N-domain exhibits 2-3 
fold higher activity than the C-domain (Liu et al., 2001), which indicates a role for domain 
cooperativity in the context of sACE (Binevski et al., 2003).  The C-domain for AngI has a 
 
Figure 1.6 Physiological and synthetic substrates of ACE.  Peptide bond cleavage position is 
indicated by an arrow which is black for dipeptidyl carboxypeptidase activity and grey for 
endopeptidase activity. Pyroglutamic acid (pGlu); amidated C-termini (CONH2); Carboxybenzyl 














higher dependence on chloride than the N-domain (Wei et al., 1991b; Liu et al., 2001).  This 
chloride dependence trend is not seen only with AngI, but also for many other domain-
selective substrates although the trend varies for each.  For instance, BK is cleaved with 
equal efficiency by both domains and exhibits no significant difference in chloride 
requirement between domains (Jaspard et al., 1993).   
This domain variability extends to most other ACE substrates, physiological or synthetic. The 
N-domain preferentially cleaves AcSDKP by 50-fold over the C-domain in vitro (Rousseau et 
al., 1995), with the C-domain having a 6-fold higher requirement for chloride (Rousseau-
Plasse et al., 1996).  The domain selectivity was confirmed in vivo by using the highly N-
domain specific inhibitor RXP407 which resulted in 6-fold higher AcSDKP levels in mice 
(Junot et al., 2001).  The N-domain also presents a higher catalytic rate over C-domain for 
LHRH (GnRH) (Ehlers and Riordan, 1991, Jaspard et al., 1993) as well as Ang(1-7) (Deddish et 
al., 1994), although Rice et al (2004) found that the specificity was similar between domains. 
Conversely, like AngI, substance P is hydrolysed faster by the C-domain in a chloride 
dependent manner (Jaspard et al., 1993).   
ACE activity has long been characterized using synthetic analogue substrates derived from 
physiological peptides.  Hippuryl-His-Leu (HHL) and Z-Phe-His-Leu (Z-FHL) are both 
analogues of AngI, yet show very different domain preferences and chloride dependent 
profiles.  Like AngI, HHL is preferentially cleaved by the C-domain in a chloride dependent 
(Friedland &  
Silverstein, 1976). However, whilst the N-domain shows no difference in chloride affinity 
between AngI and HHL, the C-domain has a 40-fold higher requirement for chloride with 
HHL than AngI (Wei et al., 1991b).  Conversely, Z-FHL has been shown to be hydrolysed at 
fairly similar rates for both domains (Danilov et al., 1994), with the Phe in the P1 position 
suggested to mediate this difference (Michaud et al., 1997). Z-FHL has been shown to be 
chloride dependent in the C-domain (Moiseeva et al., 2005), however there is no 
comparative evidence in the literature for the N-domain in this regard.   Furylacryloyl-Phe-
Gly-Gly (FAPGG) is another synthetic peptide which is cleaved in a chloride dependent 
manner to yield the Gly-Gly dipeptide, however no domain bias has been shown as it has 














Thus, the large discrepancies in chloride dependence and domain preference for the 
different substrates is well described, but poorly understood. 
1.2.4  Physiological relevance of chloride dependence 
It has long been established in the literature that ACE activity is dependent on chloride, with 
the degree of dependence being substrate specific (Shapiro et al., 1983).  As already 
mentioned, ACE’s most established physiological role is in the RAS.  It is situated mainly on 
the surface of endothelial tissue, an environment where blood plasma chloride levels rarely 
fluctuate from the 100mM average, sufficient chloride for ACE to be considered fully active 
in angiotensin I hydrolysis (Shapiro et al., 1983). However, ACE is not found solely in vascular 
endothelial tissue and has been found in other non-vascular tissues where the chloride 
levels can vary quite substantially.   
For instance, the dipeptidyl carboxypeptidase activity of tACE has been implicated in being 
essential for male fertility, where male mice with enzymatically inactive tACE produce 
normal, motile sperm yet have poor reproductive efficiency, suggesting tACE expression on 
the sperm cells is involved (Fuchs et al., 2005).  Whilst the exact substrate for tACE in this 
context is unknown, the chloride concentration in the semen environment varies from 
31.6mM (Jeyendran et al., 1989) to 45mM (Rosecrans et al., 1987), which might be 
significant if a substrate has a high requirement for chloride. 
Another tissue region with variable chloride concentrations is in the brain, where the tissue 
specific brain RAS mediates, apart from normal RAS physiological function, a role in memory 
and learning thought to be via the angiotensin IV/AT4 receptor interaction (reviewed by 
Wright & Harding, 2004).  Outside of RAS function, ACE has been shown to hydrolyse several 
neuropeptides such as enkephalin, substance P, dynorphin and neurotensin (Skidgel & 
Erdos, 2004; van den Buuse et al., 2005).  Chloride plays a major role in the repolarization of 
depolarized cells (Hille 1992; Inoue et al. 2005), most notably where the transmembrane 
distribution of chloride anions determines the direction of the chloride flux through the γ-
aminobutyric acid (GABA) and glycine receptors, thus moderating signalling in neurons (De 
Koninck, 2007; Kroeger et al., 2010).  In evaluating the GABAA receptor-mediated response 
in different layers of the rat hippocampus, Kroeger et al (2010) found large fluctuations in 














response to stimulation.  Whilst ACE is not expressed in the hippocampus (Strittmatter et 
al., 1984), this does suggest that there could be similarly large fluctuations in chloride levels 
in other regions of the brain where ACE does function. Indeed, altered chloride homeostasis 
is implicated in a number of neurological disorders, and has been suggested as a means by 
which the microglia can modulate neuronal excitability (reviewed by De Koninck, 2007).  
ACE has been implicated in regulation of dopamine turnover (Jenkins et al., 1997), which has 
been linked to sensorimotor gating and schizophrenic pathology (van den Buuse, 2005).  The 
exact mechanisms for this role are unknown, but it is modulated by captopril, suggesting 
that ACE hydrolysis might be involved and where the chloride dependent nature of ACE 
substrates may be a relevant factor. 
ACE has also been detected intracellularly in kidney mesangial cells, where it is upregulated 
by high glucose stimulation and has been suggested to modulate AngII levels along with 
chymase (Andrade et al., 1998; Cristovam et al., 2008). In the context of chloride 
dependence, the chloride concentration intracellularly is ~5mM (Lodish, 1999) which would 
have an impact on ACE catalytic efficiency. Further to this is the effect that other factors, 
such as pH, have on chloride dependent activity, factors that are not necessarily constant in 
local environments (Shapiro et al., 1983).  This has implications for localized ACE activity, not 
only with tissue RAS systems, but more likely with other non-RAS substrates and suggests 
that particular substrates can be selectively hydrolysed under certain local in vivo 
conditions, leaving other substrates relatively untouched (Shapiro et al., 1983). 
Variance in chloride activity is also seen in inhibitor binding.  The difference in affinities for 
the ACE inhibitors trandolaprilat, enalaprilat, and lisinopril between the N- and C-domains is 
greater at high chloride concentration (300 mM), whereas for captopril, the difference is 
larger at low chloride concentration (20mM) (Wei et al., 1992). The variability in chloride 
mediated enhancement of inhibitor affinity may have potential applications in design of 
inhibitors targeting tissue specific ACE activity.  Indeed, a full delineation of the exact 
structural and mechanistic aspects of ACE chloride dependence for each domain may play a 















1.3  Chloride dependent substrate hydrolysis 
 
The exact mechanisms of chloride dependence in ACE and the relation to substrate 
composition is poorly understood.  Some mutagenic and structural work has been done to 
contribute to understanding this phenomenon and is summarised in the following sections. 
1.3.1  Chloride 1 pocket 
 The chloride 1 pocket of tACE (C-domain) has been suggested to be involved in C-terminal 
stabilisation of substrates (Guy et al 2003, Natesh et al 2003, Sturrock et al 2004).  The 
crystal structure of the N-domain of ACE shows no chloride bound in this pocket, where the 
only residue difference is a H164 in place of the chloride coordinating R186 in tACE (Figure 
1.7) (Corradi et al., 2006).  Tzakos et al (2003) propose that it acts as a synergistic anion 
promoting high affinity substrate binding.  They suggest that when Cl1 isn’t bound, K511 
(K489 of N-domain), a residue important in stabilization of the C-terminal carboxylate of 
lisinopril, could form amino-aromatic interactions with three tryptophans at positions 279, 
485 & 486 (257, 463 & 464 of N-domain) that form part of the Cl1 pocket.  When Cl1 is 
bound, it is coordinated by W279 in tACE (W257 of N-domain) which may disrupt these 
interactions allowing the aforementioned lysine to stabilize the C-terminal carboxylate of 
the substrate (Tzakos et al., 2003).  Rushworth et al (2008) found that mutation of R186, 
W279 and R489 (the other chloride coordinating residue) to Glu, Ala and Glu respectively 
resulted in a marked decrease in chloride dependence in tACE for all mutants.  This was the 
first evidence that indicated that this pocket had an effect on activity.  A kinetic assessment 
by Moiseeva et al (2005) suggested that binding of chloride in this pocket in tACE had an 
inhibitory role at high chloride concentrations.  They proposed that, in the absence of 
chloride, D507 would form a salt-bridge with K511, and with chloride binding the D507 
would switch to form a salt-bridge with R501 and allow K511 to swing into the active site 
and participate in stabilization of the carboxylate of the substrate.  Liu et al (2001) evaluated 
the chloride dependent profiles for a number of tetrapeptides that differed in their P1’ and 
P2’ residue identities, yet the P2 and P1 residues were identical (an acetylated Ala and a 
Phe) across all peptides.  What was very clear was that the nature of the P’ dipeptide 
structure greatly affected chloride dependence (Liu et al., 2001). However, a lack of 















interpretation of this data.  The mutagenic work of Rushworth et al (2008) and the evidence 
that interactions of substrate within the S1’ and S2’ pockets, which share residues with the 
chloride 1 pocket, showed effects on chloride dependence indicates that chloride binding at 
this site in tACE is relevant to catalysis. 
1.3.2  Chloride 2 pocket 
The crystal structure of tACE has given us the exact positions of all residues in proximity to 
the chloride ions and active site (Figure 1.8); however, the exact mechanism has not proved 
easy to unravel.  As mentioned, Arg522 in tACE (Arg1098 in sACE) has already been 
implicated in playing a crucial role in chloride dependence with AngI as substrate (Liu et al., 
2001).  When the arginine at position 522 was mutated to a glutamine, a residue with a  
 
Figure 1.7 Residues comprising the chloride 1 pocket of ACE.  Representative stick overlay of 
tACE-Lisinopril (PDB:1o86) in blue and N-domain-Lisinopril (PDB:2c6n) in green showing residues 
comprising the chloride 1 pocket as well as C-terminal stabilizing lysine (K511/K489). Residue 
labels are shown in the same colour for each domain, with residues differing between domains 
indicated by a grey box. Lisinopril is shown bound in the active site (yellow sticks), with the active 
site zinc (grey sphere) and chloride ions (numbered purple spheres) indicated.  The position of 
the chloride 2 pocket is indicated via R522/R500 being adjacent to one of the chloride ions. 















smaller side chain that lacks a positive charge, there was a resultant loss of chloride 
dependent activation (Liu et al., 2001; Rushworth et al., 2008). When the same arginine was 
replaced with a lysine, also a basic residue, chloride dependence was largely restored 
although it had an approximately 100-fold decrease in chloride binding affinity (Liu et al., 
2001).   Activation experiments using other monovalent halides of varying radii, such as 
bromine, iodine and fluorine, on the Arg1098 to Lys substitution mutant suggests that the 
spatial geometry of anion-liganding residues within the binding site is of importance (Liu et 
 
Figure 1.8 Residues comprising the chloride 2 pocket of ACE.  Representative stick overlay of 
tACE-Lisinopril (PDB:1o86) in blue and N-domain-Lisinopril (PDB:2c6n) in green showing residues 
comprising the chloride 2 pocket as well as well as E403/R381 which is situated in the S2 active 
site sub-site pocket. Residue labels are shown in the same colour for each domain, with residues 
differing between domains indicated by a grey box. Path of proposed chloride channel mediating 
access to the chloride 2 pocket is indicated by the curved arrow.  Lisinopril is shown bound in the 
active site (yellow sticks), with the active site zinc (grey sphere) and chloride ions (numbered 















al., 2001).  Tzakos et al (2003) have suggested that R522 may act as a carrier of Y523, which 
is proposed to stabilize the tetrahedral transition-state intermediate of the substrate.  R522 
would form a salt bridge with D465 in the absence of chloride, where chloride binding 
would disrupt this salt-bridge, R522 would coordinate the chloride ion and allow Y523 to 
swing into the active site (Figure 1.8).   The chloride 2 pocket shows some variation between 
the domains, where M223 corresponds to W201 and V518 corresponds to T496 in the C and 
N-domains, respectively (Natesh et al., 2003; Corradi et al., 2006).  Conversion of V518 to a 
Thr in tACE has been shown to have reductions in both activity with a small fluorogenic 
peptide and affinity of the inhibitors RXP407 and RXPA380 (Kroger et al., 2009).  This is 
ascribed to its location in the S1 pocket where it presumably disrupts substrate/inhibitor 
interactions (Kroger et al., 2009), however whether this has any effect on chloride 
dependence is not clear. 
1.3.3  Chloride channel 
In exploring possible mechanisms of chloride dependence in ACE, Tzakos et al (2003) 
proposed the presence of a “chloride channel” medi ting access of chloride to the chloride 
2 pocket, which was based on structural comparison with Salmonella enterica serovar 
typhimurium CLC Chloride channels described by Dutzler et al (2002).  It was proposed that 
E403 (tACE numbering) forms a potent salt-bridge with R522 in the absence of chloride, and 
that chloride binding would disrupt this interaction, coordinate R522 and allow Y523 to 
swing into the active site (Figure 1.8) (Tzakos et al 2003).  Furthermore, K118 residue was 
proposed to enhance the R522-E403 salt bridge by also forming a salt bridge with E403.  
Mutation of the residues that corresponded to K118 in other ACE homologues, K154 in 
rabbit testicular ACE (Sen et al., 1993), and K694 of rabbit lung ACE (Chen et al., 1990), 
reduced chloride sensitivity, thus highlighting its potentially critical role.  That Tzakos 
suggested that R522 formed salt-bridges with both E403 and D465 in the absence of 
chloride, a seemingly unlikely occurrence given their spatial proximity, is indicative of the 
lack of clarity on the mechanisms involved (Figure 1.8). Mutagenic structure-function 
studies are required to ascertain the exact role that each of these residues, or combination 















Substrate composition and interactions within the active site are critical in modulating the 
chloride dependent response via structural disruption/facilitation of specific interactions 
governed by a few key residues. 
Aims and objectives of this study 
All ACE substrates, either physiological or synthetic, show varying degrees of chloride 
dependence, which indicates that substrate composition is important.  Variability in the 
substrate P’ composition was shown to affect chloride binding (Liu et al., 2001). 
Furthermore, the S’ sub-pockets are also affected by mutations in the chloride 1 pocket 
(Rushworth et al., 2008).  The chloride coordinating R522 in tACE has been shown to be 
catalytically important (Liu et al., 2001), and theoretical work has provided insights into 
possible mechanistic interactions of R522 (Tzakos et al., 2003), however no adequate 
experimental evidence has been produced in their support.  Tzakos et al (2003) also 
proposed a “chloride gated channel” mediated by E403 in the S2 sub-pocket, which would 
block access of chloride to the chloride 2 pocket in the C-domain alone.  The aim of this 
study was to probe how substrate interactions in the prime and non-prime sides of the 
active site contribution to the chloride mechanism(s) of tACE and how key residues 
moderate these effects.  This would be done using a combination of structural, kinetic and 
thermodynamic approaches. 
The following objectives have been identified: 
1. Design, expression and purification of key Chloride 1 and 2 pocket mutants in which 
tACE (C domain) residues were either converted to their corresponding N-domain 
residues, or converted to specific residues if conserved between domains. 
2. Assessment of mutant constructs using chloride titrations with HHL and Z-FHL to 
determine whether chloride binding is altered. 
3. Establishment of an Isothermal Titration Calorimetric method for the determination 














4. Kinetic characterisation of constructs using angiotensin I and two of its analogues, Z-
FHL and HHL to determine whether substrate interactions in the S2 pocket 
contribute to a chloride gating mechanism. 
5. To determine the contributions of key residues in both chloride pockets to the 
kinetic and thermodynamic parameters of HHL, Z-FHL and angiotensin I hydrolysis in 
the presence and absence of chloride. 
6. Generate a structural rationale for the chloride dependence mechanisms based on 















































2.1  Introduction 
In order to investigate the role that certain residues play in modulating the chloride –
dependent profile of the C-domain of ACE (as described in Chapter 1), a number of tACE 
mutants were constructed.  The rationale for these mutations was based on a number of 
points, namely:  
A) R186 within the C-domain chloride 1 binding pocket corresponds to a histidine in the 
N-domain, where no chloride binding is observed, hence mutating the R186 to a 
histidine would provide insight into the role of this pocket. 
B) The chloride 2 pocket contains certain residues that were postulated by Tzakos et al. 
(2003) as playing a role in chloride binding (M223 and V518), which were converted to 
their corresponding variable N-domain counterparts (Trp and Thr, respectively).  The 
mechanistically important R522 and potentially important D465 in the C-domain, which 
are conserved in the N-domain (R500 and D443), were converted to residues that would 
change the chemical functionality of the side-chain in order to probe their effects. 
C) E403 was suggested to act as an ionic gate to a proposed chloride channel in the 
chloride 2 pocket in the C-domain, and was converted to an Arg, which is the 
corresponding residue in the N-domain. 
Therefore, the objectives of this section of work were: 
1.  Sub-cloning of the minimally glycosylated tACEΔ36g13 coding DNA region, lacking the 
36 amino acid N-terminal O-glycosylated region and retaining only the 1st and 3rd (of 7) 
N-glycosylation sites, into the pcDNA 3.1(+) mammalian expression vector. 
2. To engineer a double stop codon to ensure termination of translation at S625, just short 















3. To generate a suitable intermediary shuttle construct using pBluescript SK(+) and 
containing only the first 3 of 4 tACE1,3 cDNA fragments to facilitate the assembly of 
fragments into the pcDNA_ tACEΔ36g13sol expression vector. 
4. Using site-directed mutagenesis to generate the mutations hypothesized to affect 
chloride activation within the appropriate gene fragments (Fig 2.1), each contained 
within the pGEM11Zf+ shuttle vector. 
5. To subclone these mutated fragments, directly for fragment 4 or via the intermediary 
shuttle construct for fragments 2 & 3, into the pcDNA_tACEΔ36g13sol expression vector 
for subsequent transfection and expression. 
 
Figure 2.1 Schematic representation of the tACEg1,3 cDNA organisation.  The relevant coding region 
for the soluble tACEg1,3 construct  is contained between BamHI and NotI, with the region between 
NotI and EcoRI containing the transmembrane anchor (TM; block containing zigzag stripes) as well as 
the natural stop codon.  For subsequent sub-cloning and mutagenesis purposes the cDNA between 
BamHI and NotI is separated into 4 fragments, using the restriction endonuclease sites indicated, 
each contained with the pGEM11Zf+ cloning vector (constructed as part of Dr Kerry Gordon’s M.Sc 
thesis).  The region encoding the zinc-binding motif (ZBM) is indicated by diagonal stripes, with the 
signal sequence/transcription initiation site (SS/TIS) and cleavage site (CS) indicated by horizontal 
and vertical stripes, respectively.  The potential N-linked glycosylation sites are indicated by the 
numbered blocks (1-6), with number 7 being a potentially O-linked glycosolation site, with the two 















2.2  Methods & Experimental Approach 
2.2.1  Chemicals 
All restriction endonucleases used (BamHI, SphI, Eco47III, NheI, NotI, ScaI, AscI, PpuMI, BseRI, 
DraIII, EcoNI), as well as their buffers, were acquired from either Roche, New England BioLabs 
or Fermentas.  Both E.coli strains (XL1-Blue and JM110) used for sub-cloning work, as well as 
the pBluescript SKII+, were purchased from Stratagene.  Promega supplied the Pfu polymerase 
with buffer, Polymerase chain reaction (PCR) nucleotide mix, MgCl2, DpnI restriction 
endonuclease with buffer, pGEM11Zf+ DNA vector and Wizard SV Gel Purification System.  The 
T4 DNA Ligase with ligation buffer were supplied by Fermentas, with I Vitrogen being the 
source of the pcDNA3.1(+) mammalian expression vector.  Fermentas supplied the Fermentas 
GeneRuler™ DNA Ladder Mix (100-10,000 bp). QIAGEN were the source of the Midi-Prep 
Plasmid Purification Kit.  All DNA primer synthesis was performed by Inqaba Biotech, who also 
performed some of the DNA sequencing, with the remainder done in-house by the Division of 
Human Genetics, Faculty of Health Sciences, UCT. 
2.2.2  Methods 
2.2.2.1  Site-directed mutagenesis 
Site-directed mutagenesis was performed using the DpnI method, with the protocol having 
been adapted from Papworth et al (1996).  The DpnI method involves using primers that 
overlay and extend either side of the nucleotide bases that are to be mutated (Figure 2.2). 
These primers are almost exactly complementary to each other, only differing in those bases 
that need to be changed, and therefore bind to both strands of the target sequence that is 
contained within a plasmid vector.  Primer extension using a high fidelity DNA polymerase with 
3’ to 5’ exonuclease activity generates a nicked daughter strand containing the desired 
mutation.  Undesired exponential amplification of the daughter strand is avoided as any 















direction.  The primers, templat  DNA, free nucleotides and DNA polymerase are subjected to a 
number of thermocycles (of template separation, primer annealing and primer extension) 
resulting in a mixed population of original template and daughter strands.  Exposure of this 
mixture to DpnI restriction endonuclease digestion, which is specific for methylated DNA, 
results in only the original template DNA being degraded, hence selecting for the 
unmethylated, mutated DNA amplicons.  Transformation of this DNA into E.coli results in repair 
of the nicked strands and facilitates amplification of the DNA for screening purposes.  
The thermocycling amplification mixture was made up as follows:  5µl 10x polymerase buffer, 4-
12µl of 25mM MgCl2, 2µl of 10mM PCR nucleotide mix, 1µl 10µM (+)sense primer, 1µl 10µM (-) 
sense primer, 10µl of 10ng/µl pCDNA3.1(+) template DNA, 2 units Pfu polymerase and made up 
 
Figure 2.2  Schematic of the DpnI site-directed mutagenesis methodology.  (Taken from Papworth 














to a total volume of 50µl with sterile dH2O.  A negative control containing no template DNA was 
included to discount any spurious amplification.  An initial incubation of 5 minutes at 94°C was 
done to activate the polymerase and ensure complete template separation, which was followed 
by 16 cycles of 94°C for 30 seconds, 55°C for 30 seconds and 75°C for 12 minutes, followed by 
an extra 20 minutes at 75°C and storage at 4°C.  3µl of each reaction mixture were then 
visualised using agarose gel electrophoresis.  The reaction mixtures were then incubated with 
5-10 units of DpnI for 2-3 hours at 37°C, thereafter 10µl of digested reaction mixture were 
transformed into competent E.coli Xl1 Blue cells for screening purposes. 
2.2.2.2  Vector/Insert Ligations 
Plasmid DNA used for ligations were taken from stock samples that were purified using a 
QIAGEN MidiPrep Kit according manufacturer’s instructions.  Double restriction digestion of 
said DNA was performed and separated by agarose gel electrophoresis; the bands of interest 
were then excised and purified using the Promega Wizard® SV Gel and Clean-Up System as per 
manufacturer’s instructions.  Two microliters of each digested, purified fragment was visualized 
via agarose gel electrophoresis, along with DNA of known concentration, in order to establish 
relative concentrations of vector and insert fragments.  The ligation reaction mixture contained 
DNA concentrations at a vector to insert molar ratio of 3:1, along with 2µl 10x ligation buffer, 1 
unit T4 Ligase and made up to a total volume of 20µl with sterile dH2O. A positive control 
(containing single digested purified plasmid) and a negative control (containing just the purified 
vector fragment and no insert) were included with each ligation to validate the efficacy of 
either the ligation or bacterial transformation reaction.  Ligation mixtures and controls were 
incubated in the absence of light and at room temperature overnight, with 10µl of each 
transformed into competent E.coli XL1 Blue cells.   
2.2.3  Site-directed mutagenesis  
Site-directed mutagenesis was used for two purposes: 1) to introduce double stop-codons just 
before the natural cleavage site in order to generate a soluble construct; and 2) to introduce 














various tACEg13 fragments contained within pGEMZ11f+ (constructs generated by Dr K. 
Gordon).  These fragments of the coding region were used to facilitate bi-directional 
sequencing data and avoid introducing any deleterious mutations into the coding region of 
tACEg13. Appropriate primers were designed for sequencing reactions (Table 2.1).   
The target DNA for the stop-codon primers was in pGEM_FR4, which contained Fragment 4 
(FR4) of the tACEg13 coding region (flanked by the restriction endonucleases NheI and NotI) 
within the pGEM11Zf+ vector (see Fig. 2.3).   Site directed mutagenesis was performed 
Table 2.1.  Primer design for site-directed mutagenesis.  Complementary primers were designed 
containing the mutation of interest as well as silent mutations to introduce restriction endonuclease 
sites that facilitated screening.  Sequences shown are that of the forward primers (5’-3’) along with 
the corresponding wildtype sequence for comparison.  The altered amino acid codon letters are 
enlarged, with those letters that have been altered in bold and the recognition sequence for the 
screening restriction endonuclease underlined.  The location of the primer target DNA is indicated in 

















Figure 2.3:  Schematic overview of the mutagenesis approach.   The three tACEg13 cDNA fragments 
(FR2,FR3 & FR4; solid black elements) that contained primer target sequences were contained within 
the pGEMZ11f+ vector and are indicated by the plasmid vector maps at the top (pGEM_FR2, 
pGEM_FR3 and pGEM_FR4).  Plasmids were subjected to site-directed mutagenesis as described in 
2.2.3 using corresponding primers (Table 2.1), screened using restriction endonuclease digestion and 
correct sequence for positive clones confirmed via DNA sequencing.  Plasmid maps containing 
correct and confirmed codon changes are indicated by the vector elements of varying colour 
(Fragment 2 is yellow, Fragment 3 is blue and Fragment 4 is red).  Below each plasmid map are linear 
vector elements to indicate the number and identity of the mutations introduced into each fragment.  
Fragment 4 was subject to an initial mutagenesis cycle where stop codons were introduced 
immediately after the natural cleavage site, with this serving as the template for the remaining 














(described in Appendix) and the plasmid products were transformed into competent E.coli XL1 
Blue cells (Appendix), clones selected and grown up so that mini-preparations of plasmid DNA 
could be performed (Appendix).  Mutations were screened via restriction digestion using 
PpuMI, the site introduced by the mutagenesis, and the FR4 insert sequenced using p13 
forward and reverse primers that bind sequences flanking the pGEM11Zf+ multiple cloning site.  
The resultant construct was named pGEM_FR4-Stop. 
The same approach was followed for the introduction of the chloride pocket mutations using 
the primers shown in Table 2.1 and is summarised in Figure 2.3.  For all mutations within FR4, 
the pGEM_FR4-Stop construct was used as the template so that the stop codon would be 
present in all subsequent constructs.  Fragment 2 and 3 mutations were generated in unaltered 
templates.  Mutations were named using conventional nomenclature and single-letter amino 
acid codes, with the amino acid identity first, followed by numbers indicating its position along 
the protein backbone and ending with the identity of the amino acid it is to be mutated to. 
2.2.4  Generation of soluble tACEg13 construct within pcDNA 3.1+ 
The pLEN_tACEg13 construct was previously prepared in our laboratory (Gordon et al., 2003).  
This minimally glycosylated form of tACE was chosen as it is readily crystallisable for X-ray 
structure determination.  The relevant tACEg13 coding cDNA was excised from pLEN_tACEg13 
via double digestion with BamHI/NotI and ligated into pcDNA 3.1+ which had also been 
BamHI/NotI digested to yield an open vector (Fig 2.4 A, see 2.2.2.2 for methods used).  The 
resultant construct of tACEg13 in pcDNA 3.1+ is referred to as pcDNA_tACEg13. 
Further to the incorporation of the tACEg13 coding region into pcDNA3.1+, it was decided to 
make the construct soluble by introducing a termination sequence (stop-codon).  The reasoning 
was two-fold: firstly, a soluble construct would not need to be cleaved from the cell surface, 
and, being extruded directly into the growth medium, would thus lead to higher yields in the 
purification process; secondly, by ensuring termination after Ser625 (which is 2 residues short 
of the natural cleavage after Arg627) a more compact form of tACEg13, without the disordered 
















Figure 2.4:  Generation of soluble tACEg13 in pcDNA 3.1+.  A) The tACEg13 cDNA was excised from 
pLEN_tACEg13 via double digestion with BamHI/NotI.  This was ligated into pcDNA 3.1+ which had 
been digested with BamHI and NotI to yield an open vector.  The resultant construct of tACEg13 in 
pcDNA 3.1+ is referred to as pcDNA_tACEg13.  B) Fragment 4 containing the inserted stop codons 
was excised from pGEM_FR4-Stop via double digestion with NheI/NotI.  This was ligated into 
pcDNA_tACEg13 which had its Fragment 4 removed, also via NheI/NotI digestion, to yield a soluble 














Fragment 4 containing the inserted stop codons (generated in 2.2.3.1) was excised from 
pGEM_FR4-Stop via double digestion with NheI/NotI.  This was ligated into pcDNA_tACEg13, 
which had also had its Fragment 4 removed via NheI/NotI digestion (Fig 2.4 B).  The resultant 
construct is pcDNA_tACEg13 containing engineered stop codons and is referred to as 
pcDNA_tACEg13sol. 
2.2.5  Construction of pBS_FR1,2,3 shuttle vector 
It was necessary to generate an intermediary shuttle vector for the cloning of Fragments 2 and 
3 (FR2 and FR3) into pcDNA_tACEg13sol. Whilst FR4 can be subcloned directly into 
pcDNA_tACEg13sol (as already described in 2.2.4), the restriction endonuclease sites that flank 
both FR2 and FR3 prevent direct sub-cloning.  The SphI restriction site that separates FR2 and 
FR3 cuts a number of times in pcDNA and would hence prevent either fragment from being 
directly subcloned.  Additionally, the Eco47III restriction site separating FR1 and FR2 is also 
present in FR4 and would also prevent any sub-cloning of FR2 into the tACEg13sol coding 
region.  This restriction enzyme sequon is not present in the wildtype sequence and was 
engineered as part of the removal of the sixth N-linked glycosylation site during construction of 
the tACEg13 minimally glycoylated isoform (part of M.Sc work of Dr Kerry Gordon).  This 
necessitated the construction of an intermediary shuttle vector containing the tACEg13sol 
coding DNA region between BamHI and NheI (FR1, FR2 and FR3) and excluding that between 
NheI and NotI (FR4).  Thus, it was necessary to generate an additional intermediary shuttle 
vector for the cloning of Fragments 2 and 3 (FR2 and FR3) into pcDNA_tACEg13sol.  pBluescript 
SKII+ was chosen, as it lacked any Eco47III or SphI sites and contained the necessary restriction 
endonuclease sites in the MCS for the construction of  a suitable intermediary shuttle vector, 
which is described below. 
The tACEg13sol coding region was subcloned from pcDNA_tACEg13sol into pBluescript SKII+ via 
















Figure 2.5  Construction of pBS_FR1,2,3 subcloning intermediary  A) The tACEg13sol gene was 
excised from pcDNA_tACEg13sol via double digestion with BamHI/NotI.  This was ligated into 
pBluescript II SK(+) which had been  BamHI/NotI digested to yield an open vector.  The resultant 
construct of tACEg13sol in pBluescript II SK(+) is referred to as pBS_tACEg13sol.  B) Double digestion 
of pBS_tACEg13sol with SphI & EcoICRI allowed removal of Fragments 3 & 4.  pGEM_FR3 was double 
digested with SphI & EcoRV to yield Fragment 3 and a small portion of non-coding DNA (shown as 
white element between NheI and EcoRV  sites), which was ligated into the pBS_tACEg13sol minus 














competent E.coli, grown under antibiotic selective media for plasmid mini-preparation.  The 
mini-preparations were screened via double digestion with BamHI/NotI, along with 
pcDNA_tACEg13sol as a size control. 
The next step was to remove FR4 (and hence the extra Eco47III site) and generate a construct 
containing FR1, FR2 and FR3 only.  pGEM_FR3 contained an extra stretch of base pairs after the 
3’ end of the FR3 coding region, which was introduced in its construction (M.Sc work of Dr Kerry 
Gordon).  This stretch of sequence contained an EcoRV restriction site, digestion of which 
produces a blunt end.  Similarly, pBS_tACEg13sol contains a blunt cutting EcoICRI restriction site 
outside the 3’ end of the tACEg13sol coding region and within the pBluescript sequence.  The 
pBS_tACEg13sol vector was prepared by double digestion with SphI/EcoICRI allowing the 
removal of FR3 and FR4, along with a small portion of pBluescript sequence, leaving a free SphI 
sticky end, along with the EcoICRI blunt end.  FR3 was excised from pGEM_FR3 using 
SphI/EcoRV, and ligated into the prepared pBS_tACEg13sol vector (see Fig 2.5B). This generated 
the pBS_FR1,2,3 construct.  The blunt end ligation of the EcoRV and EcoICRI ends resulted in 
destruction of the recognition sequon for both restriction endonucleases.  This was not of 
significance as the NheI site flanking FR3 that was required for later sub-cloning steps remained 
intact. 
2.2.6  Sub-cloning of mutated Fragment 2 and Fragment 3 into pBS_FR1,2,3 
Mutants M223W and R186H, located on FR2, were subcloned into pBS_FR1,2,3 (Figure 2.6) 
using the Eco47III and SphI restriction sites.  This produced pBS_FR1,2,3_R186H and  
pBS_FR1,2,3_M223W.  In a very similar manner to the sub-cloning of FR2 into pBS_FR1,2,3, FR3 
that has the E403R mutation introduced via site-directed mutagenesis was also subcloned from 
pGEM_FR3_E403R into the pBS_FR1,2,3 shuttle construct using the SphI & NheI restriction 
endonucleases.  This produced pBS_FR1,2,3_E403R which was pBS_FR1,2,3 with a mutation 
















Figure 2.6 Subcloning of mutated Fragment 2 and Fragment 3 into pBS_FR1,2,3. Black arrows 
indicate the sub-cloning of the 368bp FR2 containing a mutation (yellow) from pGEM_FR2* into 
pBS_FR1,2,3 which has had its Fragment 2 removed via Eco47III/SphI  digestion.  This produces 
pBS_FR1,2*,3. White arrows indicate the sub-cloning of the 503bp Fragment 3 containing a mutation 
(blue) from pGEM_FR3* into pBS_FR1,2,3 which has had its Fragment 3 removed via SphI/NheI 
digestion.  This produces pBS_FR1,2,3*.  The presence of an * after the fragment number in the 
















Figure 2.7: Subcloning of mutation-containing fragments into pcDNA_tACEg13sol. Black arrows 
indicate sub-cloning of the 1276bp FR_1,2*,3 fragment containing FR2* (yellow) from pBS_FR1,2*,3 
into pcDNA_tACEg13sol which has had its FR1,2,3 removed via BamHI/NheI digestion.  This produces 
pcDNA_tACEg13sol*.  White arrows indicate the sub-cloning of the 1276bp FR_1,2,3* fragment 
containing FR3* (blue) from pBS_FR1,2,3* into pcDNA_tACEg13sol which has had its FR1,2,3 
removed via BamHI/NheI digestion.  Chequered arrows indicate the sub-cloning of the 657bp FR4 















2.2.7  Generation of pcDNA_tACEg13sol mutant expression constructs 
The previous section described the sub-cloning of the mutated fragments FR2 and FR3 into 
pBS_FR1,2,3.  The next step involved introducing these mutations into pcDNA_tACEg13sol, 
which is illustrated in Figure 2.7.  Here, all three fragments (FR1, 2 and 3, with either FR2 or FR3 
containing a mutation) were removed from pBS_FR1,2,3 via BamHI/NheI double digestion.  
Similarly,  the corresponding stretch of DNA (FR1,2 & 3) was removed from pcDNA_tACEg13sol, 
also via BamHI/NheI double digestion, and the FR1,2,3* was inserted in its place using a ligation 
reaction.  This generated a full pcDNA_tACEg13sol expression vector, with mutations in either 
FR2 or FR3 depending upon which route had been followed via the pBS_FR1,2,3 intermediary 
shuttle vector.  Unlike the sub-cloning of FR2 and FR3, which required the additional step of 
sub-cloning into an intermediary vector, the sub-cloning of FR4 was done directly from 
pGEM_FR4* straight into pcDNA_tACEg13sol.  Site-directed mutagenesis was used to introduce 
desired chloride pocket mutations into FR4 contained within pGEM_FR4-Stop (see 2.2.3). 
Double digestion using NheI and NotI yielded FR4 containing the mutation of choice.  This was 
inserted using a ligation reaction into pcDNA_tACEg13sol, which had also been NheI/NotI 
digested, to give a full pcDNA_tACEg13sol construct with a desired mutation within the FR4 
region (see Figure 2.7).  
2.3  Results & Discussion 
2.3.1  Site-Directed Mutagenesis of tACEg13sol Fragments 
Site-directed mutagenesis was performed using primers and corresponding tACEg13sol cDNA 
fragments contained within pGEM11Zf+, as described in 2.2.3.  The DpnI digested PCR products 
for each reaction were transformed into E.coli, selected, and mini preparations of the plasmid 
DNA screened using appropriate restriction endonucleases that recognised the restriction sites 
introduced via the mutagenic process.  Positive clones were selected for each mutagenic 
reaction and exact DNA composition was confirmed via nucleotide sequencing.  A summary of 















2.3.2  Generation of solubl  tACEg13 construct within pcDNA 3.1+ 
The coding region of tACEg13 was removed from pLEN_tACEg13 via BamHI/NotI restriction 
digestion and inserted into the expression vector pcDNA 3.1+ (outlined in 2.2.2, Appendix), and 
positive constructs were identified using restriction endonuclease digestions.  The stop codons 
were introduced into pGEM_FR4 (as described in 2.2.3) and sequencing confirmed the presence 
of both stop-codons, as well as the PpuMI restriction site used for screening purposes (data not 
shown).  The sub-cloning of FR4-Stop into pcDNA_tACEg13 (described in 2.2.4) generated the 
pcDNA_tACEg13sol construct.  Restriction digestion was used to confirm identity and integrity 
of the construct (Figure 2.8).  Digestion of pcDNA_tACEg13 with PpuMI yields a very faint band 
of 768bp: the faintness of the band is due to the presence of overlapping dcm  
Table 2.2:  Site-Directed Mutagenesis of tACEg13sol Fragments.  Table shows  the location of the 
mutations with respect to potential role, name of mutation, residue in tACE that is being mutated 
along with its numerical position , identity of amino acid if it is being converted to its corresponding 
N-domain residue, and the identity of the residue if that mutation is completely novel (i.e same in 




tACE (C-domain) N-domain 
Non-domain 
mutation 
Chloride 1 Pocket R186H Arg 186 His  
S2 Pocket 
(Chloride Channel) 
E403R Glu 403 Arg  
Chloride 2 Pocket M223W Met 223 Trp  
 D465T Asp 465  Thr 
 V518T Val 518 Thr  
 R522K Arg 522  Lys 
















methylation at one of the PpuMI recognition sites (centred at 2085 on the vector diagram), to 
which PpuMI is sensitive and cleavage is reduced to about 10% of normal.  The presence of 
another PpuMI restriction site (at position 2845) along with the stop codons in 
pcDNA_tACEg13sol results in a 1528bp band appearing with PpuMI digestion.  The inefficiency 
of the 2085 PpuMI site results in the 760bp and 768bp doublet being considerably less intense 
than the 1528bp band they are produced from.  Restriction digestion of both pcDNA_tACEg13 
and pcDNA_tACEg13sol with NheI/NotI (sub-cloning enzymes) yields identical 657bp bands 
(FR4), and digestion with BamHI/NotI yielding 5378bp and 1933bp bands for both. This serves 
to show that all sizing between the constructs is the same and the only difference being the 
presence of the added PpuMI site introduced with the stop codons.  pcDNA_tACEg13sol 
represents the final expression vector and nucleotide sequencing of the entire coding region 
confirmed that everything was correct. 
 
Figure 2.8  Generation of soluble tACEg13 construct within pcDNA 3.1+. Representative 10% 
agarose gel showing restriction digestion screening comparison between pcDNA_tACEg13 and 
pcDNA_tACEg13sol:  pcDNA_tACEg13 (lane 1) and pcDNA_tACEg13sol (lane 5) undigested; 
pcDNA_tACEg13 (lane 2) and pcDNA_tACEg13sol (lane 6) PpuMI digested; pcDNA_tACEg13 (lane 3) 
and pcDNA_tACEg13sol (lane 7) NheI/NotI digested; pcDNA_tACEg13 (lane 4) and pcDNA_tACEg13sol 















2.3.3  Construction of pBS_FR1,2,3 sub-cloning intermediary 
The coding region of tACEg13sol was removed from pcDNA_tACEg13sol via BamHI/NotI 
restriction digestion and inserted into the cloning vector pBluescript II SK(+)  (outlined in 2.2.5), 
and positive constructs were identified using restriction endonuclease digestions.  Figure 2.9A 
shows a confirmatory restriction digestion of the final selected clone: restriction digestion using 
BamHI gives an approximately 4875bp band, which corresponds to the predicted size of the 
construct. Double digestion with BamHI/NotI gives expected band sizes of 2942bp and 1933bp, 
corresponding to vector and coding region, respectively. Double digestion with BamHI/NheI 
gives expected band sizes of 3599bp and 1276bp, corresponding to vector plus FR4 and the 
FR1,2,3 region respectively, serving as further evidence that the construct size is correct.  
Digestion with PpuMI gives a very similar banding pattern to that seen in Figure 2.8, with a 
more intense 1528bp band and the faint 760/768bp doublet arising from within the tACEg13sol 
coding region.   
The generation of pBS_FR1,2,3 required the removal of FR4 from pBS_tACEg13sol via the 
cloning strategy described in section 2.2.5.  Restriction digestion was used to confirm identity 
and integrity of the pBS_FR1,2,3 construct in comparison to pBS_tACEg13sol (Figure 2.9B).   
Linearization of both constructs using BamHI gave a 4245bp band for pBS_FR1,2,3 compared to 
the slightly larger 4875bp band for pBS_tACEg13sol.  Linearization doesn’t allow for clear 
differentiation of such large bands, so double digestion using BamHI/NheI was employed to 
remove FR1,2,3 from both constructs.  As expected, the 1276bp band (FR1,2,3) is identical for 
both, yet the size of the remaining vector fragments are 3599bp and 2969bp for 
pBS_tACEg13sol and pBS_FR1,2,3 respectively.  This indicates that the section of DNA between 
NheI and EcoICRI containing FR4 has been removed (outlined in 2.2.5).  To further confirm that 
this region is no longer there, double digestion using NheI/NotI showed the 657bp FR4 being 
removed from pBS_tACEg13sol (giving 3588bp band), but only linearization of pBS_FR1,2,3 due 
to the lack of a NotI site that would be there if FR4 were.  The cloning strategy that employed 
blunt end ligation destroyed both EcoRV and EcoICRI sites that were used, hence they could not 
















Figure 2.9  Generation of pBS_FR1,2,3.  A) Sub-cloning of tACEg13sol into pBluescript II SK(+):  
Representative gel showing restriction digestions for pBS_tACEg13sol: undigested DNA (lane 1); 
BamHI digested (lane 2), BamHI/NotI digested (lane 3), BamHI/NheI digested (lane 4) and PpuMI 
digested (lane 5). Lambda DNA digested with EcoRI and HindIII was used as a molecular marker.  B)  
Removal of FR4 from pBS_tACEg13sol:  Representative gel showing restriction digestion screening 
comparison between pBS_tACEg13sol and pBS_FR1,2,3:  pBS_tACEg13sol (lane 1) and pBS_FR1,2,3 
(lane5) undigested; pBS_tACEg13sol (lane 2) and pBS_FR1,2,3 (lane 6) BamHI digested; 
pBS_tACEg13sol (lane 3) and pBS_FR1,2,3 (lane 7) BamHI/NheI digested; pBS_tACEg13sol (lane 4) 
and pBS_FR1,2,3 (lane 8) NheI/NotI digested. Lambda DNA digested with EcoRI and HindIII was used 














2.3.4  Sub-cloning of mutated Fragment 2 and Fragment 3 into pBS_FR1,2,3 
The two mutations that were generated in pGEM_FR2 were R186H and M223W, which yielded 
pGEM_FR2_R186H and pGEM_FR2_M223W.  As outlined in 2.2.6, FR2_R186H and FR2_M223W 
were subcloned into pBS_FR1,2,3 via SphI/Eco47III digestion.  Comparative digestions of 
pBS_FR1,2,3 with pBS_FR1,2,3_R186H & pBS_FR1,2,3_M223W (Figure 2.10) show that 
SphI/Eco47III digestion of all three constructs yields a 368bp band, indicating that the 
subcloned FR2_R186H and FR2_M223W are of identical size to the FR2 removed from 
pBS_FR1,2,3. Digestion of pBS_FR1,2,3_R186H with BamHI and the AscI site introduced with 
the mutation yields a 598bp fragment, where similar digestion of pBS_FR1,2,3 is only linearised, 
hence confirming that FR2_R186H was indeed subcloned into pBS_FR1,2,3.  Similarly, PpuMI 
digestion was used to compare pBS_FR1,2,3 with pBS_FR1,2,3_M223W.  pBS_FR1,2,3 yields a 
very faint 768bp band, which is due the presence of overlapping Dcm methylation at one of the 
two PpuMI sites (position 1107 on the pBS_FR1,2,3_M223W plasmid map) which results in less 
than 10% cleavage.  A third PpuMI site is introduced with FR2_M223W, which results in the 
768bp band being cleaved into 466bp and 302bp bands.  The varying intensity between the 
466bp and 302bp bands further highlights the sensitivity of the one PpuMI site to Dcm 
methylation.  The issue was alleviated in subsequent cloning steps by transforming the 
constructs into a methylation negative E.coli strain such as JM110.   
For the same reasons as described for FR2, FR3 also needed to be subcloned into the 
pBS_FR1,2,3 shuttle vector (outlined in 2.2.6).  The only mutation introduced into FR3 was 
E403R, which yielded the pGEM_FR3_E403R construct. FR3_E403R was subcloned into 
pBS_FR1,2,3 using NheI and SphI restriction digestion. Comparative digestions of pBS_FR1,2,3 
with pBS_FR1,2,3_E403R (Figure 2.10) show that SphI/NheI digestion yields identical 503bp 
bands, confirming the correct FR3 size.  Digestion using BseRI produces a 372bp band in 
pBS_FR1,2,3, whereas introduction of another BseRI site in FR3 of pBS_FR1,2,3_E403R results in 
the appearance of an 806bp band.  This confirmed that the FR3_E403R fragment was subcloned 
















Figure 2.10  Subcloning of mutated Fragment 2 and Fragment 3 into pBS_FR1,2,3  A) Sub-cloning of 
Fragment 2 constructs into pBS_FR1,2,3: Representative gel showing restriction digestion screening 
comparison between pBS_FR1,2,3, pBS_FR1,2,3_R186H & pBS_FR1,2,3_M223W: pBS_FR1,2,3 (lane 
1), pBS_FR1,2,3_R186H (lane  4) & pBS_FR1,2,3_M223W (lane 6) are digested with Eco47III/SphI; 
pBS_FR1,2,3 (lane 2) and  pBS_FR1,2,3_R186H (lane 5) are digested with BamHI/AscI; pBS_FR1,2,3 
(lane3) and pBS_FR1,2,3_M223W (lane 7) are digested with PpuMI.  Fermentas O’Generuler DNA 
Ladder was used as a molecular marker.  B) Sub-cloning of Fragment 3 constructs into pBS_FR1,2,3:  
Representative gel showing restriction digestion screening comparison between pBS_FR1,2,3& 
pBS_FR1,2,3_E403R: pBS_FR1,2,3 (lane 1) & pBS_FR1,2,3_E403R (lane 3) are digested with 
SphI/NheI; pBS_FR1,2,3 (lane 2) & pBS_FR1,2,3_E403R (lane 4) are digested with BseRI.  Fermentas 














2.3.5  Generation of pcDNA_tACEg13sol mutant expression constructs 
Once it had been confirmed that the mutation containing FR2 and FR3 had been successfully 
subcloned into FR1,2,3 (Section 2.3.4), the next step (as outlined in 2.2.7) was to subclone all 
three fragments (FR1,2 & 3)  from each of these individual mutation-containing pBS_FR1,2,3 
constructs into pcDNA_tACEg13sol.  Comparative digestions of pcDNA_tACEg13sol with the 
R186H, M223W and E403R mutation containing pcDNA_tACEg13sol constructs (Figure 2.11) 
shows that BamHI/NheI digestion of all constructs yields a 1276bp band, confirming the 
identical size of the FR1,2,3 between all constructs.  To confirm presence of mutations, 
restriction digestion using screening enzymes is also shown.  Digestion of pcDNA_tACEg13sol 
_R186H with BamHI and AscI (introduced with the mutation) yields a 598bp fragment, where 
similar digestion of pcDNA_tACEg13sol is only linearised, hence confirming that R186H 
mutation is present.  In the digestion with PpuMI, the pcDNA_tACEg13sol and 
pcDNA_tACEg13sol_M223W plasmid DNA was prepared from transformations of methylation 
negative E.coli JM110 cells, which alleviated the issue of reduced cleavage with one of the 
PpuMI sites alluded to in 2.3.3 and 2.3.4.  This digestion of pcDNA_tACEg13sol produces a 
bright 760bp/768bp doublet, with a faint 1528bp band visible due to incomplete cleavage.  The 
additional PpuMI site associated with the M223W mutation in pcDNA_tACEg13sol_M223W 
causes the cleavage of the 768bp band into two smaller 466 and 302bp bands.  
pcDNA_tACEg13sol digestion with BseRI yields 2564bp and 372bp bands, with the additional 
BseRI site associated with the E403R mutation in pcDNA_tACEg13sol_E403R causing the 
2564bp band to be split into 1758 and 806bp bands.  These gels serve to confirm the successful 
generation of pcDNA_tACEg13sol_R186H, pcDNA_tACEg13sol_M223W and 
pcDNA_tACEg13sol_E403R.  Unlike the FR2 and FR3 segments that need to be subcloned via 
pBS_FR1,2,3, FR4 could be subcloned straight into pcDNA_tACEg13sol via NheI/NotI (outlined in  
2.2.8).  Five separate mutations were generated in FR4 (see 2.3.1; Table 2.2) to yield  
pGEM_FR4_D465T, pGEM_FR4_V518T, pGEM_FR4_R522K pGEM_FR4_R522Q, pGEM_FR4_VR-
















NheI/NotI restriction digestion.  Comparative restriction digestion of pcDNA_tACEg13sol and 
the D465T, V518T, R522K, R522Q and VR-TK containing pcDNA_tACEg13sol (Figure 2.12 A) 
shows that NheI/NotI digestion of all constructs yields a 657bp band, confirming the identical 
size of FR4 between all constructs.  Figure 2.12 B  gives comparative restriction digestions using 
screening restriction enzymes for each mutation.  Digestion of pcDNA_tACEg13sol and 
pcDNA_tACEg13sol_D465T with DraIII resulted in a large 2005bp band for pcDNA_tACEg13sol, 
with the additional site associated with the D465T mutation cleaving that into 1060bp and 
945bp bands in pcDNA_tACEg13sol_D465T.  Digestion of pcDNA_tACEg13sol and  
 
Figure 2.11 Sub-cloning of Fragment 1,2,3 containing mutations into pcDNA_tACEg13sol.    
Representative gel showing restriction digestion screening comparison between pcDNA_tACEg13sol 
and the pcDNA_tACEg13sol constructs containing the R186H, M223W and E403R mutations: 
pcDNA_tACEg13sol (lane 1), pcDNA_tACEg13sol_R186H (lane 2), pcDNA_tACEg13sol_M223W (lane 
3) and pcDNA_tACEg13sol_E403R (lane  4) were digested using BamHI/NheI; pcDNA_tACEg13sol 
(lane 5) and pcDNA_tACEg13sol_R186H (lane 6) digested using BamHI/AscI; pcDNA_tACEg13sol (lane 
7) and pcDNA_tACEg13sol_M223W (lane 8) digested using PpuMI; pcDNA_tACEg13sol (lane 9) and 
pcDNA_tACEg13sol_E403R (lane 10) digested using BseRI.  Fermentas O’Generuler DNA Ladder was 















pcDNA_tACEg13sol_V518T with BamHI and EcoNI resulted in a 1588bp band dropping out due 
to the presence of the EcoNI site associated with the V518T mutation, with pcDNA_tACEg13sol 
just being linearised.  The R522K, R522Q and VR-TK mutations all introduced a ScaI restriction  
 
Figure  2.12 Sub-cloning of Fragment 4 constructs into pcDNA_tACEg13sol.  Representative gel 
showing restriction digestion screening comparison between pcDNA_tACEg13sol and the 
pcDNA_tACEg13sol constructs containing the D465T, V518T, R522K, R522Q, VR-TK mutations: A) 
pcDNA_tACEg13sol (lane 1), pcDNA_tACEg13sol_D465T (lane 2), pcDNA_tACEg13sol_V518T (lane 3), 
pcDNA_tACEg13sol_R522K (lane 4), pcDNA_tACEg13sol_R522Q (lane 5) and pcDNA_tACEg13sol_VR-
TK (lane 6) digested with NheI/NotI. B) pcDNA_tACEg13sol (lane 1) and pcDNA_tACEg13sol_D465T 
(lane 2) digested with DraIII; pcDNA_tACEg13sol (lane 3) and pcDNA_tACEg13sol_V518T (lane 4) 
digested with BamHI/EcoNI; pcDNA_tACEg13sol (lane 5), pcDNA_tACEg13sol_R522K (lane 6), 
pcDNA_tACEg13sol_R522Q (lane 7) and pcDNA_tACEg13sol_VR-TK (lane 8) digested with ScaI. 














site, hence ScaI digestion of pcDNA_tACEg13sol constructs containing these mutations 
produced 4244bp and 2967bp bands, whereby without these mutations the construct is merely 
linearised due to the lone ScaI site in the pcDNA 3.1+ vector sequence.  These gels serve to 
confirm the successful generation of pcDNA_tACEg13sol_ D465T, pcDNA_tACEg13sol_V518T, 
pcDNA_tACEg13sol_R522K, pcDNA_tACEg13sol_R522Q and pcDNA_tACEg13sol_VR-TK. 
2.4  Summary 
In summary, the tACEg13 cDNA was successfully established in the pcDNA 3.1(+) expression 
vector, which had the NheI-restriction endonuclease site removed from the multiple cloning 
site to facilitate a more efficient cloning strategy.  Stop-codons were engineered into the gene 
to make the protein product soluble in order to improve potential yields and promote 
crystallization efforts, resulting in the pcDNA_tACEg13sol expression vector.  An intermediary 
shuttle vector was constructed by cloning the tACEg13sol gene into pBluescript II SK(+) and 
then removing the fourth gene fragment (FR4), which contained RE sites that would interfere 
with cloning, resulting in pBS_FR1,2,3.  Site-directed mutagenesis was employed to alter target 
nucleotide sequences within gene fragments (FR2, FR3 & FR4) contained within the pGEM11Zf+ 
cloning vectors and the sequences checked by nucleotide sequencing.  These mutated 
fragments were then subcloned into pcDNA_tACEg13sol via either direct sub-cloning (for FR4 
mutants) or sub-cloning into pBS_FR1,2,3 first and then sub-cloning that FR1-3 into 
pcDNA_tACEg13sol (for FR2 and FR3 mutants).  All final mutated pcDNA_tACEg13sol constructs 
were checked extensively via restriction endonuclease digestion and prepared for transfection 
into mammalian cells for expression.   
The cassette approach described here, where multiple cDNA fragments are mutated separately 
then substituted into the final expression vector, provides an efficient means for generating 
















Chapter 3:  Expression, Purification 






























3.1  Introduction 
A variety of mutated forms of tACEg13sol were generated (described in Chapter 2) where 
specific residues in and around the chloride binding pockets were substituted in order to 
investigate specific aspects of chloride dependence.  These constructs were stably 
transfected into Chinese hamster ovary (CHO) cells that do not express any endogenous 
ACE.  Mutant protein was expressed, purified and characterised in terms of enzymatic 
activity.  Initial characterization was done by assessing the chloride titrated activity of the 
mutant constructs using the synthetic substrate hippuryl-L-histidyl-L-leucine (HHL), which 
displays a highly chloride-dependent profile, and Z-phenylalanyl-L-histidyl-L-leucine (Z-FHL) 
which has a profile similar to the physiologically relevant peptide angiotensin I. 
Objectives: 
1. Transfect plasmids containing tACEg13sol mutant encoding cDNA into CHO cells and 
establish high expressing clones for each. 
2. Purify tACEg13sol mutants using Sepharose-lisinopril affinity chromatography. 
3. Evaluate whether mutations have affected chloride dependence profile of HHL and 
Z-FHL using chloride titrations. 
3.2  Experimental Approach 
3.2.1  Chemicals 
Dulbecco’s modified eagle’s medium (DMEM) and Ham’s F12 were obtained from Sigma, 
with Fetal calf serum (FCS), tissue culture flasks and trypsin supplied by Gibco.  N-2-
hydroxyethylpiperazine-N’-2-ethanesulphonic Acid (HEPES), genetecin G418, HHL, HL, Z-FHL 
and o-phthaldialdehyde, were purchased from Sigma.  CHO-K1 cells were obtained from 
American Type Culture Collection (ATCC® CCL-61).  The Profection Mammalian Transfection 
System was purchased from Promega, with NaCl, Boric acid and ZnSO4 from Merck and 
Lisinopril from Zeneca Pharmaceuticals.   
3.2.2  Transfection of  tACEg13sol constructs 
pcDNA_tACEg13sol mutant constructs were transfected using the ProFection® Mammalian 














growth media used to culture the cells consisted of 45% DMEM, 45% HAMS, 10% foetal calf 
serum (heat inactivated at 56°C for 30 min) and 20mM HEPES (pH 7.5), with growth 
conditions being 5% CO2 at 37°C, 80% relative humidity.  A CHO-K1 stock solution (500µl of 
cells frozen in a solution of 10% DMSO in foetal calf serum) were inoculated into 10 ml of 
culture medium and grown until confluent.  Cells were then seeded into 10 cm3 culture 
dishes at a concentration that would result in 30-60% confluency after overnight incubation.  
Three hours prior to transfection, the cells were washed with 1x phosphate buffered saline 
(PBS) and incubated further with fresh growth medium.  A 500µl solution of 10-20μg of 
plasmid DNA and 248mM CaCl2 was added to 2X HEPES-buffered saline [25mM HEPES, 
25mM NaCl, 5mM MgCl2, 0.5mM dithiothreitol, pH 7.9] whilst air was bubbled through, 
which formed a DNA-CaPO4 precipitate after incubation for 30min at room temperature. 
The precipitate was then added to cells in a dropwise manner, swirled and incubated for 4h 
at 37°C in 5% CO2. The cells were subsequently shocked by addition of a 15% glycerol in 1X 
PBS [137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4.7H2O, pH 7.3] solution for 2min at room 
temperature. The cells were washed twice with 1X PBS and incubated overnight in fresh 
culture medium. After 24h, cells were switched to media containing 0.8mg/ml G418 (Sigma), 
with daily media changes until individual colonies were observed on the plates. Individual 
colonies were transferred to 12-well plates using sterile swabs dipped in trypsin-EDTA 
[0.13M NaCl, 10mM Na2HPO4.2H2O, 2.7mM KCl, 1.5mM KH2PO4, 0.5% (w/v) trypsin, 0.1% 
(w/v) EDTA, pH 7.4]. Remaining cells (mixed stock) were trypsinized and reseeded. Highest 
expression clonal lines were screened for ACE expression by assessing ACE activity in the 
medium using substrates HHL and Z-FHL.  
 
3.2.3  HHL and Z-FHL Assays 
Hippuryl-L-histidyl-L-leucine (HHL) and Z-Phenylalanyl-L-histidyl-L-leucine (Z-FHL) are both 
cleaved by ACE, which results in an L-histidine-L-leucine (HL) product.  The free histidyl 
moiety of HL can form a fluorescent adduct with O-pthaldialdehyde, which is measured 
spectrofluorometrically (λexcitation = 360 nm; λemission = 485 nm) (Friedland and Silverstein, 
1976). Medium or purified sample (10 μl of appropriate dilution adjusted to keep 
fluorescent readings in a specific determinable range) was incubated at 37°C for 15 minutes 














0.3 M NaCl,  10  µM ZnSO4) or Z-FHL (1 mM in 0.1 M KPO4 buffer,  pH  8.3,  0.1 M NaCl,  10  
µM ZnSO4 ), with the reaction subsequently stopped by the addition of 170 µl of 0.28 M 
NaOH.  Fourteen microlitres of 20 mg/ml O-pthaldialdehyde was added, incubated at room 
temperature for 10 minutes to allow the formation of fluorescent adducts, and the reaction 
then stopped with the addition of 26µl of 3N HCl.  The entire reaction was performed in a 
96-well plate, with the 250µl final volume read using a Varian Eclipse Fluorescence 
Spectrophotometer.   An HL standard curve  (0-20 nmol HL) was generated  to convert   
fluorescent  units  into  milliunits  (mU) ACE  activity,  where  1  unit   is  defined  as  1 nmole 
of HL produced per minute per millilitre (.min-1.mL-1) at 37°C in assay buffer. 
 
3.2.4  Isolation and Purification of tACEg13sol Constructs 
The tACEg13sol clonal cell lines generated in 3.2.2 were grown using 10% FCS growth 
medium and ultimately seeded into T175 cm2 flasks, where they were grown to 90-100% 
confluency.  Growth medium was then replaced with expression medium, consisting of 50 % 
DMEM, 50 % Ham’s F12, 20 mM HEPES supplemented with 2 % FCS (heat-inactivated for a 
further 15 min at 70°C), and harvested every 3 days for between 5 and 7 cycles.  Harvested 
medium was centrifuged for 2 minutes to remove any cellular debris, pooled and stored at   
-20°C until needed for purification. 
Purification of tACEg13sol constructs was achieved via affinity chromatography, where the 
thawed expression medium harvests were passed over a Sepharose-28-lisinopril affinity 
column (Ehlers et al., 1991).  The 10ml column was then washed overnight by passing 
approximately 400-600ml of wash buffer (20 mM HEPES, pH 7.5, 0.5 M NaCl) to reduce non-
specific binding, followed by elution using 50 mM Borate buffer (pH 9.5).  The elution of 
protein was monitored by UV absorption (280nm).  Fractions were assayed for ACE activity 
using substrate HHL.  The fractions with ACE activity were pooled and dialysed in 4 x 2L of 
dialysis buffer (5mM HEPES (pH 7.5), 0.1 mM PMSF) at 4°C over a period of 48 hours.  
Protein was then removed from dialysis and applied to multiple centrifugation steps using 
4ml Amicon Ultra-4 centrifugal filter tubes (30 kDa MWCO), where it was concentrated to 
between 6 and 15μM and concomitantly equilibrated to appropriate storage conditions 
(50mM HEPES pH 7.5, 10μM ZnSO4).  Concentrations (C) were calculated based on the Beer-














established by Gill & Von Hippel (1989) and found to be 137122 M-1cm-1 for tACEg13sol and 
all mutants except M223W (142662 M-1cm-1), with N-domain D629 being 161142 
M-1cm-1.   Absorbance (A) of the samples was measured at 280 nm, and the pathlength (l) of 
the cell was 1 cm. 
3.2.5  Chloride Titrations 
Chloride titrations were performed using HHL and Z-FHL solutions containing varying 
amounts of NaCl (0-1M).   The protocol for the assay was as described in 3.2.3, the only 
difference being that for both substrates the buffer used was TAPSO (pH 7.5) at 50mM, 
which was used in order to maintain consistency with the ITC experimental approach 
(described in Chapters 4 and 5) that necessitated the use of this buffer. Enzyme sample 
(20μl of appropriate dilutions) containing no NaCl was combined with 20μl of substrate 
containing a given NaCl concentration, the final NaCl concentration is diluted by a factor of 
0.5 (hence range of 0-0.5M).  Milliunits (mU) of ACE activity were calculated as described in 
3.2.3, divided by the total number of micrograms (µg) in the reaction volume, and thus 
expressed as specific activity (mU.µg-1).  Substrate concentrations used were ≥5x Km and 
the total percentage hydrolysis in each reaction was kept below 20% in order to 
approximate first order rates (kcat/KM).  The measure of chloride binding (Kd,app) was 
calculated from activation plots of specific activity versus the logarithm of chloride 
concentration, with the resultant curves analyzed via non-linear regression using a sigmoidal 
dose-response curve with the formula: 
   
             
              
 
where SAmin is the specific activity in the absence of NaCl, SAmax is the maximum specific 
activity upon titration with chloride, X is the logarithm of chloride concentration, Y is the 
response (specific activity) and EC50 is is the X value when the response is halfway between 
SAmax and SAmin.   
3.2.6  Molecular Docking 
The short synthetic tri-peptides HHL and Z-FHL were docked into the tACE-RXPA380 crystal 
structure (PDB code 2oc2) using the Accelrys Discovery Studio© Molecular Simulation 
program.  The tACE-RXPA380 crystal structure was used as RXPA380 is a similar size to Z-FHL 














into the defined active site using CDOCKER simulation tool.  Poses were visually evaluated 
based on proximity (<2.5Å) and orientation of: A) the scissile peptide carbonyl group 
(displayed in the geminal diol form) to the active site zinc, and B) the C-terminal carboxylate 
to Lys511, a likely interaction given that this residue interacts with the lisinopril c-terminal 
carboxylate (Natesh et al 2003).  The pose that best fit these criteria and had the highest 
CDOCKER score was chosen.  
3.3  Results & Discussion 
3.3.1  Protein Expression and Purification 
All constructs were expressed in CHO cells, purified using Sepharose-lisinopril affinity 
chromatography and qualitatively assessed for purity and to determine the molecular 
weight using SDS-PAGE.  As can be seen in Figure 3.1, bands for all tACEg13sol constructs 
migrated with a mobility that correlated to a molecular weight of 70 kDa, which is in 
 
Figure 3.1  Representative SDS-PAGE (10 %) indicating purity of all tACEg13sol mutants.  Lanes 
1, tACEg13sol; 2, N-domain D629; 3, R186H; 4, M223W; 5,E403R; 6, D465T; 7, V518T; 8, R522Q; 
9, R522K.  Lanes were loaded with approximately 10 µg of protein.  Arrow indicates the size of 
the tACEg13sol constructs (~70 kDa) with the N-domain D629 being larger at ~100kDa. Protein 
yields for each construct are indicated below the gel image. 
Protein Yield  
(mg.L-1 medium) 
5.6 1.2 6.0 1.9 8.8 7.7 7.7 2.5 4.9 
70 kDa -- 
100 kDa --  
50 kDa -- 














agreement with the predicted molecular weight and previously published literature (Gordon 
et al., 2003). The N-domain construct had a molecular weight of 100 kDa as described 
previously (Anthony et al., 2010) and migrated as a broad band due to heterogeneity of the 
glycosylation. The tACEg13sol proteins are minimally glycosylated and do not have such 
heterogeneity, migrating as sharper bands on SDS-PAGE.  Absorbance of each construct was 
measured at OD280 and the protein concentration calculated (as described in 3.2.4).  This 
allowed calculation of total protein yields for each construct (Figure 3.1), with yields which  
compare very favourably with previously reported yields for tACE.  All proteins were active 
to varying degrees with both HHL and Z-FHL, allowing for further characterisation. 
 
3.3.2  Chloride Titrated Activity of tACEg13sol mutants 
In order to assess whether the mutations introduced have had an effect on the chloride 
dependence profile, the chloride titrated activity with both HHL and Z-FHL for each 
construct was performed (Table 3.1).  The Kd,app for chloride binding, along with the 
minimum and maximum specific activities (SAmin & SAmax) allow for preliminary evaluation of 
the mutants.   
3.3.2.1  Chloride 1 pocket 
Investigation of the chloride 1 pocket is of interest as the crystal structure of the N-domain, 
unlike that of the C-domain, showed that a chloride ion was not present (Corradi et al., 
2006). It has been suggested that chloride binding in this pocket in the C-domain plays an 
activation role via the structural orientation of Lys511, a residue that stabilizes the C-
terminal carboxylate group of lisinopril (Tzakos et al., 2003; Sturrock., 2001; Natesh et al., 
2003).  However, Moiseeva et al (2005) suggest the pocket plays an inhibitory role and 
proposed a mechanism whereby, in the absence of chloride, Asp507 switches from forming 
a salt bridge with Lys511 to forming one with Arg501 in the enzyme-substrate complex. 
Disruption of the Asp507-Arg501 salt bridge by chloride binding would disrupt the 
orientation of Lys511 and negatively affect catalysis.  All the residues discussed regarding 
this particular pocket are shown in Figure 3.2A.  However, very little functional work 
















was by Rushworth et al., (2008).  These authors found that the R186Q mutation reduced 
chloride dependence with AngI as well as overall level of activity in presence of NaCl.  Two 
other mutations in the chloride 1 pocket had similar effects, suggesting the overall structure 
(not just one interaction) of the pocket may be important. 
The initial assessment of the tACEg13sol_R186H (hence referred to as R186H) was done 
using short synthetic peptides HHL and Z-FHL and showed different effects.  The Kd,app for 
R186H compared to tACEg13sol was increased by only 18% for Z-FHL, yet showed a 64%  
Table 3.1 Effect of NaCl on the hydrolysis of HHL and Z-FHL synthetic peptides by ACE 
constructs.  All values were obtained from chloride titrated activity assays (described in 3.2.5).  
Units for SAmin and SAmax are mU.µg
-1 and Kd,app are in mM.  Data shown represent the average of 
two independent determinations, each in triplicate.  The ~ indicates that accurate estimations of 
Kd,app  and SAmax could not be obtained as the chloride concentration range was insufficient for 


















Figure 3.2  Chloride 1 pocket of ACE.  A)  Stick representation showing C-domain (PDB code 
1o86) aligned to the N-domain structure (PDB code 2c6n), with residues at each position shown 
in green and light blue respectively.  Residue position and identity are shown below each, with 
the tACE numbering prior to that of the N-domain and the asterisk indicating that the residue 
identity is unchanged.  The critical active site zinc ion is shown as a  grey sphere, with the chloride 
ions shown as purple spheres and numbered according to the pocket they’re in (pocket 1 or 2).  
The lisinopril (yellow) that was co-crystallised with tACE is shown in the active site coordinating 
the zinc ion.  Images were created using PyMOL 0.99 (DeLano Scientific, Palo Alto, CA, USA).  B)  
Low-High Bar graphs for the specific activity of tACEg13sol, N-domain D629 and 
tACEg13sol_R186H with HHL and Z-FHL substrates.  The bottom of each bar corresponds to the 
SAmin, with the top corresponding to SAmax (data reproduced from table 3.1).  Graphs were 














increase for HHL. Given that the main mechanistic role of chloride binding is observed in the 
chloride 2 pocket (Liu et al., 2001) where disruption of the coordinating Arg522 resulted in 
orders of magnitude increases in Kd,app, these shifts in Kd,app are relatively small.  Along with 
the distal location of the chloride 2 pocket, this indicates that these shifts can be attributed 
to minor structural shifts.   
For HHL hydrolysis at 0mM NaCl there appears to be no significant difference in activity 
between tACEg13sol, N-domain and R186H.  However, upon titration with chloride the 
maximal activity of R186H increased by 36% over tACEg13sol, as opposed to reducing to the 
lower N-domain level (fig 3.2B).  A similar trend is seen for Z-FHL hydrolysis between 
tACEg13sol and R186H, differing in that the SAmin for tACEg13sol, N-domain and R186H 
exceeds the SAmax for HHL hydrolysis.  This trend is the opposite of that observed by 
Rushworth et al (2008) where they found that the R186Q mutation reduced chloride 
dependence with AngI as well as overall level of activity in presence of NaCl.  Two potential 
explanations can be put forward:  The first being that this difference is a result of the 
different mutations, where Rushworth et al (2008) converted the R186 to a glutamine and in 
the current study it was converted to the corresponding N-domain histidine.  Both 
mutations would presumably abrogate or disrupt coordination of chloride in this pocket of 
tACE and the difference in overall activity would presumably be a result of other differences 
between the two domains.  However, there is the possibility that the His in R186H may still 
coordinate chloride, performing a similar role, hence the lack of considerable variation in 
activity.  This would then point to the lack of a chloride observed in the N-domain structure 
as either an anomaly or that chloride cannot access the pocket.  A further possibility may be 
that the His may substitute for the chloride-coordinated Arg, via interactions with other 
residues in the pocket, and thereby maintain the shape and dynamics of the pocket and 
thus rendering chloride unnecessary. 
The second explanation hinges on the greater length of the angiotensin I decapeptide over 
the shorter HHL and Z-FHL tripeptides.  There is evidence for a hinge bending mechanism of 
tACE based on its structural similarity to ACE2 (Watermeyer et al., 2006). Furthermore, if the 
chloride 1 pocket is involved in stabilizing one conformation over another, disruption of 
chloride coordination in the C-domain may affect either substrate binding, substrate access 














site, yet the smaller peptides would have better access and, with the structural shift be 
better hydrolysed.  However, the N-domain crystal structure showed no chloride bound in 
this pocket (Corradi et al., 2006) and is hence not critical for activity.  Also, the N-domain has 
been shown to be more thermally stable than the C-domain (Anthony et al., 2010) 
discounting the idea that chloride binding in the chloride 1 pocket plays a stabilising role. 
This suggests that the pocket elicits similar structural effects in the two domains yet does so 
via different interactions, as the R186H mutation does not convert C-domain activity to 
more N-domain like activity.  These assertions are all based on specific activity data reported 
here and by Rushworth et al (2008) and more definitive kinetic and structural data is needed 
to fully delineate the effects this pocket has on tACE activity.  More in-depth analysis 
regarding the roles of these residues is performed in chapter 5. 
3.3.2.2  Chloride Channel 
The presence of a channel that allowed access of chloride ions from the external milieu into 
the chloride 2 pocket of each ACE domain was proposed by Tzakos et al (2003).  They 
identified E403 in the C-domain as potentially acting as an ionic gate, blocking the channel 
via interaction with R522 and hence needing to be dislodged before chloride ions can access 
the chloride 2 pocket.  As shown in Figure 3.3A, this channel filled with a network of five 
hydrogen-bonded water molecules (764, 767, 720, 1124, 1150) is conserved in both the 
native and lisinopril-bound tACE crystal structures.  The K118 residue forms a salt bridge 
with E403 in the native structure of tACE, but not in the lisinopril-bound structure (Tzakos et 
al., 2003).  That this residue corresponds to an alanine (A94) in the N-domain suggests this 
may be of relevance due to the loss of interaction in the N-domain.  Central to this 
hypothesis is that the corresponding residue to E403 in the N-domain (R381) has the 
opposite charge and would presumably not block the channel.  This represents a potentially 
major cause of the variation in the chloride dependence profiles between the two domains. 
With the change from a Glu to an Arg in tACEg13sol_E403R mutant (hence referred to as 
E403R), 18- and 7-fold reductions in the Kd,app values were obtained with HHL and Z-FHL 
chloride titrations, respectively (Table 3.1).  This supports the idea that E403 is gating 
















Figure 3.3  Chloride channel of ACE.  A)  Stick representation showing tACE (PDB code 1o86) 
aligned to the N-domain structure (PDB code 2c6n), with residues at each position shown in 
green and light blue respectively.  Residue position and identity are shown below each, with the 
tACE numbering prior to that of the N-domain and the asterisk indicating that the residue identity 
is unchanged.  The critical active site zinc ion is shown as a  grey sphere, the chloride ion within 
Chloride pocket 2 shown as a numbered purple sphere and the hydrogen bond-linked waters that 
indicate the path of the proposed channel (described by Tzakos et al., 2003) shown as blue 
spheres.  The lisinopril (yellow) that was co-crystallised with tACE is shown in the active site 
coordinating the zinc ion.  Images were created using PyMOL 0.99 (DeLano Scientific, Palo Alto, 
CA, USA).  B) Bar graphs comparing the Kd,app values of tACEg13sol versus tACEg13sol_E403R 
(dark and light blue respectively) and N-domain D629 versus N-domain_R381E (dark and light 
green respectively) with both HHL and Z-FHL substrates (indicated on the left of the graphs). The 
residue identity at the 403 and 381 positions are indicated above the bars.  Data were 
reproduced from table 3.1 (with standard error between two means included, which are not 














that this effect is robust and reciprocal, a purified sample of N-domain_R381E mutant 
(where Arg381 has been converted to a Glu in the N-domain) was analysed.  As can be seen 
by the Kd,app values in Table 3.1, the reverse is seen with 29- and 15-fold increases for HHL 
and Z-FHL titrations, respectively,  clearly showing a reciprocal trend in both domains. This 
represents the first clear evidence of a gating mechanism in the ACE C-domain. 
The degree of activation by chloride (%SAmax) is represented by the increase in activity 
between SAmin, which is activity without NaCl, and the SAmax, which is the maximum activity 
obtained upon chloride titration. The %SAmax for both HHL and Z-FHL with the E403R 
mutation increased 2-fold over tACEg13sol (Table 3.1).  This is as a result more of an 
increase in SAmin than in SAmax, which had minor increases.  Interestingly, this trend is more 
pronounced in the Arg to Glu reversion between N-domain and R381E, where the %SAmax 
decreased by 10- and 15-fold for HHL and Z-FHL, respectively.  This effect was made more 
pronounced due to a more than 50% decrease in SAmax with both substrates.  This data is in 
accordance with the hypothesis put forward by Tzakos et al (2003) that E403 might form a 
salt bridge with R522 in the absence of chloride.  An Arg in this position would lack this salt 
bridge allowing for greater flexibility of the R522, which would allow Y523 to swing into the 
active site and thereby increase catalysis in the absence of chloride. 
Further insights can be gained by looking at the chloride titration curves for these four 
constructs (Figure 3.4A).   After initial activation of E403R and N-domain using HHL as 
substrate, there is a decrease in activity as the chloride concentration increases.  In contrast, 
both R381E and to a greater extent tACEg13sol show slower activation consistent with 
higher Kd,app values, but plateau at high chloride concentration.  A similar trend is only seen 
with the substrate Z-FHL for E403R, but it must be pointed out that the reduction in activity 
at high chloride concentration is seen for tACEg13sol and N-domain with Z-FHL in phosphate 
buffer (data not shown), but could not be ascertained here as Z-FHL was not soluble at high 
NaCl concentrations in the buffer used (TAPSO). Moiseeva et al (2005) attributed this 
phenomenon of activity reduction at high chloride concentration to an inhibitory role for 
chloride binding in the chloride 1 pocket based on kinetic modelling.  What is evident from 
the above analysis here is that an Arg in the 403/381 position appears to exaggerate this 















perturbation could to be transmitted by influencing the proposed hinging of the subdomains 
of tACE (Watermeyer et al., 2008), although how this would occur is unclear.  
 
Figure 3.4  Chloride channel of ACE.  A) Chloride titrated specific activity of tACEg13sol (dark 
blue), tACEg13sol_E403R (light blue), N-domain D629 (red) and N-domain_R381E (orange) with 
HHL and Z-FHL substrates. Each data point is the average of two independent determinations, 
each in triplicate, with error bars showing the standard error between averages. Graphs were 
generated in Graphpad Prism 5 software.  B) Stick representation of overlayed HHL (blue carbon 
atoms) and Z-FHL (yellow carbon atoms) docked into the tACE-RXPA380 crystal structure (Corradi 
et al., 2007; PDB code 2oc2) using the Accelrys Discovery Studio© Molecular Simulation program 
(described in 3.2.6). tACE residues are shown in green, with position and identity shown below 
each, the critical active site zinc ion is shown as a grey sphere, the chloride ion within Chloride  2 














A more likely scenario is that the effect is mediated by interactions with the substrate.  
Comparing HHL and Z-FHL and their potential interactions with ACE (Figure 3.4B), the 
hippuryl group of HHL only partially protrudes into the S2 pocket (where 403/381 is 
situated), whereas the Cbz group of Z-FHL is larger and occupies more of the S2 sub-site.  
The shorter E403 sidechain in tACEg13sol is less likely to have any interactions with HHL, 
and this is supported by the high Kd,app value where the “gate” would be fully closed.  This 
gating is presumably disrupted with Z-FHL hydrolysis in tACEg13sol, hence the Kd,app value 
being in a similar range to that of the N-domain hydrolysis of Z-FHL.  This gives credence to 
the idea that substrate interaction in the S2 pocket may play a role in mediating chloride 
access to the S2 pocket and opens up the possibility that substrate interactions may 
facilitate chloride 2 pocket binding. 
3.3.2.3  Chloride 2 pocket 
Mutagenic work by Liu et al (2001) identified the R522 (R1098 in somatic ACE) as being the 
critical residue in the coordination of the chloride ion, a fact that was confirmed in the 
crystal structures of both domains (Natesh et al., 2003; Corradi et al., 2006).  Despite this, 
the exact mechanisms of chloride activation remain poorly understood.  Tzakos et al (2003) 
have proposed a mechanism for the C-domain (tACE) where the R522 forms a salt bridge 
with D465 in the absence of NaCl.  Tyr523 is suggested to play a role in the stabilisation of 
the enzyme-substrate transition-state and is right next to R522 on the protein backbone 
(Sturrock et al., 2004). It is suggested that the R522-D465 salt bridge would keep Y523 
oriented away from the active site, and disruption of this interaction by chloride entering 
the pocket and coordinating R522 would push Y523 further into the active site, facilitating 
catalysis.  These residues are highly conserved in the N-domain, suggesting the overall 
mechanism is shared between the two domains.  The mutation of R522 to a glutamine or a 
lysine was originally described by Liu et al (2001) and evaluated for its effect on angiotensin 
I hydrolysis.  They reported a complete abolition of chloride dependence with the glutamine 
mutation and a considerable increase in the Kd,app for lysine, indicating that the charge and 
sidechain length is critical for coordination.  These mutations were repeated in tACEg13sol 
in order to further evaluate their role with HHL and Z-FHL, and to provide context for the 
















As can be seen in Table 3.1, the Kd,app values for R522Q and R522K are considerably higher 
than that for tACEg13sol with both HHL and Z-FHL, with the estimated values for R522Q 
being higher than those for R522K.  This is consistent with the data reported by Liu et al 
(2001) and supports the hypothesis that coordination is largely abolished by Gln in this 
position and greatly reduced by Lys.  The %SAmax values for both are also higher than 
tACEg13sol, indicating reduced activation upon chloride addition.  Interestingly the SAmin 
value for R522K with Z-FHL is very similar to tACEg13sol, yet for R522Q it is about 2-fold 
 
Figure 3.5  Chloride 2 pocket of ACE.   Stick representation showing tACE (PDB code 1o86) 
aligned to the N-domain crystal structure (PDB code 2c6n), with residues in the chloride 2 pocket 
shown in green and light blue, respectively.  Residue position and identity are shown below each, 
with the tACE numbering prior to that of the N-domain and the asterisk indicating that the 
residue identity is unchanged.  The critical active site zinc ion is shown as a  grey sphere, with the 
chloride ion in pocket 2 shown as  a purple sphere.  The lisinopril (yellow) that was co-crystallised 
with tACE is shown in the active site coordinating the zinc ion, with the 2 zinc coordinating 
histidines (H383 and H387) shown as black lines.  Images were created using PyMOL 0.99 














higher.  An explanation may be that the Lys in R522K may still be able to form a salt bridge 
with D465, unlike a Gln substitution, keeping it in a similar conformation as tACEg13sol. This 
would result in greater flexibility and an increased likelihood for Y523 to move towards the 
active site and increase catalysis.  This differs with HHL where both R522K and R522Q have 
only slightly higher SAmin levels than tACEg13sol.  Also of note is that the %SAmax for R522Q 
with Z-FHL is higher than that with HHL, and at 74% is very much in line with the values 
described for angiotensin I (Liu et al., 2001). This suggests that R522K may be more 
rotationally restricted than R522Q (presumably due to a salt bridge with D465), potentially 
explaining the difference between the two mutations. 
In order to determine whether D465 participates in a salt bridge with R522, a 
tACEg13sol_D465T mutant (referred to as D465T) was generated, where the polar acidic 
D465 (conserved as D443 in N-domain) was converted to the smaller polar uncharged 
threonine in order to prevent salt bridge formation.  What is immediately apparent is that 
the Kd,app with HHL for D465T is 4-fold lower than tACEg13sol, yet for Z-FHL, the Kd,app is only 
marginally higher than both tACEg13sol and N-domain.  That an appreciable change in Kd,app 
is seen with one substrate versus the other would indicate that D465 is not mechanistically 
important.  Further variation between HHL and Z-FHL is seen with the %SAmax values for 
D465T which are about 4-fold and 15-fold lower than tACEg13sol respectively, which is due 
to the combined lowering of SAmin and SAmax values to varying degrees (Table 3.1).  The 
D465 residue is situated on the opposite side of the chloride pocket to the active site, which 
precludes direct interactions with substrate (Figure 3.5).  The variability in %SAmax values 
seen for D465T between HHL and Z-FHL may be due to the mutation somehow inducing a 
structural alteration of either the chloride 2 pocket or the active site sub-site structure.  This 
would indicate a structural role for D465 over the proposed mechanistic role suggested by 
Tzakos et al (2003).  
The tACEg13sol_M223W and tACEg13sol_V518T mutations were constructed based on the 
fact that the residues lined the chloride 2 pocket and were variable between the C- and N-
domains.  The Kd,app values for both HHL and Z-FHL with these mutations showed no change 














Some minor effects on overall activity were observed suggesting other interactions may be 
affected.  M223W showed reductions in both SAmin and SAmax for both HHL and Z-FHL with 
its effects presumably due to the bulky tryptophan residue results in a differential 
interaction affecting the overall structure of the chloride 2 pocket.  Indeed, the SAmax values 
for both HHL and Z-FHL with M223W more closely resemble those of the N-domain and this 
may represent a determinant in the variation in overall levels of activity between the two 
domains.   
For V518T, the SAmax values are seen to be marginally elevated for both HHL yet more 
pronounced for Z-FHL relative to those of tACEg13sol.  The Val to Thr mutation changes the 
nature of the side-chain from hydrophobic to polar uncharged without any major change in 
size, yet this has a large effect on Z-FHL hydrolysis. The V518 residue borders the chloride 2 
pocket and active site S1 binding pocket, and molecular minimisation studies show that it is 
in close proximity to the Z-FHL Phe in the P1 position.  Presumably, the Thr mutation 
removes a hydrophobic interaction between the V518 and substrate Phe, resulting in 
increased catalysis in the presence of chloride.   
Where the R522K and R522Q mutations showed significant effects on chloride dependence 
and activation, the M223W, D465T and V518T mutations effects were relatively minor, 
indicating they were not mechanistically relevant but may be the result of minor structural 
effects.   
3.4  Summary 
All active-site mutant proteins were successfully transfected, expressed and purified. 
Constructs were analysed using chloride titrated activity with substrates HHL, which has 
been shown to be C-domain selective and more chloride dependent than N-domain, and Z-
FHL, which is less domain selective and has a similar chloride binding profile between both 
domains.  The R186H mutation in the chloride 1 pocket showed increases in overall activity 
and Kd,app values for both substrates, suggesting that the effect of replacing the aliphatic 
chain and guanidinium group of Arg with a an imidazole may be more structural than 
mechanistic.  The E403R and R381E mutations provided clear evidence for a gating 














suggested that substrate interaction in the S2 pocket may disrupt this gating mechanism, 
providing a potential explanation for the differences in chloride dependence with different 
substrates.  The D465T mutation showed some effect on activity and chloride binding, yet 
this was variable between HHL and Z-FHL indicating that its role is unlikely to be mechanistic 
and more likely a structural.   The R522Q and R522K showed similar profiles for HHL and Z-
FHL to that described by Liu et al (2001) using angiotensin I, with the difference between the 
mutations with the different substrates highlighting the role of substrate interactions.  The 
M223W and V518T mutants did not show major deviations from wildtype, particularly in 
their Kd,app values, and hence it is presumed they would not be mechanistically important.  
Taken together, most mutations in the relevant chloride pockets were shown to affect 
activation to varying degrees, yet only those varying in their Kd,app values and hence having 














Chapter 4:  Isothermal Titration 
Calorimetry as a method for 











































4.1  Introduction 
Evaluation of ACE enzyme kinetic constants has traditionally been limited to a few specific 
methods of detection, dependent on the nature of the substrate used.  For enzyme kinetic 
measurements to be made, it is required that there be some observable event associated 
with the transformation of substrate into product.  For ACE kinetics all the methods 
described in the literature employ some way of evaluating product concentrations and are 
based on the pseudo-first order method originally described by Michaelis & Menten (1913), 
which is used predominately in enzyme kinetic evaluation throughout the literature.   
The physiological substrates, such as angiotensin I and bradykinin, have predominantly had 
product formation determined by High Performance Liquid Chromatography (HPLC) (Rice et 
al., 2004; Liu et al., 2001; Jaspard et al., 1993; Wei et al., 1991b).  Whilst HPLC has proved 
suitable over the years, it is limited in its capacity for extensive and efficient kinetic 
evaluation of multiple constructs. 
Monitoring of reaction progression of smaller synthetic peptides has usually been done 
either via HPLC, spectrophotometrically, or, as described by Friedlander & Silverstein (1976), 
fluorometrically via a coupled derivitization step for HHL and Z-FHL.  More recently, the 
advent of Fluorescence Resonance Energy Transfer (FRET) technology has allowed for the 
synthesis of modified peptides that fluoresce upon cleavage, making kinetic evaluation 
more efficient.  While FRET is suitable for shorter peptides, and has been applied to 
evaluating the kinetics of the tetrapeptide substrate AcSDKP (Araujo et al., 1999, Araujo et 
al., 2000), the technology is not applicable to the larger physiological peptides such as 
angiotensin I and bradykinin.  The use of FRET also has the disadvantage that the substrate 
needs to be covalently modified via the addition of fluorescence acceptor and donor groups, 
which is not always ideal when looking at specific enzyme/substrate interactions.  In recent 
years, the use of Isothermal Titration Calorimetry (ITC) to evaluate enzyme kinetics has 
started to become more widespread and presents an option in kinetics evaluation of ACE 
activity towards a wide range of substrates. 
ITC is a powerful, well-established technique for the thermodynamic determination of 
equilibrium binding/association reactions.  A single titration experiment directly measures 














the equilibrium binding constant (Kb) and stoichiometry of binding (n) (Wiseman et al., 1989; 
Ladbury, 1995; Haq et al., 2000/1).  The broad applicability of this technique, where no 
specific assay development is required, and the commercial availability of high-sensitivity 
ITC equipment, has led to a dramatic increase in publications utilizing ITC to investigate 
molecular interactions over the last decade (Haq, 2005 Microcal application notes).   
Apart from its more extensive application towards reversible association interactions, ITC 
has also been evaluated and successfully applied to the observation of enzyme kinetic 
reactions (Spink & Wadso, 1976; Watt, 1990; Morin & Freire, 1991; Williams & Toone, 1993; 
Lonhienne et al., 2000; Todd et al., 2001).  ITC serves as a direct and observable means of 
monitoring an enzyme catalysed reaction, as the heat absorbed or released by an enzyme 
reaction as it proceeds over time (thermal power) is directly proportional to the rate of the 
reaction (Todd et al., 2001).  The primary method for obtaining enzyme rate parameters is 
where multiple injections of substrate are made into the reaction cell containing low 
enzyme concentration, resulting in multiple steady-state rate determinations in a single 
reaction volume.  The alternative, less commonly used method involves a single injection of 
substrate (at concentrations greater than Km) into enzyme (or vice versa) followed by 
continuous rate measurements as substrate conversion to product runs to completion.  
Both of these methods yield rate data as a function of substrate concentration, which is 
readily analysed via non-linear regression using the integrated form of the Michaelis-
Menten equation or a derivative thereof.   
The two previous methods described represent two different strategies in determining 
Michaelis-Menten kinetics.  The Multiple Injection Method represents a steady-state system 
where initial rates are determined at varying substrate concentrations, a method used 
widely for enzymes that obey the traditional Michaelis–Menten mechanism.  The Single 
Injection Method represents a non-steady-state system where substrate depletion is 
tracked over time, with rate and substrate concentrations calculated, plotted and fitted to 
the Michaelis-Menten equation.  The drawback of both of these methods is that they do not 
directly measure the initial rates, but use the determination of product formation or 
substrate depletion to approximate initial rates and hence calculate the Michaelis constant 
(Km) and catalytic rate (kcat) using the Michaelis-Menten equation (Golicnik 2010).  Schnell & 














which the measurement of initial rates are valid and can be applied to the Michaelis-
Menten equation, questioning the accuracy of this approach.  In this regard, any errors in 
the determination of rates can have a compounding effect on the calculation of Km and kcat, 
and hence a larger effect on kcat/Km. 
The initial rate of a reaction can be (as is routinely done in the literature) determined using a 
progress curve, which is a plot of product formation over time.  The initial rate is calculated 
using linear regression from the origin through the initial 10% of the curve (Eisenthal, 1992).  
Indeed, this method has been applied to ITC by Stockbridge & Wolfenden (2009, 2011).  
However, using this linear approach has drawbacks, the most notable being that the initial 
part of the curve may not be completely linear around or below Km (Golicnik 2010).  This not 
only makes linear fitting prone to error, but places severe limitations on usable substrate 
concentrations.  Furthermore, this method provides no way of devolving kcat/Km into the 
separate kcat and Km constants in a single experiment, and would require separate 
determination of either for all constants to be unveiled.  Fortunately, in recent years 
progress has been made in developing non-linear regression analysis methods to fully utilize 
the progress curve in determining Michaelis-Menten constants (Schnell & Mendoza 1997; 
Goudar et al., 1999; Goudar et al., 2004; summarized by Golicnik, 2010).  These attempts 
had always been hampered due to the computational complexity involved in solving the 
Lambert W function, an integral component of the formulae. Only recently, with the advent 
of commercial non-linear regression software (such as Excel, Prism, SigmaPlot) could 
progress curve data be fitted to explicit formulae containing this function.  This approach 
was pioneered by Duggleby (2001), and has since been refined by Golicnik (2010, 2011), 
who presents a robust formulation in the analysis of progress curve data.  Combining this 
approach with the method of ITC data transformation put forward by Stockbridge & 
Wolfenden (2009) provides a viable approach to determine Michaelis-Menten kinetic 
parameters with a high throughput for potentially any substrate. 
The aim of the work presented here was to evaluate the feasibility of applying the ITC-based 
enzyme kinetic methods to the study of ACE using a short synthetic peptide (HHL) and a 
larger physiological peptide (Angiotensin I).  The work presented many challenges and 
highlighted the limitations of the above methodology in evaluating a more complex enzyme 














not have been identified by alternate methods.  Furthermore, we present a robust 
methodology that circumvents many of the limitations of the common methods and allows 
for accurate and reproducible determination of enzyme reaction rate constants. 
Objectives: 
1. Determine whether the hydrolysis reactions between tACEg13sol and its substrates 
HHL and angiotensin I produce detectable changes in thermal power and ascertain 
the role buffer choice plays in this. 
2. Evaluate the suitability of the Multiple and Single Injection Methods for the study of 
tACEg13sol enzyme kinetics. 
3. Determine whether the use of Progress curves and the non-linear regression analysis 
of these curves correlate with either method in objective 2. 
4. Evaluate the effect that different buffers have on the kinetic parameters of 
tACEg13sol hydrolysis of HHL and Angiotensin I 
5. Determine the optimal assay approach for the study of chloride dependence 
mutants generated in Chapter 3. 
 
4.2  Methods and Experimental Approach 
 
4.2.1  Chemicals and Equipment 
All ITC experiments were performed using an iTC200 microcalorimeter purchased from 
MicroCal LLC (GE Healthcare), with raw data either extracted for custom calculations using 
Microsoft Excel or analysed using Origin 7 software with proprietary MicroCal analysis 
module.  All enzyme samples used were purified as described in Chapter 3.  HHL, HL, 
angiotensin I, angiotensin II, HEPES, TES and TAPSO were obtained from Sigma.  TRIS, NaCl, 
KH2PO4 and K2HPO4 were obtained from Merck. Sephadex® G-10 Medium was obtained 
from Sigma-Aldrich. Custom data manipulation and calculations were performed in 














4.2.2  Sample Preparation 
Preparation of enzyme and substrate samples needs to be done to ensure that there is 
minimal mismatch in buffer concentrations as this can have a negative effect on data 
quality.  Enzyme samples were equilibrated by dialysing 3- times against 500ml of reaction 
buffer (50-100mM buffer, pH 7.5; 10uM ZnSO4; either 0mM, 20mM or 300mM NaCl).  
Substrate was prepared by either dissolution directly into dialysate, to desired 
concentration (for HHL), or by equilibrating against a 1ml G10 Sephadex desalting column 
(for Angiotensin I).  The purchased angiotensin I powder contained appreciable amounts of 
Trifluoroacetate (TFA), which, when dissolved directly in dialysate, resulted in significant 
decrease in signal-to-noise ratio.  Angiotensin I was dissolved in dialysate at high 
concentration then passed through a 1ml G10 column (equilibrated with dialysate in order 
to reduce TFA concentrations) under gravity.  200µl fractions were collected and tyrosine 
absorbance measured at 275nm to determine peptide containing fractions.  These were 
pooled and the final concentration determined spectrophotometrically via absorbance at 
275nm, using the empirically calculated extinction coefficient of 1280 M-1.cm-1. 
4.2.3  Calorimetric Assays 
Calorimetric assays were performed using an iTC200 microcalorimeter, which consists of a 
sample cell and a reference cell (filled with either dH2O or reaction buffer) held at constant 
temperature.  An automated stirring syringe is inserted into the sample cell and serves as 
the configurable titration vehicle, as well as a means of ensuring rapid mixing of reaction 
volume.  Reaction cells (0.2027 mL) were filled with degassed solutions and equilibrated at 
the indicated temperatures, with stirring speed being 500 rpm. The exact power-
compensation mechanisms of the instrument are summarized by Todd et al., (2001).  
Addition of either substrate, inhibitor or enzyme to the sample cell through the stirred 
injection syringe initiates the reaction, which, if exothermic will result in a negative 
deflection in observed thermal power or, if endothermic, will give a positive deflection in 
observed thermal power (Todd et al., 2001).  Reaction rates are determined by measuring 
this change in instrumental thermal power. 
4.2.4  Calorimetric Rate Equations 
The following descriptions of the theoretical underpinnings for measuring enzyme kinetic 














Toone, 1993; Todd & Gomez, 2001).  An enzyme-catalysed reaction is driven by a 
thermodynamically favourable decrease in free energy (ΔG), which is the combination of its 
entropy (ΔS) and enthalpy (ΔH), and is summarised in the formula: 
           
 [1] 
The enthalpic component (ΔH) represents the amount of heat absorbed or released by the 
reaction.  Thus, measuring the rate of heat generation associated with the conversion of 
substrate to product gives a measure of the reaction rate. 
 
In order for reaction rates to be determined, the apparent molar enthalpy (ΔHapp) needs to 
be determined experimentally.  This is done by allowing a given reaction to run to 
completion with thermal power returning to the original baseline.  Integration of the area 
under this curve (minus the heat of dilution obtained via control experiments) gives the 
experimental ΔHapp : 
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[2] 
Here [S]Total is the total substrate concentration, V is the volume of the reaction cell (µL) and 
dQ/dt represents the thermal power output of the calorimeter as a function of time (µcal/s). 
This experimentally determined ΔHapp is the amount of heat associated with the conversion 
of n moles of substrate, and it’s relation to product formation is given by the following 
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[3] 
where V is the reaction cell volume, [P]Total is the molar concentration of product generated. 
It can be seen from Equation 3 that measuring the thermal power as substrate is catalysed 
by enzyme, gives a measure of reaction rate: 
 





















where d[P]/dt is the rate of product formation.  Rearranging, we get: 
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There are two methods by which assays can be performed using the titration calorimeter 
and where this rate equation can be applied in the determination of Michaelis-Menten 
kinetic constants. 
4.2.4.1  Multiple Injection Method (Pseudo-First Order kinetics) 
Here, multiple injections of substrate solution are injected from the syringe into the reaction 
cell containing enzyme solution.  Time is allowed subsequent to each injection for heat of 
dilution to dissipate and for the instrument to equilibrate to a new power level due to the 
increased substrate concentration.  This change in power level after each injection 
corresponds to the heat released/absorbed by the reaction at that concentration of 
substrate.  The aim here is to ensure that no more than 5% of substrate is depleted prior to 
the next injection so as to ensure that steady-state conditions are maintained.  This is done 
by having as low an enzyme concentration as possible (whilst maintaining adequate signal) 
and having as short a time between injections as possible, so that excessive substrate 
depletion is avoided.  Thus, at each injection point the rate and substrate concentration is 
determined: the change in thermal power (dQ/dt) is converted to a rate value using formula 
5 and the experimentally determined ΔHapp, and the substrate concentration is calculated 
with adjustments for dilution into the reaction cell taken into account.  Data are plotted as 
Rate vs [S] and fitted to the Michaelis-Menten equation 
 ate  
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[6] 
using non-linear regression analysis (see Figure 4.2 B), where kcat is the catalytic rate 
constant for substrate decomposition, KM is the Michaelis constant, [E]tot is the total enzyme 















4.2.4.2  Single Injection Method (Continuous Kinetics) 
An alternate assay strategy for determining kinetic rate constants involves continuous rate 
measurements following a single injection of substrate into enzyme contained within the 
reaction cell, or vice versa, so long as the substrate concentration in the reaction cell is 
greater than 5X KM.  Immediately after injection, substrate concentration is at a maximum 
which results in a large shift in instrumental thermal power away from established baseline 
(either exothermic or endothermic).  Here, the thermal power remains constant because 
the reaction is occurring at maximal velocity (Vmax).  As substrate is depleted, the rate 
decreases and the instrumental thermal power returns to the initial baseline, the point at 
which substrate has been completely depleted.  At any specific time point, the rate is 
determined from the thermal power (using equation 5) and the remaining substrate 
concentration from the integral of the heat evolved using: 
[ ]     [ ]      [ ]     [ ]       
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[7] 
The rate plotted as a function of the substrate concentration generates a continuous kinetic 
curve which can be fitted to equation 6 via non-linear regression analysis to yield kinetic 
parameters.  All of these calculations are done automatically in an Origin 7 software add-on 
supplied with the iTC200 instrument.  Rate and substrate concentration values were 
removed and analysed using non-linear regression analysis in GraphPad Prism 5, which 
allowed for greater flexibility of data manipulation and variety in fitting functions. 
4.2.5  Progress Curve Kinetics  
Similar to the Single Injection Method (4.2.4.2), the assay setup for the titration calorimeter 
involves a single injection of substrate into enzyme, or enzyme into substrate, and the 
continuous monitoring of thermal power as substrate is catalysed to completion.  
Stockbridge & Wolfenden (2009) describe a means of converting this thermal power into a 
reaction curve of product formed over time.  Given that heat released or absorbed by the 
enzyme reaction is directly proportional to the amount of substrate hydrolysed, the amount 
of product formed over time can be calculated and a progress curve generated.  Integration 














the substrate.  Integrating the area between substrate injection (t=0) and each time point 
(t), and then dividing by the total integrated area, gives a percentage of the product formed 
at time (t). Multiplying this fraction at each time point by the total substrate concentration 
at t=0 (S0) relates it to molar concentration.  The formula describing this relationship is 
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with the resultant progress curve being a plot of P(t) (product formed) versus t (time). 
Where this methodology deviates from that of Stockbridge & Wolfenden (2009) is in the 
starting concentration used, where they use amounts approximately 5-10X below KM.  The 
reasoning for this was that, because they were using the linear approximation method to 
calculate initial rates (alluded to in 4.1), more of the progress curve represented initial rate, 
hence allowing for a more accurate estimation.  However, the non-linear regression analysis 
functions put forward by Golicnik (2010, 2011) are not bound by these constraints, which 
allowed for the use of initial substrate concentrations above or below KM allowing greater 
flexibility in experimental design.  
Progress curves were generated and analysed according to functions described by Golicnik 
(2010).  The temporal closed-form solution of the Michaelis-Menten equation used is given 
by 
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where W is the Lambert W (x) function (Corless et al., 1996).  Golicnik (2010) evaluated a 
number of approximations of W and found one version that produced an acceptably low 




















    





  (  (
  
 







       {
    
          
} 
[10] 
where ε = 0.4586887.  Progress curves were generated in Microsoft Excel using Equation 8 
and analysed using the combined Equations 9 & 10, which were written into Graphpad 
Prism 5 software according to instructions provided by Golicnik (2010) Supplementary Data. 
4.2.6  ITC binding curves 
Samples were prepared as per 4.2.1 and experiments performed at 20°C as described in 
4.2.3, with enzyme in the reaction cell and inhibitor (lisinopril) in the syringe.  
Concentrations of enzyme used were in the range of 6-15µM, whilst concentrations of 
lisinopril in the syringe (60-150 µM) were maintained at approximately 10-12X the enzyme 
concentration for each experiment in order to ensure the correct range for lisinopril (which 
has an established 1:1 binding stoichiometry). All experiments in this chapter were 
performed in either Tris buffer (100mM) or TAPSO (50mM), both at pH 7.5, and either 0mM, 
20mM or 300mM NaCl.  The enzyme solution in the cell was titrated via a series of 24 
consecutive 1.5µL injections with 240 second intervals. Dilution heat experiments were 
initially performed (as per MicroCal experimental procedures), but were found to produce 
negligible heat effects and were thus deemed unnecessary.  Integration of the raw 
thermogram peaks using Equation 2 (described in 4.2.4, with inhibitor concentration being 
substituted for substrate concentration in this case) yields the final ΔHapp for each injection, 
which is then plotted against the molar ratio after each injection.  These binding isotherms 
were subjected to non-linear regression fitting using the following equation: 
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where Q is the total heat evolved, n is the number of binding sites, V0 is the total cell 
volume, [E]tot is the total enzyme concentration in V0, ΔHapp is the change in enthalpy upon 
binding, It is the total concentration of inhibitor and K is the binding constant.  Experimental 
data was analysed using Origin7 software with iTC200 analysis module (MicroCal).   
4.2.7  HPLC of angiotensin I hydrolysis products 
HPLC was performed using a Sephadex® C18 Jupiter column.  Reaction samples were 
removed from the reaction cell after ITC ΔHapp determination, where hydrolysis had run to 
 
Figure 4.1  Raw vs Transformed data for calorimetric titration of tACEg13sol with lisinopril.   
Upper panel shows the raw calorimetric output of 24 consecutive injections of lisinopril into the 
reaction cell containing tACEg13sol.  Lower panel shows the integrated heat (black squares) 
evolved per mole of lisinopril upon binding as a function of the molar ratio.  The solid line 
through the points represents the line of best fit after nonlinear regression analysis using 
Equation 11 in Origin 7. Enthalpy of the reaction (ΔH) is the maximum heat evolved by the 
binding reaction and is indicated by the amplitude of the sigmoidal curve (double arrow). The 
stoichiometry of binding, N, is equal to the fraction of active protein and corresponds to the 
molar ratio at the inflection point of the curve where a ratio of 1.0 corresponds to 100% 














completion, and kept @ 4°C.  Sample was separated by HPLC over a 0-75% ACN gradient in 
0.1% TFA.  Sample runs were compared to pure substrate and products (Angiotensin II and 
L-Histidyl-L-Leucine (HL)) in order to confirm peak identity. Absorbance was read at λ   
215nm to detect peptide bond absorbance and λ   275nm to detect the absorbance of the 
tyrosine contained within Angiotensin I and Angiotensin II, but not HL. 
4.3  Results & Discussion 
4.3.1  Determination of Molar Enthalpy of Reaction 
Given that no prior work has been published for enzyme hydrolysis reactions for ACE using 
ITC, it was necessary to do an initial assessment of the molar enthalpies of reaction (ΔHapp) 
in different buffers.  This was done primarily to determine whether the total heats evolved 
were high enough for further study. A secondary aspect is that the ΔHapp can vary if the 
reaction involves the uptake or release of protons from the surrounding aqueous 
environment (Eftink et al., 1981).  The ΔHapp is made up of the intrinsic molar enthalpy of 
the reaction (ΔHint) and an enthalpy of ionisation of the buffer (ΔHion) dependent on the 
number of protons taken up or released (nH), as described by the formula ΔHapp = ΔHint + 
nH ΔHion (Haq 2005).  Whilst the proposed mechanism of action for ACE catalysis (Sturrock et 
al., 2001; Matthews, 1988) doesn’t specifically indicate a mechanistic proton transfer, there 
is no clear evidence for or against and we sought to verify this.   
In order to address these goals, we determined the ΔHapp (as described in 4.2.4 using 
equation 2, see Figure 4.2) for tACEg13sol with two substrates (HHL and Angiotensin I) using 
a variety of buffers.  A linear plot of ΔHapp versus the ΔHion for each buffer (Figure 4.3A) gives 
the nH (slope of the linear fit) and the ΔHint (y-intercept at x=0).  As can be seen, there does 
appear to be a variation in ΔHapp with varying ΔHion for both substrates assessed.  The 
positive  ΔHint  values for both reactions indicates an endothermically driven process, where 
breaking of the peptide bond contributes 2-5 kcal/mol to the energy of stabilisation in the 
protein.  The difference in ΔHint between the two substrates is about 1 kcal.mol
-1 and is 
probably due to a greater number of interactions of the larger decapeptide Angiotensin I 
over the short tripeptide HHL, which gives off more heat (exothermic) and is hence more 















that protons are released during the hydrolysis reaction (Todd et al., 2001; Bianconi, 2003).  
A discrepancy in this data is that the nH values of -0.37 for both substrates are not integers, 
where a value of 1 would represent a single proton exchange.  If the mechanism of ACE 
hydrolysis is assumed to be the same as that proposed by Matthews (1988), then the proton 
release must be attributed to some other mechanism.  One suggestion would be that, upon 
hydrolysis, a subset of one or more charged amino acids may change their protonation 
state.  The imidazole groups of histidines are known to be sensitive to their 
microenvironments, and with a pKa value near 6 may be responsible.  What is evident is 
that this is consistent between substrates and should presumably be attributable to the  
 
Figure 4.2  Representative data for the determination of apparent molar enthalpy (ΔHapp).  Raw 
calorimetric output (solid black line) with thermal power P (µcal/sec) on the Y-axis and Time (sec) 
on the X-axis. Two separate experiments are performed as described in 4.2.4 with the resultant 
peaks overlayed: 1) The larger peaks (white fill) are the result of injecting substrate into an 
enzyme solution of high concentration and allowing all substrate to be hydrolysed, with 
integration and calculation of molar enthalpy resulting in ΔHobserved.  2) The smaller peaks (grey 
fill) are the result of injecting substrate into buffer containing no enzyme, which accounts for the 
enthalpy associated with dilution of the substrate, with integration and calculation of molar 
enthalpy resulting in ΔHdilution   The ΔHapp is determined by subtracting the ΔHdilution from the 
















Figure 4.3  Determination of reaction molar enthalpies.  A) The molar enthalpies of reaction 
(ΔHapp) for tACEg13sol with HHL and Angiotensin I were determined as described in 4.2.4 (Eqn 2). 
Samples were prepared as described in 4.2.1.  Successive injections (between 6 and 12µl in 
volume) of either HHL (10mM) or Angiotensin I (1-1.5mM) into the reaction cell with 
concentrations of tACEg13sol between 0.8 and 1.2µM were performed. All reactions were at 
37°C, in 100mM of buffer (pH 7.5), 10uM ZnSO4 with either 20mM NaCl (for AngI) or 300mM NaCl 
(for HHL).  Buffers include phosphate (ΔHion =1.22 kcal/mol), Maleate (ΔHion = -0.86 kcal/mol), 
Hepes (ΔHion = 4.89kcal/mol), TAPSO (ΔHion = 9.37 kcal/mol), and Tris (ΔHion = 11.37 kcal/mol). The 
ΔHion values for these buffers were taken from Goldberg et al (2002).  The graph shows a plot of 
the determined ΔHapp values against their ΔHion energies for each buffer, analysed via linear 
regression with those values for AngI in red and those for HHL in blue.  The ΔHint for each 
substrate corresponds to the Y-intercept of the linear fit, with the slope reflecting nH and these 
values tabulated alongside the graph. B) Samples were subjected to HPLC as described in 4.2.7.  
Panel 1 shows the raw data for a control of pure samples of Angiotensin I and Angiotensin II, 
which were combined, and ran at 17 16’ and 16 5’ respectively.  Panel 2 shows the raw data for 
an Angiotensin I hydrolysis sample which was removed from the ITC reaction cell after ΔHapp 
determination.  Angiotensin II and HL, the products of Angiotensin I cleavage, are seen running at 
16 5’ and `11’ respectively   Panel 3 shows the raw data for the same hydrolysis product shown in 
panel 2 but spiked with Angiotensin I.  Here, we see pea s at ~11’, 16 5’ and 17 16’, 














general catalytic mechanism.  Whilst this data provides some interesting leads, the primary 
goal was to assess which buffer system, if ΔHapp was variable, would evolve the largest heat 
and hence be suitable for further investigation of ACE catalysis.  For this purpose Tris buffer 
was chosen, as it gave the largest signal with AngI and, whilst not the largest for HHL, was 
sufficiently large so that we could maintain consistency and use it for both substrates. 
As an added measure to ensure that the ΔHapp values were accurate, immediately after the 
thermal signal had returned to baseline, representative samples were removed from 
reaction cells and subjected to HPLC in order to assess whether the reaction had gone to 
completion (Figure 4.3B).  Panel 2 shows that there is no Angiotensin I present, with only 
the products of cleavage (Angiotensin II and the HL dipeptide) visible.  Appropriate controls 
were performed (Panels 1 and 3) to verify that the peaks observed were identified correctly.  
This served to confirm that the reactions were running to completion and that the ΔHapp 
values determined were representative of the reaction being studied. 
4.3.2  Multiple Injection Method 
This experimental approach (outlined in 4.2.4.1) was first described by Todd et al., (2001) 
and is the most widely used method in the literature for the determination of the Michaelis-
Menten constants Km and kcat.  Like the pseudo-first order method described by Michaelis & 
Menten (1913), determination of the initial reaction rates at varying substrate 
concentrations allows for calculation of these constants via non-linear regression analysis.  
Where it differs from normal experimental setups is that the whole experiment happens in 
one reaction volume and substrate concentration is increased by consecutive injections into 
a cell containing low amount of enzyme.   
Initially this method was evaluated for its feasibility in determining the rate constants for 
tACEg13sol using Angiotensin I and HHL (representative data in Figure 4.4).  In assessing 
this, it is important for the reaction to produce sufficient change in thermal power (dQ/dt) 
and it was advised that the thermal power at Vmax should be no lower than 0.2µcal/sec 
[personal correspondence Dr Luminita Damian (MicroCal, GE Healthcare)].  This was in order 
to maintain a signal-to-noise ratio greater than 100:1 and stay within the instruments 
detection limits.  As can be seen in Figure 4.5A, where the thermal power (dQ/dt) obtained 















concentration (S), this requirement was achieved.  Conversion of the thermal power to the 
rate of product formation (using equation 5) and fitting to the Michaelis-Menten equation 
via non-linear regression gave rate constants very similar to those obtained in our 
laboratory using a fluorescence-based assay (data not shown).  However, when the same 
approach was attempted with a similar concentration of tACEg13sol (90nM) using 
Angiotensin I as the substrate, the thermal power never exceeded the 0.2µcal/sec minimum 
cut-off (Figure 4.5B).  The expected kcat for this reaction was around 10-34 .s
-1 (Rice et al., 
2004; Rousseau-Plasse, 1996), which is fairly comparable to other proteases described by 
Todd et al., (2001). Given that the Vmax, and hence thermal power change, is enzyme 
concentration dependent, we looked to determine whether Vmax could be increased without 
breaking pseudo-first order requirements.  As evident in Figure 4.7B, using higher enzyme 
concentrations did not result in a proportional increase in Vmax, suggesting that substrate 
hydrolysis exceeded 5% at greater than 90nM of enzyme.  The ΔHapp values for HHL and AngI 
in Tris buffer differ by only ~1 kcal/mol (see 4.3.1), yet the kcat values are approximately 10- 
 
Figure 4.4  Representative data for the Multiple Injection Method.  Methodology is described in 
4.2.4.1.  A)  Raw calorimetric ouput (solid black line) with thermal power P (ucal/sec) on the Y-
axis and Time (sec) on the X-axis.  Extrapolation of baseline re-equilibration prior to subsequent 
injection (dotted lines) shows the change in baseline thermal power as a function of time (dQ/dt).  
Peaks represent dilution heats associated with injection of substrate into enzyme.   B)  The 
resultant rate versus substrate data (solid black circles), which were calculated from raw data, is 















fold higher for HHL (based on values for both as reported by Wei et al., 1991b) suggesting 
that the difference in molar enthalpies of reaction is not the problem.  It appears that the 
magnitude of the ΔHapp values for HHL and AngI in Tris buffer (-1.83 and -2.62 kcal/mol 
respectively) puts a lower limit on the determinable kcat values.  This is indirectly supported 
by review of the literature, where very few reactions reported have ΔHapp values less than 7-
10 kcal/mol, which is considerably higher than those for tACEg13sol.  This suggests that this 
is a fundamental limit of this method and, given that activity is expected to drop 
considerably when these reactions are performed in the absence of chloride (Liu et al., 
2001, Wei et al., 1991b), it is clearly not viable for further study of tACEg13sol reactions. 
4.3.3  Single Injection Method 
The Single Injection Method was then assessed for its feasibility in determining tACEg13sol 
kinetics using HHL and AngI.  Krokeide et al (2007) reported the use of this method for a 
chitinase hydrolysis reaction with a ΔHapp (-0.55 kcal/mol), which is lower than that of AngI 
with tACEg13sol in Tris buffer, and a comparable kcat (40.9 .sec
-1).  Given that this method 
(described in 4.2.4.2, representative data shown in Figure 4.6) continuously monitors 
substrate depletion, and doesn’t rely on pseudo-first order conditions where total substrate 
hydrolysis needs to be kept below 5% at each point, the thermal power change at Vmax  
 
Figure 4.5  Thermal power limitations for Angiotensin I using the Multiple Injection Method. 
The change in raw thermal power (dQ/dt) associated with the change in substrate concentration 
(S) after each injection are shown for the reaction between tACEg13sol and HHL (A) and AngI (B) 
in 20mM NaCl, 100mM Tris(Acetate) buffer (pH 7.5), 10uM ZnSO4.  Varying concentrations of 
tACEg13sol were used and are indicated by the key on the right of each graph.  The straight line 
corresponding to 0.2 µcal/sec indicates the minimum thermal change required for a greater than 















should be proportionally higher for the same enzyme concentration.  One of the parameters 
when designing these experiments is the initial substrate concentration (Si) that is loaded 
into the reaction cell (where S0 is the substrate concentration at t=0 which is adjusted for 
dilution by enzyme addition; in all cases S0 is 5-10% lower than Si). The Si concentration 
needs to be in the range of 5-10X Km so that a steady state can be established at Vmax before 
excessive hydrolysis takes place. Based on values reported by Gordon et al (2003) for the 
identical construct, the expected Km for this reaction should be around 2.7mM.  A 
consideration here is the fact that HHL is not very soluble above 5mM and it was established 
that the highest soluble concentration was 10mM, lower than the 13.5mM necessary for the 
Si to be above 5X Km.  High substrate concentrations resulted in substrate inhibition using 
the Multiple Injection Method (data not shown), a trend reported in the literature (Baudin 
et al., 1999). Thus, a range of Si concentrations was explored in order to determine whether 
this variable plays a factor in the resultant kinetic constants.  Figure 4.7A shows the raw 
calorimetric traces of the complete hydrolysis of four different HHL Si concentrations with 
the same concentration of tACEg13sol.  As expected, the time taken for complete hydrolysis  
 
Figure 4.6  Representative data for the Single Injection Method. Methodology is described in 
4.2.4.2.  A)  Continuous raw calorimetric output (solid black line) with thermal power P (ucal/sec) 
on the Y-axis and Time (sec) on the X-axis. B)  The resultant rate versus substrate data 
(continuous thick black line), which was calculated from raw data, is fitted to the Michaelis-
Menten formula using non-linear regression analysis (thin white line line, which is aligned exactly 















to occur increased proportionally with increased Si concentration, with the magnitude of the 
thermal peak (which is proportion to rate) only decreasing slightly with increased Si 
concentration.  These curves were converted to rates (using the method in 4.2.4.2) and 
 
Figure 4.7  Effect of starting substrate concentration (Si) on HHL hydrolysis using the Single 
Injection Method. Representative examples of the reaction between tACEg13sol and HHL in 
300mM NaCl, 100mM Tris(Acetate) buffer (pH 7.5), 10uM ZnSO4. Enzyme concentration was kept 
constant (52nM) between all runs. Units are all indicated on each axis.  A) The change in raw 
thermal power (dQ/dt) associated with the change in substrate concentration (S) over time as it 
is hydrolysed after a single injection of 52nM tACEg13sol into the reaction cell containing HHL.  
Four different initial substrate concentrations (Si) are shown; 2mM HHL (green), 4mM HHL (light 
blue), 6mM HHL (dark blue) and 8mM HHL (black). B) Raw thermal power was converted to 
enzyme turnover (as described in 4.2.4.2) and fitted to Equation 6 using non-linear regression 
analysis.  The rate data for the four different Si concentrations are in the same colours as in A, 
with the non-linear regression fits (solid black lines) for each was extended to highlight the 
variation between the fits.  All fits had R2 values greater than 0.999. C) The resultant Km values of 
the non-linear regression in B, plotted against the initial substrate concentration (Si) on the X-
axis. D) The resultant kcat (black circles; left hand Y-axis) and kcat/Km (red squares; right hand Y-
axis) values of the non-linear regression in B, plotted against the initial substrate concentration 














fitted via non-linear regression analysis to the Michaelis-Menten equation (equation 6) 
(Figure 4.7B).  None of the rate data produced clearly plateauing curves that could be 
confidently fitted to the Michaelis-Menten equation without extrapolation of Vmax.  
However, given that the data is continuous and represents hundreds of data points, this 
extrapolation can be assumed to be fairly accurate for the higher Si concentrations but 
decreasingly so for the lower the concentration used (i.e. 2mM and 4mM).  With this in 
mind, we can also see that Vmax decreased proportionally with increased Si concentration, a 
clear demonstration of substrate inhibition.  Indeed, plotting the resultant Michaelis-
Menten constants (Km, kcat, kcat/Km) against the Si concentration used for each determination 
(Figure 4.7C & D) further bears out this point.  It is clear that the Km, which is consistent with 
published values (Gordon et al., 2003) doesn’t change that much over the  i range, yet the 
kcat and hence kcat/Km does, further supporting the substrate inhibition model.  It is also clear 
that the kcat and kcat/Km calculated using the lower Si concentrations are far more in line with 
those reported by Gordon et al (kcat=170±25 .s
-1 and kcat/Km=63 .mM
-1.s-1), suggesting that 
the lower the Si used, the more representative the data is of the actual rate constants.  The 
problem with that is that the lower the Si concentration used, the more extrapolation of the 
curve fit is required and therefore, the confidence in reported constants is lowered.   
A similar evaluation of the angiotensin I reaction was done in order to ascertain whether a 
similar effect would be observed.  The range of Si concentrations used was based on the 
reported Km values of 47±1.5mM at 20mM NaCl (Liu et al., 2001) and 55.6±6.4mM at 
100mM NaCl (Rice et al., 2004), thus an angiotensin I range of approximately 5-20 X Km 
(200-1000µM) was used. Figure 4.8A shows the raw calorimetric traces of the complete 
hydrolysis of five different angiotensin I Si concentrations with the same concentration of 
tACEg13sol. The raw data differed from that of HHL in that there was an increase in both 
peak height and time taken to total hydrolysis with increasing Si concentration.  What is also 
not entirely evident from the raw calorimetric traces is that the total reaction heat 
(characterised by the height of the peaks in 4.8A) at the lower Si concentrations (200-
300µM) are bordering on the lower detection limits of the instrument.  It is recommended 
that the height at Vmax should be no less than 0.2µcal/sec and ideally not much less than 
0.5µcal/sec (personal correspondence with Dr Luminita Damian - MicroCal).  The only way 















explored (data not shown) with higher concentrations resulted in faster hydrolysis and 
reduced steady-state plateau at Vmax, an important consideration in the analysis of the 
subsequent rate data.  We thus had to use the lowest concentration (293nM) that produced 
heat change at Vmax greater than 0.2µcal/sec. The conversion of these raw traces to rate 
values (using method in 4.2.4.2) and non-linear regression analysis to the Michaelis-Menten 
 
Figure 4.8  Effect of starting substrate concentration (Si) on Angiotensin I hydrolysis using the 
Single Injection Method.  Representative examples of the reaction between tACEg13sol and 
Angiotensin I in 20mM NaCl, 100mM Tris(Acetate) buffer (pH 7.5), 10uM ZnSO4.  Enzyme 
concentration was kept constant (293nM) between all runs. Units are all indicated on each axis.  
A) The change in raw thermal power (dQ/dt) associated with the change in substrate 
concentration (S) over time as it is hydrolysed after a single injection of tACEg13sol into the 
reaction cell containing AngiotensinI.  Five different initial substrate concentrations (Si) are 
shown; 200µM (green), 300µM (violet), 500µM (light blue), 750µM (dark blue) and 1000µM 
(purple).  B) Raw thermal power was converted to enzyme turnover (as described in 4.2.4.2) and 
fitted to Equation 6 using non-linear regression analysis.  The rate data for the four different Si 
concentrations are in the same colours as in A, with the non-linear regression fits (solid black 
lines) for each extended to highlight the variation between the fits.  All fits had R2 values greater 
than 0.995.  The resultant Km (C), kcat (D), and kcat/Km values (E) of the non-linear regression 














equation (equation 6) is shown in Figure 4.8B.  Here, it is seen that not only is Vmax 
increasing with increased Si, but so is the Km.  Similarly to the HHL data, steady-state 
plateaus at Vmax were not obtained, and could not be obtained using higher Si 
concentrations.  The resultant Michaelis-Menten constants were plotted against the Si 
concentration used for each determination (Figure 4.8C, D & E) confirming the 
concentration dependent increase in both kcat and Km, which results in a sharply decreasing 
kcat/Km.  The increase in Km with increased Si concentration is consistent with product 
inhibition, which has been shown for ACE (Shapiro & Riordan, 1984) and specifically with 
Angiotensin I as substrate and Angiotensin II as competitive inhibitor using rabbit lung ACE 
(Tsai & Peach, 1976).  Karim et al (2005) proposed a method of accounting for the effect of 
product accumulation on the kinetic rate constants based on the Single Injection Method.  
By plotting the Km values against the Si concentration (as has been done in Figure 4.8C), they 
showed a linear increase in Km with increased Si concentration, which they subjected to 
linear regression analysis to obtain the positive Y-intercept and calculate an apparent Km.  
However, as can be seen in Figure 4.8C, a linear least-squares fit to the data would not yield 
a positive Y-intercept.  A cornerstone of this approach is that the kcat remains constant 
across all Si concentrations, which is not the case here (see Figure 4.8D). 
Further illustration that product inhibition is playing a role is shown in the separate 
determination of ΔHapp, which is required for the conversion of raw assay data to rate data.  
Figure 4.9A shows the raw data for multiple injections of Angiotensin I into a cell containing 
tACEg13sol (with a control for heat of dilution), with Figure 4.9B showing the calculated 
ΔHapp for the hydrolysis of each injection of Angiotensin I.  A product concentration 
dependent endothermic (more positive) shift in the ΔHapp was observed, an effect that can 
be attributed to product inhibition (Todd et al., 2001).  Cai et al., (2001) looked at employing 
this product inhibition effect as a probe to measure the kinetic parameters of a reaction, 
thus this approach was investigated to determine applicability.  The approach required a 
separate determination of the Ki (Kd of binding) for the product(s) (either His-Leu or 
Angiotensin II), which was attempted using the ITC binding approach (described in 4.2.6) in 
line with their methodology.  ITC has been used to determine binding of a dipeptide (Asp-
Phe) to somatic ACE (Andujar-Sanchez et al., 2007) with a Kd of ~110µM using up to 10µM 















in the reaction cell could not be ascertained (data not shown).  Whilst binding of 
Angiotensin II could be determined, the enthalpies were very low, resulting in very erratic, 
unreliable data (not shown).  The enthalpies for these reactions could have been improved 
by the use of higher tACEg13sol concentrations; however, the amounts required for the 
effect to be appreciable would have been wholly impractical given the limited scalability of 
the mammalian expression system used.  Taking into account the fact that reliable Kd values 
could not be obtained for both Angiotensin II and His-Leu, and that the model presented by 
Cai et al., (2001) assumes product inhibition only and does not factor in the potential 
disparate effects of two products, this approach was found to be unsuitable. 
Given that Angiotensin I hydrolysis results in two products (Angiotensin II and His-Leu), the 
effect these individual components have on Angiotensin I hydrolysis kinetics was 
investigated.  Assays were performed as before using 300µM Angiotensin I in the reaction 
 
Figure 4.9  Enthalpic contribution of product accumulation from Angiotensin I hydrolysis.  A) 
Raw calorimetric output of 12 injections (each 3µL in volume) of 10mM Angiotensin I into the 
reaction cell containing either 802nM tACEg13sol (black line) or buffer containing no enzyme (red 
line).  Sufficient time (1000 seconds) was allowed between each injection for the hydrolysis 
reaction to run to completion.  Reactions were performed in 20mM NaCl, 100mM Tris(Acetate) 
buffer (pH 7.5), 10uM ZnSO4 using the method described in 4.2.4 (Figure 4.1).  B) Molar 
enthalpies for each injection were calculated (using equation 2) and the ΔHapp determined by 
subtracting the ΔHdilution from the ΔHobserved (see Figure 4.1).  These are plotted against the total 
product concentration, which, for each injection, is equal to the cumulative substrate 
concentration injected preceding that injection.  This is the case given that all substrate prior to 















cell and 293nM tACEg13sol introduced via a single injection.  In order to ascertain the 
effects of the reaction products, the substrate mixture in the cell contained 300µM 
Angiotensin I mixed with either 400µM Angiotensin II or 400µM His-Leu.  As can be seen in 
the raw calorimetric traces in Figure 4.10A and the subsequent Michaelis-Menten fitted rate 
data (Figure 4.10B), the effects are notably different for the two products.  The experiments 
were repeated using varying concentrations of products (not shown) and found to be 
concentration dependent.  The presence of 400µM Angiotensin II had the effect of 
increasing the Km by two-fold with no increase in kcat (data not shown), suggesting its 
inhibitory effect is purely competitive in nature.  By contrast, the presence of 400µM His-
Leu caused a threefold increase in both kcat and Km.  The most likely explanation is that His-
Leu binds to tACEg13sol and modulates the activity.  Michaud et al (1997) report a Ki (using 
ACE C-domain) for His-Leu of 150 and 170µM using Hipp-His-Leu and Hip-Ala-Pro as 
substrates respectively.  This suggests that the increased Km, which would be associated 
with competitive inhibition, is balanced by the observed rise in kcat, with the overall kcat/Km 
values being approximately equal.  The fact that enthalpic heat of binding was not detected 
with His-Leu alone, as mentioned before, indicates that its effect is more than likely non-
competitive and allosteric in nature   It’s quite possible that HL requires substrate binding to 
occur before it can bind, possibly in the active site groove which is quite large.  Evidence for 
dual binding in the active site is reported by Ortiz-Salmerón et al (1998) who show that two 
molecules of captopril, a potent ACE inhibitor, bind highly entropically to each monomer of 
ACE, with the second molecule presumably binding within the active site, supporting the 
idea that His-Leu could bind along with the substrate.   
Due to the fact that product accumulation is playing such a prominent role, it can’t be 
discounted that the early part of the curve is being skewed, hence affecting the non-linear 
regression and accounting for the increased kcat and Km values.  To negate this effect, a 
method originally described by Lonhienne et al (2000) to independently determine kcat 
without fitting to the Michaelis-Menten equation was used.  This involved multiple 
injections of small volumes of tACEg13sol into the reaction cell containing saturating levels 
of Angiotensin I (see Figure 4.10C), with the enthalpic change (hence rate) proportional to 
Vmax.  This allowed multiple determinations of kcat for two saturating conditions (500µM and 
















Figure 4.10  Effect of product formation and substrate concentration on kinetic parameters of 
Angiotensin I hydrolysis. Representative examples of the reaction between tACEg13sol and 
Angiotensin I in 20mM NaCl, 100mM Tris(Acetate) buffer (pH 7.5), 10uM ZnSO4. A) The change in 
raw thermal power (dQ/dt) associated with the change in substrate concentration (S) over time, 
as it is hydrolysed after a single injection of tACEg13sol (293nM) into the reaction cell containing 
300µM AngiotensinI (black), 300µM AngiotensinI + 400µM Angiotensin II (red) and 300µM 
AngiotensinI + 400µM HL (blue).  B) Raw thermal power was converted to enzyme turnover (as 
described in 4.2.4.2) and fitted to Equation 6 using non-linear regression analysis.  The rate data 
for the four different Si concentrations are in the same colours as in A, with the non-linear 
regression fits (solid black lines) for each extended to highlight the variation between the fits.  All 
fits had R2 values greater than 0.995.  Annotations in red (Angiotensin II) or blue (HL) indicate the 
effect of the presence of product on the kinetic constants Km and kcat.  C) The change in raw 
thermal power (dQ/dt) upon multiple consecutive injections (indicated by arrows) of equal 
amounts of tACEg13sol into a saturating amount of Angiotensin I (method described by 
Lonhienne et al., 2000).  Under these conditions, a steady state is reached prior to the 
subsequent injection, with the thermal change being proportional to Vmax (indicated by dotted 
lines). Conversion of the thermal change to a rate value (using equation 5) and division by the 
enzyme concentration at each point yields multiple kcat determinations in a single experiment. D) 
Comparison of the kcat data determined using Single Injection Method (black squares; taken from 
4.X D) and from two separate determinations of kcat at 500µM and 1000µM Angiotensin I (red 
dots) using method descibed in (C).  Each red dot is the average of six injections from a single 














via normal non-linear regression (Figure 4.10D).  What is clear is that the Si concentration 
dependent increase in kcat is still occurring, though not quite to the same degree, suggesting 
that the substrate is playing a role in this effect.  Angiotensin I is quite a large peptide and in 
very high concentrations (>1mM) was found to be quite viscous.  High viscosity is generally 
associated with having a negative effect on kcat by interfering with catalytically important 
structural changes in the enzyme (Gavish & Werber, 1979).  Given that the kcat increases, it 
can only be surmised that the effect is of a more stabilising nature which would promote 
catalysis.  What is clear is that product accumulation and high substrate concentrations 
adversely affect determination of kinetic rate constants for Angiotensin I using Si 
concentrations greater than 200µM with this methodology, making it unfeasible. 
4.3.4  Progress Curve Analysis 
Rather than look for a way to account for the confounding effects at high Si concentrations, 
the use of progress curves was investigated as a means of utilizing lower substrate 
concentrations.  As discussed in section 4.1, the application of a non-linear regression 
analysis proposed by Golicnik (2010) to progress curves generated using a method adapted 
from that described by Stockbridge & Wolfenden (2009) provided a viable alternative 
(representative data shown in Figure 4.11).  Duggleby (2001) suggested that, for continuous 
kinetics assays, an appropriate starting substrate concentration (Si) would be about 2-3X Km.  
However, Golicnik (2010) showed using simulations that the non-linear regression analysis 
(using the combined equations 9 & 10) of a progress curve generated with a Si 
concentration equal to Km would produce accurate constants with a very low degree of 
error.  In follow up work, Golicnik (2011c) showed, using the same analysis, with data 
obtained from the literature, that using a Si concentration as low as half that of the Km 
would still produce accurate constants with a very low standard deviation.  Thus, this 
approach was compared to the normal Single Injection Method. 
Figure 4.12A shows progress curves for HHL generated from the same raw calorimetric data 
as that used for the Single Injection Method (shown in 4.8A), as well as an additional 
experiment performed with a Si concentration of 1mM HHL (raw data not shown).   The Km 
values are in strong agreement with those generated using the Single Injection Method over 
a wide range of Si concentrations (Figure 4.12B).  An Si concentration for HHL as low as 















concentrations, showing that the analysis is consistent at such low Si concentrations.  The 
high consistency with the Single Injection Method is also observed with the kcat values 
(Figure 4.12C), which also translates to the kcat/Km values shown in Figure 4.12D.  There is 
some variation for the kcat/Km values at low Si concentrations, a phenomenon more likely 
attributed to the fact that the Single Injection Method rate data does not reach a plateau 
and hence kcat is based on an extrapolation. In contrast, the progress curves at all Si 
concentrations are complete, providing a higher degree of confidence in the constants 
obtained. Thus, the Progress Curve method has been shown to be highly comparable to the 
Single Injection Method for HHL, and, more importantly, allows the use of Si concentrations 
below Km which would then vastly reduce influence of substrate inhibition in determining 
accurate rate constants.  
The same approach was then followed in order to see if the Si concentration could be 
lowered for Angiotensin I.  In 4.3.3 it was ascertained that the Single Injection Method was  
 
Figure 4.11  Representative data for the Progress Curve Method. Methodology is described in 
4.2.5 A) Continuous raw calorimetric output (solid black line) of a single injection of enzyme into 
the reaction cell containing substrate, with thermal power P (ucal/sec) on the Y-axis and Time 
(sec) on the X-axis. Total integrated area is shown in light grey shaded area and the integrated 
area between t=0 and t is shown in dark grey.  The dotted line represents the raw calorimetric 
output of a control experiment where the same amount of enzyme is injected into the reaction 
cell containing only buffer. Figure adapted from Stockbridge & Wolfenden (2009).  B)  The 
resultant reaction progress curve (thick black line), which was calculated from raw experimental 
data using equation 8, is fitted to the temporal closed form of the Michaelis-Menten equation 















not viable below 200µM due to the combination of low enthalpies associated with low Si 
concentration and the need to keep enzyme concentration low so that as close to steady-
state Vmax could be achieved.  Figure 4.13A shows fitted progress curves from assays done 
using Angiotensin I Si concentrations ranging from 128-183µM, approximately 2-3X Km as 
suggested by Duggleby (2001), using a higher enzyme concentration to increase the 
maximum enthalpy (raw data not shown).  The maximum peak height of the lowest  
 
Figure 4.12  Comparison of Single Injection Method and Progress Curve Method for HHL 
kinetics.  Representative examples of the reaction between tACEg13sol and HHL in 300mM NaCl, 
100mM Tris(Acetate) buffer (pH 7.5), 10uM ZnSO4. Units are all indicated on each axis. A)  
Progress curve (thick black lines) for a range of HHL Si concentrations (8, 6, 4, 2, 1mM) calculated 
from raw data using equation 8 and fitted to equation 9 & 10 using non-linear regression analysis 
(thin red lines) as described in 4.2.5.  The raw data used was identical to that for the Single 
Injection Method.  R2 values for all fits were greater than 0.998.  The resultant Km values (B), kcat 
values (C), and kcat/Km values (D) of the non-linear regression analysis in A (all red dots), plotted 
against the initial substrate concentration (Si) on the X-axes. For comparison, the corresponding 
values calculated from the same raw data using the Single Injection Method (identical to Figure 















concentration (128µM) was greater than 0.4µcal/sec, double the minimum requirement of 
0.2µcal/sec.  Using a Si concentration lower than 128µM proved to be unviable, as the low 
enthalpies encountered caused the data to become irreproducible.  The Km values obtained 
in this range show that the trend from the Single Injection Method data is continued into 
the lower Si concentrations (Figure 4.13B). The inset shows that the progress curve Km data 
 
Figure 4.13  Comparison of Single Injection Method and Progress Curve Method for Angiotensin 
I kinetics.  Representative examples of the reaction between tACEg13sol and Angiotensin I in 
20mM NaCl, 100mM Tris(Acetate) buffer (pH 7.5), 10uM ZnSO4. Units are all indicated on each 
axis.  A)  Progress curve (thick black lines) for a range of Angiotensin I Si concentrations (128µM, 
143µM,160µM,183µM) using constant tACEg13sol concentration (434nM) calculated from raw 
data using equation 8 and fitted to equation 9 & 10 using non-linear regression analysis (thin red 
lines) as described in 4.2.5.  The raw data used was identical to that for the Single Injection 
Method.  The resultant Km values (B), kcat values (C), and kcat/Km values (D) of the non-linear 
regression analysis in A (all red dots), plotted against the initial substrate concentration (Si) on 
the X-axes. For comparison, values calculated using the Single Injection Method (identical to 
Figure 4.8) are shown (black triangles). Each data point represents a single experiment.  Insets 

















is fairly consistently level, a trend observed repeatedly using other ACE constructs (data not 
shown), and agrees very well with the reported values of 47±1.5 at 20mM NaCl (Liu et al., 
2001) and 55.6±6.4 at 100mM NaCl (Rice et al., 2004).  Similarly in Figure 4.13C, the trend 
from Single Injection Method data to Progress curve kcat values is fairly consistent as the Si 
concentration decreases.  Only the Km at 200µM deviates from the trend, which can be 
accounted for as poor data, as this has been established as the lower detection limit for the 
Single Injection Method. As with the Km data inset (Figure 4.13B), the progress curve data in 
the Si range used is consistent.  However, the expected kcat for this reaction was around 10-
34 .s-1 (Rice et al., 2004; Rousseau-Plasse, 1996), somewhat higher than the ~2.s-1 observed 
here (Figure 4.13C).  Figure 4.13D shows the same comparison of kcat/Km values obtained 
between the two techniques with the same trends observed.  These kcat/Km values 
(calculated from the kcat) are generally lower than those reported in the literature, which 
range from 180.mM-1.s-1 (Rice et al., 2004) up to ~1900.mM-1.s-1 (Rousseau-Plasse et al., 
1996; Liu et al., 2001).  A possible explanation for this inconsistency with the literature is 
that the active enzyme concentration was not determined which would be a factor that 
would affect the calculation of kcat.  A report by Schulleck & Wilson (1989) determined that 
the Tris, phosphate and borate buffers inhibited ACE activity, unlike HEPES that had no 
effect on enzymatic activity.  They also reported a Km of 0.21mM for HHL in HEPES (at 37°C, 
pH 7.0 and 100mM KCl), which is an order of magnitude lower than was obtained for HHL 
using Tris buffer (see Figure 4.12B).  This value is contrary to those obtained for the more 
widely used phosphate buffer, that correlate well with the values reported here using Tris 
buffer, which suggested that the buffer was playing a role in modulating the kinetic 
constants obtained.  Further to this, reports in the literature regarding assays of Angiotensin 
I hydrolysis by ACE routinely use HEPES as the buffer system, where thus far only Tris due 
has been investigated based on the fact that it contributes significantly to the overall 
enthalpy.  This would go some way to explain why the kcat for Angiotensin I hydrolysis (see 
Figure 4.13C) is considerably lower than the reported values which were obtained in HEPES 
buffer. 
4.3.5  Effects of Buffer on ACE Activity 
We investigated the effect of a variety of buffers on the kinetic constants obtained for the 














buffer range, which needed to encompass pH 7.5 to allow for comparable evaluation and 
exclude pH effects.  The enthalpies of ionisation (ΔHion) of these buffers (significance is 
described in 4.3.1) needed to be close to either 0 or 10kcal/mol so as to maximise overall 
ΔHapp (see figure 4.3).  Assays were performed as described in 4.2.5 using the Progress Curve 
method and multiple Si concentrations, with the only variation (apart from minor enzyme 
concentration differences) being the buffer system used.  As can be seen in Figure 4.14A, 
there is a distinct difference between the Km values obtained for Tris (values reproduced 
from Figure 4.12) and phosphate (2.69±0.046 and 3.4±0.09 mM respectively), and the rest 
of the buffers, which ranged from 0.4 to 0.8mM.  This supports the findings of Schulleck & 
Wilson (1989), with the Km for HEPES, as well as Maleate, TES and TAPSO, being much closer 
to the 0.21mM quoted.  The kcat values at various Si concentrations do not vary extensively 
between the buffers, with all buffers maintaining a similar degree of substrate inhibition 
suggesting it is not a buffer related effect (Figure 4.14B).  It must be noted again that active 
enzyme concentration was not determined for these assays as it was investigatory in nature, 
so the kcat values must be taken as guidelines only and may vary.  This must be taken into 
account as well when looking at the kcat/Km values in Figure 4.14C, as minor variations in kcat 
and Km can translate into large variation in these values.  One can only postulate as to the 
mechanism behind these effects, but it is unlikely to be due to ionic effects, as this has been 
explored by Liu et al (2001) and Schulleck & Wilson (1989) and found not to be significant.  
Upon examination of the structures of the buffers, a trend can be seen where Tris and 
phosphate physically occupy a very small volume in comparison to HEPES, TES, Maleate and 
TAPSO, suggesting that they may be infiltrating the interior of tACEg13sol.  There is evidence 
for a large hinge-bending mechanism, based on crystallographic data and comparison with 
the ACE homolog ACE2 (Watermeyer et al., 2006). It is possible that the smaller buffers are 
potentially locking the enzyme in one of two or more specific conformations associated with 
the hinge motion and modulating activity somehow. 
To investigate this buffer effect further the tACE activity at different chloride concentrations 
was determined using substrates HHL and angiotensin I.  Whilst the logical choice of buffers 
to compare to Tris would be HEPES, its ionisation enthalpy (ΔHion) of 4.89kcal/mol resulted 
in the overall ΔHapp being too close to zero (see Figure 4.3), which made kinetic assays 















and the fact that its Km for HHL aligned fairly closely with that of HEPES (see Figure 4.14A).  
Irrespective of purification method and storage conditions (which have been optimally 
determined in our lab), degradation of enzyme can occur when stored for long periods of 
 
Figure 4.14  Effects of varying buffers on the kinetic constants of HHL hydrolysis by tACEg13sol.  
Representative examples of the reaction between tACEg13sol and HHL in a variety of buffers, all 
at pH 7.5, 300mM NaCl, 10uM ZnSO4. Six different buffers (100mM phosphate, 100mM Tris, 
50mM HEPES, 50mM Maleate, 50mM TES and 50mM TAPSO) were investigated with the key on 
the right indicating the colour for each.  For each buffer condition, multiple single injection 
hydrolysis reactions were performed and analysed as described in 4.2.5 using progress curve 
approach, with enzyme concentrations kept constant (between 200 and 600nM) and multiple Si 
concentrations were used.  The resultant Km values (A), kcat values (B), and kcat/Km values (C) of the 
non-linear regression analysis are plotted against the initial substrate concentration (Si) on the X-














time, which lowers the concentration of active enzyme (Knight, 1995). Thus, lisinopril 
binding curves using ITC were performed for all enzyme samples in order to determine the 
active enzyme concentration (outlined in 4.2.6, data not shown), a factor that would provide 
confidence in the kcat values determined.   
The Km, kcat and kcat/Km values for HHL hydrolysis by tACEg13sol with either Tris or TAPSO are 
shown in Figure 4.15 A, B & C respectively.  What is readily apparent is that increasing the 
chloride concentration with TAPSO results in a concentration dependent lowering of Km for 
HHL, which is in contrast to what is observed with Tris.  The kcat values show an increase 
from 0mM to 20mM NaCl using Tris buffer, yet very little difference at the much higher 
300mM NaCl.  The same conditions for TAPSO by contrast, show a chloride dependent 
increase in kcat up to 300mM NaCl. The same pattern extends to the kcat/Km values, with the 
increase in kcat/Km from 20mM to 300mM being only 1.22X with Tris, yet 12.5X for TAPSO.   
The greater increase in kcat/Km compared to what was observed with the tACE chloride 
titration curve is likely due to different substrate concentrations.  This pattern for TAPSO 
confirms its greater chloride dependency and suggests that Tris is somehow disrupting the 
enzyme catalytic mechanism at high chloride levels.  This supports the idea that the smaller 
Tris molecule is somehow locking ACE in a specific conformation. 
The same buffer comparison was done for Angiotensin I hydrolysis, but only used 0mM and 
20mM NaCl, which is the reported chloride concentration of maximal activity (Liu et al., 
2001).  The Km, kcat and kcat/Km values for hydrolysis by tACEg13sol with either Tris or TAPSO 
are shown in Figure 4.15 D, E & F, respectively.  Whilst there is very little variation in the Km, 
with Tris values unchanged between 0 and 20mM NaCl and TAPSO decreasing slightly, the 
major variation occurs with kcat.  There was very little variation at 0mM NaCl with Tris and 
TAPSO, however, at 20mM NaCl the TAPSO kcat value was more than 2-fold that of Tris.  This 
pattern carries through to the kcat/Km values for both buffers and further highlights the 
negative impact of Tris on tACEg13sol catalysis in the presence of chloride.  The 
approximate 6-fold increase in kcat/Km values between 0 and 20mM NaCl using TAPSO is not 
as high as the 20-fold increase between the same chloride concentrations reported by both 
Wei et al (1991b) and Liu et al (2001) , who used an HPLC based methodology.  This 
variation could be attributed to a combination of both detection technique and analysis 
















Figure 4.15  Comparison of Tris and TAPSO buffers in the hydrolysis of Angiotensin I and HHL at 
varying chloride concentrations.  Progress curve approach (described in 4.2.5) was used to 
evaluate the kinetic parameters (Km, kcat & kcat/Km) for tACEg13sol hydrolysis of either HHL (A, B, 
C) or Angiotensin I (D, E, F) using either Tris (white bars) or TAPSO (chequered bars) at pH 7.5, 
10uM ZnSO4.  Varying NaCl concentrations were used; 0mM, 20mM & 300mM for HHL and 0mM 
and 20mM for Angiotensin I.  For HHL, Si concentrations were all 1mM HHL and for Angiotensin I 
they were kept in the range of 120-180µM.  Each bar represents a minimum of 3 repeats with the 
error bars indicating standard error.  For each condition, ITC binding curves were performed on 
the enzyme sample using lisinopril (as described in 4.2.6, data not shown) in order to ascertain 
the stoichiometry of binding N (see Figure 4.5).  The stoichiometry of binding acts as an active 
site titration and indicates the percentage of active enzyme in the sample.  These values were 














have a chloride dependent profile more akin to that of HEPES than Tris.  The effect that Tris 
is exhibiting appears to affect the chloride profile for both HHL and Angiotensin I, and given 
that investigation of chloride dependence is the primary focus of this study, it would be ill-
advised to use this buffer.  For the purposes of further study of tACEg13sol chloride mutants 
generated in Chapter 3, the evidence here indicates that the best approach would be to use 
TAPSO buffer with all substrates investigated.  
4.4  Summary 
The feasibility of using ITC to determine the kinetic rate constants for ACE hydrolysis was 
investigated using the short synthetic peptide HHL and the large physiological peptide 
Angiotensin I.  It was shown that the hydrolysis reactions produced measurable enthalpies, 
which varied due to contributions of various buffers, with the use of Tris buffer giving the 
largest ΔHapp for Angiotensin I and one of the largest for HHL.  Tris was employed as the 
buffer of choice in investigating the Multiple and Single Injection Methods.  The Multiple 
Injection Method proved viable for HHL, but failed to produce adequate changes in enthalpy 
for Angiotensin I due to a combination of relatively low ΔHapp, low kcat and a requirement for 
pseudo first-order conditions.  The Single Injection Method produced viable enthalpies for 
both substrates, but was extremely sensitive to high substrate concentrations for HHL and 
accumulation of reaction products for Angiotensin I.  The use of Progress Curves was 
explored in order to use lower starting substrate concentrations and thus avoid the 
problems associated with the Single Injection Method.  This approach proved highly 
comparable and effective at Si concentrations below Km.  Concerns over the kinetic 
constants obtained using Tris prompted evaluation of a range of buffers, the results of 
which showed that Tris negatively affects ACE hydrolysis.  More specifically, this negative 
effect altered the chloride dependence profile for both substrates.  It was shown that 
TAPSO buffer produced kinetic constants and chloride profiles far more consistent with 
those reported in the literature.  It was concluded that the use of the ITC-based Progress 
Curve Method with Si concentrations low enough to avoid substrate and product inhibition 
effects and using TAPSO as the buffer system is a viable, consistent and reproducible 














Chapter 5:  Investigation of Chloride 






























5.1  Introduction 
Chapter 3 described the initial characterisation of a number of tACEg13sol mutants 
generated to probe the underpinnings of the chloride dependence observed in the C-
domain of ACE.  It was established that the chloride 1 pocket mutant R186H showed a small 
increase in Kd,app from tACE, as well as an increase in overall activity, with HHL and Z-FHL 
substrates.  Rushworth et al (2006) showed a decrease in activity for their R186Q mutant 
with angiotensin I, indicating that the Arg identity is important in chloride dependence in 
the C-domain.  Further investigation of R186H was warranted using angiotensin I as 
substrate to assess the implications of having the bulkier aromatic His in that position and 
whether this contributes to variable chloride dependence between the domains.  
A number of mutants in the chloride 2 pocket were generated with varying effects.  The 
V518T and M223W C to N-domain mutants showed no change in Kd,app for either HHL or Z-
FHL, though there were some differences in overall activity.  The D465T mutant showed 
some variation in Kd,app, however this was inconsistent with HHL being lower and Z-FHL 
being higher, with maximal activity also being lower with both substrates.  The R552K and 
R522Q mutations had a similar effect with HHL and Z-FHL as that observed by Liu et al 
(2001) with AngI, with Kd,app values  for R522K and R522Q increasing considerably and 
activation considerably reduced.  The relatively minor differences observed for V518T, 
M223W and D465T suggest they were not having significant roles in the chloride 
dependence mechanism, thus R522K and R522Q were chosen as the focus of further 
analysis as they showed the largest effects. 
The E403R mutant was generated in order to probe the mechanism of the proposed 
chloride gating.  This mutation had markedly reduced Kd,app values for HHL and Z-FHL relative 
to tACE, as well as very similar levels of maximal activity but with reduced degree of 
activation.  The effect on Kd,app was shown to be reversible in the N-domain with the R381E 
mutation showing increased Kd,app values, though not to the same extent.  This was the first 
clear evidence that E403 was clearly modulating chloride binding, though the exact 
mechanism was unclear, and it was hypothesized that substrate interactions in the S2 sub-
site might be modulating this interaction.  Thus, it was felt that further evaluation was 















The following mutants, R186H, E403R, R522K and R522Q, were evaluated with HHL, Z-FHL 
and Angiotensin I under different salt conditions using three different approaches:  
Firstly, molecular docking simulations of HHL and Z-FHL into both the C-and N-domains were 
performed.  This was to complement work done by collaborators who have done complex 
simulations of Angiotensin I interacting with the C- and N-domains of ACE (unpublished).  
Having an idea of the potential interactions of these substrates allowed for informed 
conclusions to be made in relation to the kinetic analysis. 
Secondly, the effect these mutations had on the kinetic constants of tACE in the presence or 
absence of chloride was assessed.  In order to effectively characterise these mutants, a 
novel approach using ITC to determine the Km, kcat and Kcat/Km was developed, which is 
described extensively in Chapter 4.  This allowed the differentiation of whether the 
mutations are affecting binding (Km) or the catalytic mechanism (kcat), and their combined 
contribution to overall activity (Kcat/Km). Of importance with this method is that it permits 
the precise evaluation of the kinetic parameters of all three substrates (HHL, Z-FHL and 
AngI) using the same technique. 
Thirdly, the ITC-based technique developed in Chapter 4 permitted the evaluation of 
thermodynamic profiles of the reaction under different chloride conditions.  This is the first 
thermodynamic analysis of chloride activation to be carried out, and provides a link 
between kinetic rate constants and structural interpretation associated with structural 
inspection and molecular docking simulations.  Changes in Km or kcat associated with chloride 
binding could be associated with either enthalpic or entropic effects. 
ITC is routinely used to evaluate the thermodynamic contributions of inhibitor binding, 
allowing experimental evaluation of structural changes in the lead optimization process 
(Velasquez Campoy et al., 2000; Velasquez Campoy et al., 2001; Ohtaka et al., 2003; Olsson 
et al., 2008).  Whilst this approach is readily applied to binding experiments, it is rather 
uncommonly used for enzyme kinetics in the literature, due almost entirely to the fact that 
the vast majority of assay methods used do not provide a viable measure of enthalpy.  
Fortunately, the Progress Curve method described in 4.2.5 allows for the determination of 
the reaction enthalpy (ΔHapp) by virtue of the fact that the entire curve represents the 














(ΔHint; referred to as ΔH), and subsequently the Gibbs free energy change (ΔG) and 
temperature dependant change in entropy (TΔS), to be calculated, which represent the 
thermodynamic parameters associated with the hydrolysis of substrates by tACE.  Enthalpy 
and entropy both contribute to ΔG, with each having a different role. The enthalpic 
contribution (ΔH) is composed primarily of hydrogen bond formation, protonation events, 
van der Waals interactions and ionic interactions, and reflects the strength of the ligand-
target interaction relative to those with solvent. When ΔH is negative, binding is 
enthalpically favoured which requires correct placement of hydrogen bond acceptor and 
donor groups at the binding interface. Entropically favourable binding is reflected by a 
positive TΔS (i.e. more negative – TΔS), with changes primarily due to any combination of 
increased hydrophobic interactions, increase in solvent entropy from burial of hydrophobic 
groups, release of water or ions upon binding, as well as minimal loss of conformational 
degrees of freedom. So, where lead optimization of inhibitors uses these parameters 
(calculated in a similar manner for a reversible binding reaction) to inform the effect of 
change (either inhibitor functional groups or specific residues in target protein), these 
measures were used to probe the mechanistic underpinnings of chloride dependent 
substrate hydrolysis.   
In a comprehensive review of molecular interactions, Bissantz et al (2010) ascertain that, 
whilst tempting, speculation about the link between thermodynamics and geometry of 
protein-ligand complexes via crystal structure information should be treated with care.  Any 
practically useful relationships between structure and calorimetrically determined 
components of free energy (entropy and enthalpy) have proven difficult to establish as both 
terms contain solute and solvent contributions (Bissantz et al., 2010).  Experimental 
determination of these solvent effects have been attempted (Chervanak et al., 1994), but 
given that a number of assumptions were required, means that to date, only computer 
simulations can delineate these contributions (Gilson et al., 2007; Bissantz et al., 2010).  
Furthermore, detailed contributions of protonation and deprotonation steps, along with 
other enthalpic contributors, need to be fully understood (Klebe et al., 2001; Bissantz et al., 
2010).  In the context of drug lead optimisation, it has been shown that small structural 
changes can lead to significant shifts in relative ΔH and TΔS contributions, making structural 














data obtained with the ITC-based enzyme assay was applied with caution in the evaluation 
of chloride mutant proteins.  It should be emphasized that full interrogation of all enthalpic 
or entropic contributions was not attempted, but instead the variation seen in either was 
used to qualitatively strengthen the interpretations of kinetic and structural data from the 
chloride dependence mutants.   
In evaluating the tACE chloride mutants, the kinetic and thermodynamic data were 
evaluated and related to the crystal structure and molecular docking of substrates to 
provide a mechanism by which chloride dependence was related to substrate composition 
Objectives: 
1. Determine kinetic constants (Km, kcat and kcat/Km) using HHL, Z-FHL and Angiotensin I 
substrates for tACE mutants constructs under different chloride concentrations. 
2. Calculate thermodynamic parameters (ΔG, ΔH and TΔS) associated with HHL, Z-FHL 
and angiotensin I hydrolysis under different chloride concentrations. 
3. Perform molecular dynamic simulations to dock HHL and Z-FHL into the C and N 
domains of ACE and characterise potential binding interactions. 
5.2  Experimental Approach 
5.2.1  Chemicals & Equipment 
Chemicals and equipment used are identical to those described in 4.2.1, with the exception 
being that only TAPSO buffer was used.  Additionally, Z-FHL was purchased from Bachem. 
5.2.2  Sample preparation 
Preparation of enzymes, substrates and lisinopril samples was as described in 4.2.2, with Z-
FHL prepared in an identical manner to HHL.   
5.2.3  ITC Progress Curve Assays  
Assays were performed at 37°C using the Progress Curve protocol described in 4.2.5.  Buffer 
conditions for all substrates used (HHL, Z-FHL and Angiotensin I) consisted of 50mM TAPSO 
buffer (pH 7.5), 10µM ZnSO4 and either 0, 20 or 300mM NaCl.  Enzyme concentrations used 
varied between 2nM and 1000nM and were optimized for each assay to ensure substrate 














Assays were performed in triplicate as a minimum and all kinetic constants are reported as 
the mean of the three separate determinations along with standard error. 
5.2.4  ITC Binding Curves 
Assays were performed at 20°C using the protocol described in 4.2.6.  Data was analysed 
using Origin 7 software provided, primarily to provide the stoichiometry value N to adjust 
total protein concentration to active protein concentration via the assay acting as an active 
site titration (see Figure 4.1). Binding assays were performed with every preparation of 
enzyme used in Progress Curve kinetic assays in order to improve the accuracy of the kcat 
(=Vmax/[E]) values obtained in those experiments.  
5.2.5  Calculation of Thermodynamic parameters 
The thermodynamic parameters (ΔG, ΔH, ΔS) were determined using the kinetic data 
(kcat/Km) and the raw data from each of those assays.   The Gibbs free energy (ΔG) was 
calculated by the formula ΔG = -RT ln(kcat/Km), with R being the gas constant (1.9858  
cal.K-1.mol-1) and T being assay temperature (310 Kelvin).  The apparent enthalpy (ΔHapp) 
was determined for each assay via integration of the area under the curve using formula 2 
(see 4.2.4).  To exclude the contribution of buffer to enthalpy the intrinsic enthalpy (ΔHint) 
was calculated using the relationship ΔHapp = ΔHint + nH.ΔHion (ΔHion for TAPSO buffer = 9.378 
kcal/mol; nH = -0.37 for all substrates).  Incorporation of ΔG and ΔHint into ΔG= ΔHint – TΔS 
allows calculation of minus TΔS which is the entropy as a function of temperature.  These 
values were calculated separately for each assay, which were done in triplicate as a 
minimum, with values shown as mean and standard error.  The ΔG, ΔH, and ΔS values for 
lisinopril binding were calculated using Origin 7 with the iTC200 MicroCal Software Addon. 
5.2.6  Docking of substrates into tACE active site 
The short synthetic tri-peptides HHL and Z-FHL were docked into both the tACE-RXPA380 
crystal structure (PDB code 2OC2) and the N-domain389-RXP407 crystal structure (PDB code 
3NXQ) using the Accelrys Discovery Studio© Molecular Simulation program.  These crystal 
structures for both domains were used as RXPA380 and RXP407 are larger than lisinopril and 
extend further into the non-prime binding site where Z-FHL is likely to interact.  The HHL 
and Z-FHL molecules were built and minimized into the defined active site using CDOCKER 














ligands into a receptor binding site.  A minimum of ten poses were generated for each 
substrate in both tACE and N-domain structures.  These poses were visually evaluated based 
on proximity (<2.5Å) and orientation of: A) the scissile peptide carbonyl group (displayed in 
the geminal-diol form) to the active site zinc, and B) the C-terminal carboxylate to Lys511, a 
likely interaction given that this residue interacts with the lisinopril C-terminal carboxylate 
(Natesh et al 2003).  The pose that best fit these criteria and had the highest CDOCKER score 
was chosen.  
5.3  Results & Discussion 
Mutant tACEg13sol constructs showing greatest effect on chloride dependence and 
activation were characterised using HHL, Z-FHL and AngI under conditions of both 0mM and 
20mM NaCl.  Kinetic constants and thermodynamic parameters are displayed in Tables 5.1 
and 5.2 respectively and are represented graphically in the following sections in context 
with the discussion. 
5.3.1  Energetic Contributions in ACE binding and catalysis 
In order to assess the effect of chloride concentration on the thermodynamics of substrate 
hydrolysis, first the thermodynamics of inhibitor binding and substrate hydrolysis had to 
first be compared at constant chloride concentrations. Once a comparative framework had 
been established, the thermodynamic parameters associated with substrate binding and 
catalysis in the presence and absence of chloride were evaluated to determine the effects of 
chloride binding on enthalpy and entropy values. 
Figure 5.1A shows a representation of three different types of thermodynamic signatures 
that may be associated with drug binding, each having the identical ΔG and binding affinity, 
but differing in the relative contributions of ΔH and TΔS.  Scheme A displays a favourable ΔH 
and an unfavourable TΔS, with ligands showing this profile typically have large degree of 
flexibility and high polarity, which could negatively affect membrane permeability in vivo. 
Conversely, Scheme B shows a favourable TΔS and an unfavourable ΔH, indicating that 
binding is driven by hydrophobic interactions. Scheme C, with its favourable ΔH and TΔS, is 
















Table 5.1  Kinetic parameters for the cleavage of HHL, Z-FHL and Angiotensin I by ACE 
constructs.  Cleavage of HHL, Z-FHL and Angiotensin I by tACE, N-domain and a number of tACE 
mutant constructs. Constants were determined using ITC assay as described in 5.2.3 at 0mM and 
20mM NaCl (including 300mM for tACE with HHL) in 50mM TAPSO (pH 7.5) and 10µM ZnSO4.  
Values are shown as the mean of three separate determinations of Km, kcat and kcat/Km along with 
















Table 5.2  Thermodynamic parameters for the cleavage of HHL, Z-FHL and Angiotensin I by ACE 
constructs. Thermodynamic parameters associated with the cleavage of HHL, Z-FHL and 
Angiotensin I by tACE, N-domain and a number of tACE mutant constructs corresponding to the 
data from table 5.1.  Values were determined as described in 5.2.5 at 0mM and 20mM NaCl 
(including 300mM for tACE with HHL).  Values are shown as the mean of three separate 
determinations of ΔG, ΔH, -TΔS along with standard error of the mean. 
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Figure 5.1B shows the thermodynamic profile for the potent ACE inhibitor lisinopril with 
both tACEg13sol and N-domain at 20mM NaCl.  As is clearly evident, the profiles for both 
 
Figure 5.1  Thermodynamic signatures and energetic contributions.  A) Representative 
schematic showing three different thermodynamic signatures. Scheme A: good hydrogen 
bonding and a conformational change. Scheme B: binding dominated by hydrophobic 
interactions. Scheme C: Favourable hydrogen bonding and hydrophobic interactions. Key on the 
right indicates designated colours for ΔG, ΔH, -TΔS. (Adapted from Freire (2004))   B) 
Thermodynamic signature for lisinopril binding to tACE and N-domain at 20mM NaCl (calculated 
as described in 5.2.5).  C) Thermodynamic signature for the hydrolysis of HHL, Z-FHL and 
Angiotensin I by tACE and N-domain at 20mM NaCl, except for tACE with HHL which has maximal 














domains matches that of Scheme B exactly, with unfavourable ΔH and favourable TΔS 
showing the interaction is dominated by hydrophobic interactions.  The thermodynamic 
profiles shown here correlate strongly with those reported by Andujar-Sanchez et al (2007) 
who investigated lisinopril binding to somatic ACE. The relative binding of the tACE and N-
domain (13.5 and 4.6 nM respectively) is not as C-domain specific as previously reported 
(Wei et al., 1992). However, this could be attributed to high C-values (917 and 1226 for tACE 
and N-domain respectively) which, as a measure of the accuracy of the Kd estimation, should 
ideally be between 50 & 500, yet not exceed 1000.  Yet whilst the Kd estimations are on the 
lower limit of accurate detection, the calculated ΔG is largely unaffected, and, given that the 
determined ΔH values are quite accurate, there is a high degree of confidence in the overall 
thermodynamic profiles.   Of interest, the N-domain shows markedly more favourable 
enthalpy than tACE, as well as less favourable entropy, suggesting a greater degree of 
specific interaction points at the binding interface.   
The focus here though was not to evaluate inhibitor binding, but more to provide 
comparison with the thermodynamic parameters associated with substrate binding and 
catalysis.  In Figure 5.1C, the enthalpic and entropic trend is maintained for the 
thermodynamic parameters calculated for HHL, Z-FHL and AngI hydrolysis at chloride 
concentration of maximum activity (values in Table 5.2).  The ΔG values for Z-FHL for tACE 
and N-domain (-9.06 and -8.50 respectively) are far more favourable than those of either 
HHL or AngI by virtue of its considerably higher kcat, and the fact that these substrates have 
higher Km (HHL) and low kcat (AngI) values, respectively.  Furthermore, the enthalpy is very 
similar between the domains as well as between substrates for both domains.  This suggests 
that the enthalpic contributions, and presumably any mechanisms, are highly similar 
between the domains.  What is also evident for all substrates with both domains is the far 
larger contribution to ΔG by entropy (-TΔS) than enthalpy (ΔH), showing that binding is most 
likely driven by hydrophobic interactions, with desolvation of substrate and potentially 
structural changes being possible contributions.   
In comparing the ΔH values between lisinopril and the three substrates, it can be seen that 
the values for lisinopril are considerably higher.  This can be attributed to the large negative 
heat capacity change (ΔCp) reported by Ortiz-Salmeron et al (1998) for captopril, and 














considerably lower ΔHobs values at higher temperatures for the buffer system, hence poorer 
signal and data, thus the lisinopril binding assays were performed at 20°C.  Whilst the trend 
suggests that the ΔHobs for lisinopril should be comparable to those for the various 
substrates, comparison of ΔH values between lisinopril and the three substrates cannot be 
done with the available data due to the different reaction temperatures used.   
The large entropy contribution observed with lisinopril (and mirrored with HHL, Z-FHL and 
AngI) is indicative of the hydrophobic effect.  Andujar-Sanchez et al (2007) used the 
approach of Spolar & Record (1994) to deconvolute the entropic change in order to 
discriminate between rigid body associations and those involving coupled conformational 
change.  They found that a significant proportion of the entropy component could be 
attributed to conformational changes, which, along with the large ΔCp indicates that binding 
is not a rigid body interaction. This suggests that there is a fair degree of conformational 
change upon binding and supports the proposed ACE hinge bending mechanism 
(Watermeyer et al., 2006).  The closing of the active site would result in the association of 
numerous residues that would otherwise be bound to ordered solvent molecules when the 
protein is in an open conformation (Andujar-Sanchez et al., 2007).  In considering the types 
of interactions involved and the associated bond energies (summarised in Table 5.3), the 2-5  
Table 5.3  Enthalpic contribution associated with different types of bonding interactions. Values 















kcal/mol of energy heat that would be released by cleavage of the peptide bond could be 
counteracted by heat absorbed by a combination of other bond formations with the 
presumed structural change.  This provides a possible explanation for the endothermic 
(positive enthalpy) nature of the reactions, although considerably more information would 
be needed to fully delineate the exact contributions.  Thus, the enthalpy-entropy 
relationship is the same between inhibitor and substrate; hence it can readily be assumed 
that the structural mechanisms are shared between substrate hydrolysis and inhibitor 
binding. 
5.3.2  Effect of chloride on energetic contributions 
In evaluating the effect of chloride on the thermodynamic profile of tACE and N-domain, the 
thermodynamic parameters were determined in the presence or absence of chloride (Figure 
5.2).  There was a significant decrease in ΔG, hence lowered catalysis, in the absence of 
chloride for tACE and N-domain using AngI, HHL and Z-FHL.  For all three substrates there 
were negligible changes in the ΔH values suggesting that increased activity in the presence 
of chloride is entropically driven.  The fairly consistent ΔH with and without chloride 
between substrates suggests that the main interactions that form part of the catalytic 
mechanism are preserved, which is consistent with the observation that catalysis does occur 
in the absence of chloride.  Moreover, it is likely that the mechanism  does not involve 
majorly variable formation or breaking of bonds with the addition of chloride, which likely 
precludes the salt bridge breaking mechanisms proposed by Tzakos et al (2003). 
In order to better evaluate the chloride dependent shifts in thermodynamic data, the 
changes in ΔG, ΔH and -TΔS (ΔΔG, ΔΔH and –TΔΔS) between 0mM NaCl and the 
concentration of maximal activity (300mM for HHL, 20mM NaCl for Z-FHL and AngI) were 
calculated for both domains (Figure 5.2C).  For the C-domain the greatest change in ΔG is 
seen with HHL, with reduced change seen for Z-FHL and even less for AngI.  These changes 
in free energy are almost completely entropy driven, as evidenced by the –TΔS values 
showing an almost identical trend.  There is also almost no change in the enthalpy for AngI, 
with minor increases for HHL (0.236 kcal/mol) and Z-FHL approaching 0.5kcal/mol (0.475 
kcal/mol).  Given the magnitude of the bond energies shown in table 5.3, the cleavage of a 
peptide bond would presumably lead to a lowering of enthalpy by 2-5kcal/mol.  However, it 















would result in the formation of sufficient interactions, presumably stabilising in nature, to 
counterbalance the effect of peptide bond cleavage and result in an overall slightly positive 
ΔΔH.  The entropy linked increase in enthalpy would be a result of hydrophobic forces, 
either via desolvation of hydrophobic groups upon binding of substrate or via the formation 
of new bonds with a structural shift.  By contrast, the corresponding ΔΔG, ΔΔH and –TΔΔS 
 
Figure 5.2  Effect of chloride concentration on thermodynamic parameters associated with ACE 
hydrolysis.  Thermodynamic signature for the hydrolysis of HHL, Z-FHL and Angiotensin I at 0mM 
and 20mM NaCl by A) tACE and B) N-domain (values taken from table 5.2). The values for tACE 
with HHL at 300mM NaCl are included as this is the concentration of maximal activity and 
chloride saturation for this substrate and domain (whereas 20mM is the maximum for the other 
values). C) The ΔΔG, ΔΔH and –TΔΔS values for tACE and N-domain represent the difference in 
ΔG, ΔH, -TΔS between 0mM and 20mM (0mM and 300mM for HHL with tACE). D) Relative Kd,app 
values (left Y-axis) and fold increase in kcat/Km from 0mM to maximal activity (right Y-axis) for 














values for the N-domain present far less variation between the different substrates.  The 
ΔΔG and –TΔΔS for HHL are considerably less negative, whereas, in comparison, those for Z-
FHL are relatively unchanged with the AngI values being slightly more negative than those 
for tACE.  The larger entropic shift for AngI hydrolysis with the N-domain is driven by a 
~0.5kcal/mol increase in the enthalpy, which could be a loss of specific interactions due to 
variability of interactions with AngI between the two domains.  It could be expected, given 
the much larger size and presumably larger number of interactions, for there to be a greater 
degree of variability in the enthalpic component for AngI versus the two shorter peptides.  
However, if it is assumed that a fair degree of structural movement is occurring, presumably 
via the proposed hinge-bending mechanism (Watermeyer et al., 2006), it is possible that the 
larger peptide could be restricting this movement.  This would balance the enthalpic 
component, as the bonds formed by AngI binding would compensate for those that would 
presumably form due to the structural shift.  With this in mind, it could be surmised that the 
less variable entropic changes between substrates for the N-domain could be interpreted as 
the N-domain having a lesser degree of structural movement.  That the largest variation 
between domains is seen with HHL would indicate that the difference in substrate 
composition, and hence interactions, compared to Z-FHL and AngI could be responsible for 
the observed shift.  To highlight this variation, the Kd,app values (from 3.3.2, table 3.1) were 
compared with the fold increase in kcat/Km between 0 mM NaCl and maximal activity (using 
values from table 5.1) for HHL, Z-FHL and AngI for both domains (Figure 5.2 D).  The Kd,app 
and fold increase in activity for tACE with HHL is considerably higher than with all the other 
substrates for either domain.  This leads to two key questions: 1) How do the interactions of 
HHL with both domains lead to such variable degrees of chloride dependence and 
activation?; and 2) How do the interactions of Z-FHL and AngI differ to those of HHL in that 
their levels of activation and dependence are relatively similar between the two domains?  
These questions will be addressed in sections 5.3.4-5.3.7 in the evaluation of the tACE 
chloride mutants. 
5.3.3  Molecular Docking  
In order to evaluate potential interactions of the various substrates and provide context to 
the kinetic and thermodynamic data, molecular docking simulations for HHL and Z-FHL with 














active site residues are shown in Tables 5.4 and 5.5 along with corresponding interactions 
for the molecular docking simulations of AngI which were kindly provided by Dr Georgios 
Spyroulias (University of Patras, Greece).  It must be noted that the methodology employed 
for HHL and Z-FHL differs from that used for AngI. In the latter full global minimisations of 
both ligand and structure were performed, whereas HHL and Z-FHL ligands were docked 
into a rigid structure with local minimisations only.  Furthermore, the docking program 
described here did not allow for evaluation of specific hydrophobic interactions (light blue 
squares), thus for comparison if these residues were within 4Å of either HHL or Z-FHL they 
are indicated in smaller italicised font.   
The docking of HHL and Z-FHL into tACE (C-domain) showed interactions that correlate 
strongly with those of AngI, with the P2’ Leu extending into the S2’ pocket in all cases.  
Lys511, Tyr520 and Gln281 were shown to form either hydrogen bonds or salt bridges with 
the C-terminal carboxylate group of the peptide substrates, indicating good positioning of 
the peptide for presumed stabilization (Table 5.4; Figure 5.3 A & B).  Similar interactions are 
observed in the tACE-Lisinopril crystal structure (Sturrock et al., 2004; Natesh et al., 2003), 
adding further confirmation that the C-terminal carboxylate groups of the docked substrates 
are correctly positioned. 
The P1’ His of all three substrates extends into the S1’ pocket, although the relative 
orientation of the AngI imidazole ring does vary compared to that of HHL and Z-FHL.  This is 
where some discrepancy in the interactions with Ala354 becomes noticeable.  In Figure 
5.3A, Ala354 hydrogen bonds directly with the imidazole nitrogen of the HHL histidine, 
whereas for Z-FHL this interaction is not present due to differential positioning of the His 
side-chain.  Like HHL, Ala354 interacts with the P1’ His of AngI, however this is not via the 
imidazole ring but rather via the peptide backbone amide (Figure 5.3B). As mentioned, 
Ala354 doesn’t appear to bond directly to Z-FHL, however there is a compensatory 
interaction with Ala356 via the backbone amide of the P2 carboxybenzyl group.  Ala356 
doesn’t form interactions with HHL as the hippuryl group is positioned in the opposite 
direction thus orienting the amide away from the alanine.  The Ala356 to P2 amide 
hydrogen bond is not observed in the AngI simulation; however, the orientation more 
closely resembles that of Z-FHL suggesting the interaction may occur.  Visual inspection and 















Ala354 and Ala356 between HHL, Z-FHL and AngI suggest that there is a fair degree of 
differential rotation around the bonds to either side of the scissile bond carbonyl 
(represented by gem-diol in HHL and Z-FHL).  This, along with the observed shift in the 
orientation of the scissile bond carbonyl group relative to the catalytic zinc (which is clear 
for HHL vs Z-FHL, but less obvious for AngI due to lack of alignment), could account for the  
Table 5.4  Comparative molecular docking interactions for Angiotensin I, Z-FHL and HHL with 
tACE (C-domain).  All interactions for Angiotensin I were provided by Dr Ravi Acharya (University 
of Bath, UK).  HHL and Z-FHL were docked into the C -domain of ACE as described in 5.2.6 and 
interactions evaluated using Accelrys Discovery Studio software.  Only interactions that occurred 
in >25% of valid poses are shown.  Direct H-bonding interactions (X-H < 3.5 Å) are shown 
unaltered. Major hydrophobic interactions with non-polar residues: blue boxes. Pi-cation 
interactions between a hydrophobic residues and a charged cation group: blue shading.  Salt 
bridge/ionic interactions have the residues underlined. Substrate C-terminal COO- stabilization 
interactions: yellow shading.  Cl2 binding group/residues: grey shading. Residues within 3 Å of Z-
FHL or HHL that are shown to interact with Angiotensin I are shown in smaller, italicized font).   
  
P8 P7 P6 P5 P4 P3 P2 P1 P1' P2' 
tACE  Ang I   Asp    Arg   Val   Tyr   Ile   His   Pro   Phe   His   Leu 
  
Thr92  Lys118  Lys118  Tyr360  Trp357  Glu403  Phe391  Glu411  Glu162  Gln281  
  




Tyr523  His353  Lys511  
  
Asp121  Glu123  Pro407  
    











        
Val380  
           
Phe457  
           
Phe527  
            
 
Z-FHL 
      
Cbz Phe   His   Leu 
        
Ala356 
 
Tyr523 Lys511  
           
Tyr520 
           
Gln281 
        
Phe391 Phe512  Glu162  Phe457 
        
Glu403 Val518  His 353 His 513 




            
 
HHL 
       
Hipp His   Leu 
         
Arg522 Ala354 Lys511 
           
Tyr520 
           
Gln281 
            
         
Glu411 Glu162  Phe457 
         
Phe512 Val380 His 513 




















Figure 5.3  Stick representation of HHL, Z-FHL and AngI docked into the C-domain of ACE.             
A) Best representative overlaid poses for molecular docking of HHL and Z-FHL are shown in 
yellow and light blue sticks respectively; and B) Lowest energy conformation of AngI 
(sequence:DRVYIHPFHL) are shown as green sticks (HPFHL) and lines (DRVYI); both in the C-
domain of ACE which has key residues displayed as grey sticks and lines of ACE.  Active site zinc 
and chloride 2 pocket chloride ion are represented by the grey and green spheres respectively.  
Positions of the S2, S1, S1’ and S2’ sub-sites relative to substrates are indicated by faded blue 
half-circles.  Hydrogen bonds are indicated by dashed black lines.  Images were created using 














variability in overall catalytic rate between substrates.  Although this is unlikely to be the 
sole explanation, this could possibly explain the AngI maximal kcat being almost 40-fold 
lower than that of Z-FHL, which itself has a 2-fold lower kcat at maximal activity than HHL 
(Table 5.1).  In support of this assertion, Tyr523 forms a hydrogen bond with the primary 
amine of the P1’ His of Z-FHL, another differential interaction with that observed with AngI 
and HHL (table 5.1).  Where Tyr523 interacts with the AngI P1 Phe side-chain, the Tyr523 
doesn’t appear to form a hydrogen bond with the HHL P1 hippuryl amide but is similarly 
positioned and within 3Å.  It has been suggested that Tyr523 promotes formation of the 
tetrahedral gem-diolate intermediate (Sturrock et al., 2004; Hangauer et al., 1984) 
indicating its importance.  Given that the hydroxyl group of Tyr523 is positioned within 3Å of 
the scissile bond amide for all docked structures, yet positioned differently, supports the 
idea that orientation of the peptide backbone has an effect on catalytic efficiency. 
What did appear quite prevalently (~75% of poses) in the analysis was the presence of a 
potential Pi-cation interaction between the benzene ring of HHL hippurate and the 
positively charged Arg522, which is known to coordinate chloride (Liu et al., 2001; Natesh et 
al., 2003).  This type of interaction was not assessed in the docking simulations done for 
AngI, so it is difficult to draw conclusions.  However, the only part of AngI that could 
potentially form this interaction with R522 would be the P3 His and it is shown to hydrogen 
bond with E403, rendering Pi-cation interactions unlikely. 
In assessing the docking of HHL and Z-FHL into the N-domain, somewhat different substrate 
binding interactions were observed (Table 5.5).  The pattern of Z-FHL interactions with N-
domain shows a very similar pattern to that of the C-domain, with some key differences.  
The N-domain Ala334, like Ala356 in C-domain, forms a hydrogen bond with the backbone 
amide of the P2 carboxybenzyl group of Z-FHL (Figure 5.4 A). In the N-domain, Ala334 also 
interacts with AngI, although this is hydrophobically via the P2 Pro, a trend not observed for 
C-domain where AngI was not shown to interact with the corresponding Ala356. Also in 
common for both Z-FHL and AngI are interactions with Tyr501, Lys489, Tyr498 & Gln259 
(Tyr523, Lys511, Tyr520 & Gln281 in C-domain respectively).  Where they differ is that Z-FHL 
in the N-domain showed interactions with either Ala332 (backbone amide) and Thr358 
(imidazole nitrogen) which varied between poses and which were not observed in C-















Thr358 interactions.  Another point of variation is in the orientation of the Cbz benzene 
group of Z-FHL in the N-domain which allows it to form a Pi-cation bond with R381, an 
interaction that could not occur in the C-domain given that there is a Glu in that position 
(E403).   
Inspection of HHL interactions in the N-domain revealed the lack of Lys489 & Tyr498 (Lys511 
& Tyr520 in C-domain respectively) interactions with the C-terminal carboxylate group of 
HHL, whereas both Z-FHL and AngI show clear interactions with these residues (table 5.4).  
Firstly, it must be pointed out that all three residues that could potentially coordinate the C-
terminal carboxylate of HHL (Lys489, Tyr 498, Gln259) were less than 3Å away, with the 
maximum distance for hydrogen bonding to occur needing to be below 3Å.  Secondly, for 
the molecular dynamic simulations for HHL docking into the N-domain, 40 poses (4X that of 
the other simulations) had to be generated in order to get a single pose that met  
Table 5.5  Comparative molecular docking interactions for Angiotensin I, Z-FHL and HHL with 
ACE N-domain.  Methods, labels and descriptors are identical to those described in the legend for 
Table 5.4. 
  
P8 P7 P6 P5 P4 P3 P2 P1 P1' P2' 
N-domain Ang I   Asp    Arg   Val   Tyr   Ile   His   Pro   Phe   His   Leu 
  
 Arg90  Thr97  Trp201  Arg500  Leu32  Asp43  Ala334  Glu389  His331  Gln259  
   
Arg381  Pro385  
 
Val36  Thr496  
 
Tyr501  Ala332  His331  
      
Trp335  Arg500  
 
Phe490  Glu362  Lys489  
          
His491  Tyr498  
           
Phe435  
           
Phe505  
            
 
Z-FHL 
      
Cbz Phe   His Leu 








          
Ala332 Lys489 
        
Tyr369 Phe490 His491 Phe435 
         
Thr496 His331 Phe505 
            
 
HHL 
       
Hipp  His   Leu 
         
Arg500 His331 Gln259 
          
Glu362 
 
            
         
Phe490 Phe435 Lys489  
         
Arg381 His491 Tyr498 
          
Phe505 
 


















Figure 5.4  Stick representation of HHL, Z-FHL and AngI docked into the N-domain of ACE. A)  
Best representative overlaid poses for molecular docking of HHL and Z-FHL are shown in yellow 
and light blue sticks respectively; and B) Lowest energy conformation of AngI 
(sequence:DRVYIHPFHL) are shown as green sticks (PFHL) and lines (DRVYIH); both in the N-
domain of ACE which has key residues displayed as grey sticks and lines of ACE.  Active site zinc 
and chloride 2 pocket chloride ion are represented by the grey and green spheres respectively.  
Positions of the S2, S1, S1’ and S2’ sub-sites relative to substrates are indicated by faded blue 
half-circles.  Hydrogen bonds are indicated by dashed black lines.  Residues represented by boxes 
are done so for visualisation purposes. Images were created using PyMOL 0.99 (DeLano Scientific, 














requirements (outlined in 5.2.6).  As is evident from Figure 5.3B, there is a significant 
rotation to the HHL peptide backbone to the C-terminal side of the scissile bond, resulting in 
the His and Leu swapping pockets.  Whilst this is not ideal, the positioning of the gem-diol 
relative to the active site zinc was almost identical to that of the other docked substrates 
(HHL & Z-FHL), as well as that of the N-domain-AngI docked structure (not shown).  Looking 
at the composition of the S2’ pocket, into which the Leu of HHL should fit, it contains a 
number of residues that that vary between domains, with the N-domain being generally less 
hydrophobic.  Mutagenic work performed by Kroger et al (2009) where they converted all 
the variable residues in the tACE S2’ pocket to their N-domain counterparts, showed 
reductions in affinity for RXPA380, which had a bulky hydrophobic tryptophan in this pocket.  
This would indicate that the S2’ pocket is less hospitable for the hydrophobic Leu, and more 
hospitable to the polar acidic histidine.  The S1’ pocket shows no major variability in 
hydrophobicity between domains so it is unlikely that it drives this switch.  It could be 
suggested that the greater number of interactions in the S1 and S2 pockets of the N-domain 
for Z-FHL and AngI would prevent this rotational swapping of the His and Leu.  The only 
interaction observed in the P1 position for HHL with either domain is a Pi-cation bond 
between the Hippurate benzene and R500/R522 (N-domain/C-domain), suggesting that this 
is not a point of major variation between the respective substrate interactions.  This further 
enmeshes the idea that interactions in the P1’ and P2’ pocket may be key variables in the 
differing activity towards HHL between domains.  The switched orientations in the P1’ and 
P2’ residues of HHL could be written off as an artefact of the docking process.  However, if 
one relates it to the considerably lower maximal activity and reduced chloride dependence 
with HHL observed for the N-domain relative to tACE it may make some sense. Given the 
lack of interactions of HHL in the S1 and S2 pockets, it can be reasonably suggested that 
interactions in the S1’ and S2’ pockets may play an important role in the variable activity 
observed between domains.  
The key summation of this section would be that there is the potential for a degree of 
rotation around the peptide backbone.  This could be mediated by interactions of substrate 
P’ or P residues and represents a potential explanation for the variation in catalytic activity 
observed not only between domains (for the same substrate) but between substrates for 














affecting the P’ and/or P interactions and thereby modulating not only substrate affinity but 
catalysis as well.  These assertions form the basis with which to evaluate the effect that the 
chloride dependent tACE mutants have on substrate catalysis. 
5.3.4  Chloride 1 pocket 
The role of the chloride 1 pocket has been suggested to be involved in C-terminal 
stabilisation of substrates (Guy et al., 2003, Natesh et al., 2003, Sturrock et al., 2004), and 
initial mutagenic work by Rushworth et al (2008) showed that mutations in this pocket 
abrogated chloride activation with Angiotensin I.  In order to further our understanding of 
the role of the chloride 1 pocket and how it may affect interactions in the S1’ and S2’ 
subpockets, the R186H mutation was evaluated. This mutation involved the coordinating 
Arg in the C-domain being mutated to a His, the corresponding residue in the N-domain and 
the only difference in the respective pockets between the two domains.  The initial chloride 
titration evaluation (see 3.3.2.1) showed that R186H produced no significant change to 
either the overall activity or chloride binding for both HHL and Z-FHL.  Thus, chloride 
activation of AngI was also investigated.    
In Figure 5.5A the relative comparison in the overall levels of activity between tACE and 
R186H for HHL, Z-FHL and AngI is shown. The pattern of overall activity for HHL and Z-FHL 
correlates fairly well with that reported in 3.3.2.1, differing only in the HHL kcat/Km at 20mM 
NaCl for R186H being marginally lower than that for tACE.  The AngI kcat/Km for R186H 
relative to tACE is 40.38%, which compares extremely favourably with the 42.8% reported 
by Rushworth et al (2008), suggesting that both mutations are having a similar impact on 
the chloride 1 pocket.  Interestingly these variations in kcat/Km for AngI are due to the Km for 
R186H (0.095mM) being almost 3-fold higher than tACE (0.036mM), with very little change 
in kcat (7.83.s
-1 and 7.38.s-1 respectively).  This is in contrast to Z-FHL where the change is due 
to an almost 2-fold increase in kcat from tACE (282.0 s
-1) to R186H (509.5 s-1), with a 
concomitant minor increase in Km (0.120 and 0.150mM respectively).  HHL showed a similar 
pattern to AngI with an increased Km from tACE to R186H, yet a change in kcat with Z-FHL is 

















However, when the amount of activation between 0 mM and 20 mM NaCl is compared the 
effect is not the same. R186H maintains a very similar degree of activation for both Z-FHL 
and AngI relative to tACE and N-domain, with all showing a greater than 5-fold degree of 
activation (Figure 5.5B).  This is contrary to the observed activation for the R186Q mutation, 
 
Figure 5.5  Kinetic and thermodynamic comparisons for R186H. A) The kcat/Km for tACE (black 
bars) and R186H (white bars) taken as the percentage of the kcat/Km for tACE. The kcat/Km values 
were taken from table 5.1 and are for HHL, Z-FHL and AngI hydrolysis at 20mM NaCl.  B) The Z-
FHL and AngI kcat/Km means at 0mM NaCl for tACE (black bars), R186H (white bars) and N-domain 
(chequered) taken as the percentage of their respective kcat/Km means at 20mM, represented as a 
single bar of 100% for each construct. C) The Kd values (nM) for lisinopril binding to tACE (black 
bar) and R186H (white bars) at 0mM and 20mM.  Values were determined as described in 5.2.4 
and error bars indicate the standard deviation calculated by the non-linear regression fitting 
function provided. D) The ΔΔG, ΔΔH and –TΔΔS values for tACE and R186H represent the 














where Rushworth et al (2008) reported just a 1.2-fold activation when compared to the 8.1-
fold activation of the wildtype.  A  large change in binding affinity with lisinopril for R186H 
relative to tACE is also observed, with the Kd for R186H (132±6.2 nM) being ~3-fold higher 
than tACE (45.5±4.24 nM) at 0mM NaCl, as well as ~3-fold lower at 20mM NaCl (4.42±0.5 
and 13.5±2.06 respectively) which is displayed in Figure 5.5C.  This further indicates that 
chloride is somehow modulating the conformation via the chloride 1 pocket.  This suggests 
that a Glu in the 186 position of tACE (Rushworth et al., 2008) would be abolishing chloride 
coordination, given that chloride sensitivity is seemingly abrogated.   
Whilst it is tempting to assume that the R186H mutation would also abrogate chloride 
binding given lack of observed chloride in this pocket for the N-domain crystal structures, it 
is clear that chloride sensitivity is maintained whilst overall activity is affected.  The 
imidazole ring of histidine carries a positive charge and is potentially capable of coordinating 
chloride if orientated correctly, thus it is possible that the R186H mutation still binds 
chloride.  When comparing tACE to the R186H mutant, there is some difference (10-50%) in 
the enthalpic change upon chloride binding (ΔΔH) for the substrates, yet not more than 11% 
change in the overall ΔH values (Figure 5.5D and Table 5.2), which would suggest that there 
is no significant variation in interactions allowing for the possibility of chloride still 
interacting within the pocket.  If this were the case, it would suggest that there might be 
some steric hindrance preventing chloride  from accessing the chloride 1 pocket in the N-
domain.  However, other mutations generated by Rushworth et al (2008), namely W279A 
and R489Q in tACE, showed similar abrogation of chloride dependence to that of R186Q, 
indicating that coordination of chloride by R186 is not the only relevant interaction.  Tzakos 
et al (2003) suggested that, in the absence of chloride in the C-domain chloride 1 pocket, 
any of W279, W485 or W486 may form amino-aromatic interactions with K511, rendering 
its positive charge unavailable for coordinating the C-terminal carboxylate of the substrate.  
However, they didn’t describe any mechanism whereby binding of chloride, or lack thereof 
in the N-domain, may moderate this interaction.  Further structural inspection was 
warranted given the additional insights that the mutagenic and kinetic work presented here 
has provided.  
Figure 5.6 shows a schematic representation of the potential interactions observed in the 
















Figure 5.6  Comparative structural interrogation of the Chloride 1 pocket of the C and N-
domains of ACE. Interactions in the chloride 1 pocket and region between S2’ region were 
explored for A) C-domain crystal structures tACE-Lisinopril (PDB:1o86) and tACE-RXPA380 
(PDB:2OC2), and B) N-domain crystal structures N-domain-Lisinopril (PDB:2C6N) and N-
domain389-RXP407 (PDB:3NXQ).  Amino acids for both domains are shown in light blue boxes 
with the 2D side-chain structure attached, except for W279/257 and M278/256 where the 
protein backbone structure is shown and the boxes are placed next to the 2D sidechain structure. 
Boxes that are shaded in light red are those that were mutated by Rushworth et al (2008).  The 
grey box labelled ligand represents either a substrate or inhibitor bound in the active site, with 
the C-terminal carboxylate group structure attached.  Chloride ion is represented by the purple 
sphere. Bonding interactions are: salt bridges (solid green lines), hydrogen bonding (dashed 
green lines), Pi-cation bonds (dashed yellow lines), Pi-Pi bonds (solid yellow lines) and Pi-Sigma 














crystal structures were evaluated for each domain; namely, the lisinopril bound crystal 
structures of both domains as well as those with the domain selective inhibitors RXPA380 
(tACE) and RXP407 (N-domain), and found the pattern of interactions to be consistent for 
each domain.  Amino-aromatic (Pi-cation) interactions are formed between W279 and K511 
in tACE (Figure 5.6A), a pattern of binding that is also observed in the N-domain between 
W257 and K489 (Figure 5.6B).  Whereas Tzakos et al (2003) suggested that this interaction 
only forms in the absence of chloride in the C-domain, it is possible that it serves to both 
stabilize the orientation of K511/489 and that W279/257 acts as its carrier in transmitting 
effects of interactions in the chloride 1 pocket of both domains.  This is based on the idea 
that the amino group of Lys can form a Pi-cation interaction with W279 and hydrogen bond 
with the substrate carboxylate simultaneously (Mao et al., 2003). That the W279A mutation 
(Rushworth et al., 2008) abrogated chloride activation in tACE is indicative of how key this 
residue is in transmitting effects from the chloride 1 pocket.  
Interactions in the chloride 1 pocket were inspected to determine how a structural effect 
might be transmitted to W279 (W257 in N-domain).  As can be seen for both domains in 
Figure 5.6 A & B, R489 (R467) hydrogen bonds with the primary carbonyl group of W279 
(W257).  R489 in tACE is also involved in coordinating the chloride ion and hence only one of 
its amino groups contributes hydrogen bonds to the W279 carbonyl, whereas for the N-
domain, due to a lack of chloride coordination, dual hydrogen bonding of the R467 amino 
groups to the W257 carbonyl can be seen.  The R489Q mutation of Rushworth et al (2008) 
reduced activation with AngI as well, confirming its key role in chloride coordination but also 
supporting the assertion that it transmits its functional effects via interaction with W279 in 
tACE.  Given that chloride is not observed in the N-domain in this pocket, R467 would not be 
disrupted and it can be assumed that it’s binding of the W257 carbonyl would play a purely 
stabilizing role.  This suggests that, in the absence of chloride in this pocket in tACE, both 
amino groups of R489 would interact with the W279 carbonyl.  Both tACE and the N-domain 
show W486/464 forming a Pi-cation interaction with R489/467, the relevance of which is 
most likely that of stabilisation. 
The only variable residues between tACE and the N-domain in this pocket are R186 and 
H164, which occupy the same position within the pocket.  As can be seen for tACE in Figure 














other residues.  One of these is W182, where multiple Pi-cation interactions can form 
between the aromatic rings of the Trp and the amino groups of R186.  Interestingly, W160 
(W182 in tACE) is the only residue that H164 forms bonds with in the N-domain chloride 1 
pocket, which are instead of Pi-Pi interactions between the aromatic rings of both residues.  
Despite the different types of interactions between R186/H164 and W182/W160, their 
consistency between domains suggests they may be important in stabilisation.  Due to the 
nature of the arginine sidechain of R186 in tACE, it appears to make more interactions than 
H164.  One of these is the possibility of hydrogen bonding the M278 carbonyl group, which 
happens to be adjacent to W279 which has been suggested here to be of significance in 
orientating K511.  This represents another direct avenue (apart from R489) through which 
chloride coordination in the chloride 1 pocket can influence substrate.  Of interest in the N-
domain is a Pi-sigma interaction between M256 and W257 which was not observed 
between M278 and W279 in tACE.  This may be due to the R186 bonding with the M278 
carbonyl and affecting positioning of the M278 side-chain preventing this interaction.  
Another potential variation between domains is a Pi-cation interaction directly between the 
chloride coordinating R186 and W279.  
Thus far, a number of interactions that vary between the domains have been described; 
however, this has been with chloride bound in tACE pocket, whereas there is none bound in 
the N-domain.  From these interactions, certain potential mechanisms can be postulated as 
to what may be occurring in the chloride 1 pocket of tACE in the absence of chloride.  Given 
that the chloride is coord nated by arginines (R489 and R186), which can form multiple 
electrostatic interactions, there is unlikely to be any major change in their binding pattern 
apart from the loss of interaction with chloride.  R489 would still interact with W486 and the 
carbonyl of W279, and R186 would still interact with W182, W279 and the carbonyl of 
M278.  What could be suggested is that coordination of the chloride by these two arginines 
would shift their relative positions and thereby result in subtle shifts propagated via W279 
to K511.  Where tACE and the N-domain structures are overlaid, subtle differences in the 
positioning and orientation of all the residues described can be seen, and most markedly in 
those of R489 and R467 (Figure 5.7).  Overall, it is unlikely that there is any significant 
















subtle changes to the positioning of K511 and possibly the conformation of the S2’ sub-site 
are sufficiently large to affect overall ACE activity. 
In the absence of a crystal structure of the R186H mutant it is difficult to make any 
prediction as to what may be occurring and whether chloride would be present in the 
pocket.  In the absence of chloride the histidine of R186H could potentially form Pi-Pi 
interactions with W182 as H164 does with W160, with R489 showing similar dual 
coordination of the W279 carbonyl.  However, this does not explain the R186Q mutant of 
Rushworth et al (2008) that abrogated chloride dependence.  A glutamate in this position 
would be capable of coordinating chloride, but not be able to make as many additional 
 
Figure 5.7  Proposed key interactions between chloride 1 pocket and S2’ active site pocket. 
Representative stick overlay of tACE-Lisinopril (PDB:1o86) and N-domain-Lisinopril (PDB:2C6N) 
showing key interactions indicated in Figure 5.5 in and around the chloride 1 pocket.  tACE 
residues are shown in light blue sticks and N-domain residues are shown in green sticks, with 
residue labels shown in the same colour for each domain. Lisinopril is shown bound in the active 
site (yellow sticks), with the active site zinc (grey sphere) and chloride ions (purple spheres) 
indicated.  The position of the chloride 2 pocket is indicated via R522/R500 being adjacent to one 
of the chloride ions.  Bonding interactions are: hydrogen bonding (dashed green lines), Pi-cation 
bonds (dashed yellow lines), Pi-Pi bonds (solid yellow lines). Images were created using PyMOL 














interactions as an arginine, and, given its shorter side-chain length, be unlikely to coordinate 
the M278 carbonyl.  If the glutamate coordinated chloride, its shorter side-chain may force 
R489 to coordinate the chloride via the more distal ε-amino groups rather than the ε-amino 
linking the guanidinium group to the side-chain, thus potentially preventing R489 from 
binding to the W279 carbonyl.  This would explain the reduction of activation observed for 
the R489Q mutation of Rushworth et al (2008), where the differential chloride coordination 
between the shorter glutamate and R186 might preclude interaction with the W279 
carbonyl.  The R489Q mutation still showed some activation, and this could be explained via 
R186 still being able to interact with the M278 carbonyl.  In tACE this all serves to indicate 
that interactions of R489 and R186 with the M278 and W279 carbonyls, respectively, 
transmit the effects of chloride coordination in the chloride 1 pocket to the substrate 
coordinating K511.  In the N-domain there would be no chloride mediated shift and hence 
only the R467 to W257 carbonyl interaction would occur.   
For the sake of simplicity, the transmitted effects from the chloride 1 pocket to the S2’ 
active site pocket where K511 is situated could be described as resulting in two 
conformational “states” in tACE (due to chloride binding) and one conformational “state” in 
the N-domain.  In this context, the work done by Liu et al (2001) can be considered, where 
they evaluated a number of tetrapeptides that differed in their P1’ and P2’ residue 
identities.  The P2 and P1 residues were an acetylated Ala and a Phe and were consistent 
across all peptides.  What was very clear is that the nature of the prime positioned dipeptide 
structure greatly affected chloride dependence.  The one peptide that shared the same P1’ 
and P2’ identity as HHL, Z-FHL and AngI, AcAFHL, displayed a Kd,app of 30mM which suggests 
that it behaves far more like HHL (Kd,app = 47mM) than either Z-FHL (1.8mM; table 3.1) or 
AngI (5.4mM; Wei et al., 1991b).  However, tetrapeptides containing a P2’-Arg greatly 
increased chloride binding affinity (e.g. AcAFHR Kd,app = 5mM), and even these were 
influenced up to 2-4 fold by varying the P1’ residues (e.g. AcAFAR Kd,app = 1.6mM).  These 
P2’-Arg tetrapeptides also had lower Km values and had higher activity at 0mM NaCl relative 
to that at maximal chloride concentration.  Conversely, tetrapeptides with P2’-Gly 
substitutions (AcAFAG & AcAFGG) showed increased Kd,app and Km values relative to AcAFHL.  
This data shows that interactions in the S1’ and S2’ pockets are not only important for 














these interactions would affect the positioning of the C-terminal carboxylate of the 
substrate.  Thus, dependent on the composition of P1’ and P2’ residues, the C-terminal 
carboxylate may be positioned either favourably or unfavourably relative to the K511.  
Taking into consideration that tACE would have two different conformational states (due to 
chloride binding in the chloride 1 pocket) and the N-domain only one, this may be a way in 
which chloride further modulates activity in a substrate dependent manner in the C-domain.   
 
5.3.5  Chloride 2 pocket 
Whilst the nature of the prime binding dipeptide and interactions within the chloride 1 
pocket may help explain the varying levels of overall activity between domains, it does not 
adequately describe how these interactions affect binding of chloride in the chloride 2 
pocket, which has been shown to be the mechanistically important (Liu et al., 2001; section 
3.3.2.3).  Evidence from the molecular docking simulations (Section 5.2.6) suggested that 
the orientation of the peptide backbone varied considerably between substrates.  Excluding 
the influence of S1 and S2 interactions for now, this could be determined by the 
combination of P’ dipeptide interactions and the relative orientation of the K511 moderated 
by the chloride 1 pocket, both affecting how the C-terminal carboxylate could be positioned.  
The C-terminal carboxylate coordination would determine (at least partially) what 
orientation the substrate backbone settled in and hence what interactions could be formed.  
In this regards, there was shown to be variability in the positioning of the scissile bond 
relative to Y523 in tACE and Y501 in the N-domain, both of which are suggested to be of 
importance in stabilizing the tetrahedral substrate intermediate.  This all suggests that the 
positioning of this tyrosine relative to the peptide backbone varies between substrates and 
affects the catalytic efficiency. Thus, the role of Y523/Y501 relative to the chloride 2 pocket 
was investigated to elucidate the mechanism of action upon chloride ion coordination by 
R522/R500.  
5.3.5.1  Pi-cation interactions between R522/500 and Y523/501 
Upon inspection of the various ACE crystal structures, Pi-cation interactions between R522 
and Y523 (R500 and Y501 in N-domain) were observed, which were remarkably consistent 















(1993) describe a similar arrangement found in Glutathione S-Transferase (GST).  They found 
that a Thr on-face hydrogen bonding with the Pi-cloud of a Tyr affected catalysis by 
“contributing a second-sphere interaction which influences the hydrogen bond between the 
hydroxyl group of tyrosine 6 and the sulphur of bound glutathione anion (GS-)”.  This 
interaction with the Pi-electron cloud of a Tyr contributed measurably (-4 kJ/mol) to the 
ability of the hydroxyl group of tyrosine 6 to stabilize the thiolate anion.  They also suggest 
that this effect could translate to Pi-cation interactions, which is what is observed between 
R522 and Y523 (R500 and Y501 in N-domain).  If this is the case, it would likely enhance the 
ability of Y523/Y501 to stabilize the transition-state intermediate in ACE hydrolysis.  This 
 
Figure 5.8  Pi-Cation Interactions between R522/500 and Y523/501.  Stick representation 
showing Pi-Cation bonding between R522 and Y523 in tACE (A & B) and R500 and Y501 in the N-
domain (C & D) with lisinopril (A & C), RXPA380 (B) and RXP407 (D) inhibitors bound in the active 
site.  Residues are shown as grey sticks, chloride and zinc as green and grey spheres respectively, 
with inhibitors bound in the active site as yellow sticks.  Crystal structures shown are A) tACE-
Lisinopril (PDB:1O86), B) tACE-RXPA380 (PDB:2OC2), C) N-domain-Lisinopril (PDB:2C6N) and D) N-















would also explain the critical nature of chloride coordination by R522 (R500), as this would 
stabilize the positioning of Y523 (Y501).   
5.3.5.2  A structural role for D465/443 
The question then is whether this Arg-Tyr interaction occurs in the absence of chloride or is 
induced by chloride binding, given that all crystal structures of both ACE domains show 
chloride present in the chloride 2 pocket.  One point of evaluation is the potential for the 
formation of a salt bridge between the R522 (R500) and D465 (D443) as proposed by Tzakos 
et al (2003).  In evaluating the crystal structures of tACE and the N-domain complexed with 
lisinopril, extensive hydrogen bonding between the D465 (D443) carboxylate and primary 
amides of both Y520 (Y498) and I521 (I499) is seen (see Figure 5.9A).  Y520, I521, R522, Y523 
(Y498, I499, R500, Y501 in N-domain) are the first four residues on the C-terminal end of the 
α23 helix (Y520-A541), with P519 representing the end of the helix and the beginning of a 
highly variable loop.  Tzakos et al (2003) indicate there would have to be some structural 
rearrangement of this variable loop for a salt bridge to form between R522/500 and 
D465/443.  Figure 5.9B shows the positioning of this variable loop situated between 
R522/500 and D465/443, indicating that there would have to be some movement of the 
P519 kink for a salt bridge to form.   
However, this region of α23 helix is within subdomain II of both domains, a region predicted 
to have little major structural variation relative to the proposed hinge region which is part of 
subdomain I (Watermeyer et al., 2006).  This would suggest that there is insufficient 
structural change in this region to facilitate a salt bridge between D465/443 and R522/500 
and would suggest that D465/D443 plays role in stabilization of the end of the variable loop 
and helix α23.  Figure 5.9A indicates the relative positioning of helices α23 and α20, which 
indicates that the C-terminal end of α23 is the main point of contact with α20, supporting a 
structural role for D465/443.  Further to this, in tACE D465 hydrogen bonds with R468 which 
interacts strongly with the variable loop via hydrogen bonds with backbone primary 
carbonyl groups of H513 and V518.  In N-domain the D443 doesn’t interact with the 
corresponding R446, but R446 does hydrogen bond with T496 which corresponds to V518 in 
tACE.  Both V518, which lines the S1 active site subpocket, and His513, which interacts with 















residues which reside on this variable loop.  Suffice to say, given that D465/443 is one of 
very few contacts between helices α23 and α20, its role is most likely in stabilisation of the 
C-terminal end of helix α23. 
Supporting this assertion is the chloride titration data from Chapter 3 determined for HHL 
and Z-FHL using the D465T tACE mutant (Table 3.1).  The mutation was generated in order 
that the charge, hence its ability to form a salt bridge, was abolished yet it maintained a 
similar size and reduced capacity for hydrogen bonding with the single hydroxyl group of 
threonine.  The anticipated result for D465T, if D465 forms a salt bridge with R522, would 
have been higher %SAmax values compared to tACE as R522 would presumably have allowed 
 
Figure 5.9  Interaction of D465/D443 with the Chloride 2 pocket.  A)  Representative stick 
overlay of tACE-Lisinopril (PDB:1o86) and N-domain-Lisinopril (PDB:2C6N) showing positioning of 
D465/D443 relative to R522/R500 in the chloride 2 pocket.  tACE residues are shown in light blue 
sticks and N-domain residues are shown in green sticks, with residue labels shown in the same 
colour for each domain. Alpha helices α15 and α17 are labelled. Lisinopril is shown bound in the 
active site (yellow sticks), with the active site zinc (grey sphere) and chloride ions (purple spheres) 
indicated. Hydrogen bonding is indicated by dashed yellow lines. Images were created using 
PyMOL 0.99 (DeLano Scientific, Palo Alto, CA, U.S.A).  B) Representative stick overlay of tACE-
Lisinopril (PDB:1o86) and N-domain-Lisinopril (PDB:2C6N) showing a close-up of the region 
between R522 (R500) and D465 (D443).  D465 (D443), P519 (P497) and R522 (R500) are shown as 
orange, yellow and grey sticks respectively.  Chloride coordinated by R522 is shown as a purple 















Y523 to swing into the active site.  Instead, both the SAmax and the %SAmax (activity at 0mM 
NaCl as percentage of maximal activity) for D465T with both HHL and Z-FHL were lower than 
that of tACE.  An increase in Kd,app for Z-FHL and a decrease for HHL with D465Twas also 
observed which cannot be explained using the salt bridge hypothesis.  This also does not 
correlate with the chloride channel hypothesis where E403 in tACE is supposed to “gate” 
access, which would presumably mean a fairly constant Kd,app for chloride binding.  That 
D465/443 is on the opposite side of the chloride 2 pocket to the proposed channel area 
precludes any direct interaction.  These results make more sense in the context of the 
suggestion presented here that D465/443 stabilizes the C-terminal end of helix α23 and the 
variable loop via hydrogen bonding with the primary amides of Y520/498 and I521/499.  A 
Thr in this position would be capable of fewer potential hydrogen bonds, presumably 
resulting in greater structural movement which could affect the C-terminal carboxylate 
coordinating Y520/498 (lowering of SAmax).  Its effect on %SAmax and Kd,app would presumably 
be due to structural destabilization, which suggests that structural rotation or movement 
around the C-terminal end of helix α23 which contains R522/500 and Y523/501 moderates 
not only activity, but chloride affinity. 
 
5.3.5.3  R522 mutants and interactions with Y523 and chloride. 
The previous section established that there is a low likelihood that D465/443 forms a salt 
bridge with R522/500 in the absence of chloride in the chloride 2 pocket.  This would 
suggest that the R522/500 sidechain would occupy roughly the same position it does when 
chloride is not present, obviously though with a fair degree of rotational freedom given the 
lack of chloride coordination.  This begs the question of whether the R522/500 to Y523/501 
Pi-cation interaction described earlier is present in the absence of chloride or whether 
chloride binding induces this interaction. 
To probe this interaction, the effect of replacing R522 with a Lys and Gln on the enzyme 
kinetics constants was investigated. In order to evaluate the data, however, it must be 















affect the type of interactions.  The potential interactions between Y523, chloride and either 
the Arg, Lys or Gln residues which are in the 522 position of tACE, R522K and R522Q 
respectively are depicted in the schematic shown in Figure 5.10.  As has been described for 
tACE, R522 forms a Pi-cation interaction with Y523 (NH1) (5.3.5.1) and coordinates the 
chloride ion (NE) (Natesh et al., 2003).  The change to a Lys in R522K means that there is 
only one amino group available to form hydrogen bonds.  In unpublished work, 
collaborators (Dr Ravi K. Acharya, University of Bath, UK) have determined the R522K crystal 
structure and have found that chloride is present in the active site and is being coordinated 
to the Lys amino group via a water molecule, which is presumably part of its hydration shell.  
Not having the structure available at time of writing does restrict evaluation of whether the 
Pi-cation interaction is occurring.  The change to Gln in R522Q presents an alternate 
scenario where the terminal amino group might form Pi-cation bonds with Y523.  This can 
be suggested as the shorter chain length would actually put the amino group closer to the 
optimal angle (90° to the plane of the Tyr ring structure).  Pi-cation interactions are at their 
strongest when the cation is perpendicular (90°) to the plane of aromatic ring atoms, with 
variations in this geometry still exhibiting a significant interaction which weakens as the 
angle approaches 0 degrees (Marshall et al., 2009).  Looking back at Figure 5.7, the Pi-cation 
interaction for R522-Y523 is actually offset from 90°, indicating that a shorter Gln side-chain 
might result in a more favourable reaction with the amino group closer to 90°.  The carbonyl 
group of Gln is also capable of hydrogen bonding, but whether it directly coordinates  
 
Figure 5.10  Potential interactions with Y523 and chloride for R522K and R522Q mutants. 
Shown are two dimensional representations of amino acid residues Y523 and either Arg, Lys or 
Gln in tACE, R522K and R522Q respectively. Chlorides are indicated by purple spheres. Bonding 
interactions are: hydrogen bonding (dashed green lines), Pi-cation bonds (dashed orange lines). 
















Figure 5.11  Trends in chloride binding and activity for R522Q and R522K. Graphical 
representation of chloride binding and kinetic values obtained for tACE (black bar), R522K (dotted 
bars) and R522Q (chequered bars) with HHL, Z-FHL and AngI as substrates. A) The Kd,app values 
(mM) for chloride binding. Values for HHL and Z-FHL were taken from Table 3.1, and those for 
AngI were estimated from the report of Liu et al (2001) (the red “x” indicates no available data) 
B) The maximal kcat/Km values taken from table 5.1 for HHL, Z-FHL and AngI hydrolysis at 20mM 
NaCl (except for HHL with tACE which was at 300mM NaCl).  C) The kcat/Km values from B 
(indicated by blue arrow) taken as the percentage of the kcat/Km for tACE for each substrate. D) 
The minimal kcat/Km values taken from table 5.1 for HHL, Z-FHL and AngI hydrolysis at 0mM NaCl. 
E) The kcat/Km values from D (indicated by blue arrow) taken as the percentage of the kcat/Km for 














chloride or does so via the hydration shell like Lys is not readily apparent.   
Given these potential interactions, the kinetic data obtained for R522K and R522Q mutants 
relative to tACE can be assessed.  Comparing the Kd,app values for HHL and Z-FHL (see 3.3.2.3) 
with those reported by Liu et al (2001) for AngI (see Figure 5.11A), the largest increases over 
tACE are seen for HHL with R522K (7-fold) and R522Q (9-fold).  These increased Kd,app values 
for HHL correlate with the lack of activation seen when comparing the kcat/Km values 
obtained at highest concentration of NaCl and 0mM NaCl (Figure 5.11 B & C).  In light of the 
evidence that R522K interacts with the chloride hydration shell, it can be suggested that, 
given the similar Kd,app values, R522Q might conceivably indirectly interact with chloride in a 
similar manner via the Gln carbonyl group (see Figure 5.10).   
A similar trend is seen with the Kd,app values for Z-FHL, though not to the same degree as 
HHL.  A chloride titration protocol was not established for AngI in this study, hence the Kd,app 
values Liu et al (2001) reported for tACE and the R522K mutant have been displayed (they 
stated that the R522Q Kd,app could not be detected).  Where Liu et al (2001) saw no change 
in kcat/Km for R522Q, an increase in kcat/Km between 0 and 20mM NaCl (141.75 and 179.5 
.mM-1.s-1 respectively; table 5.1) is seen indicating that some activation is occurring and that 
the difference is too small for an accurate detection of Kd,app.  It can be suggested that the 
Kd,app trend for AngI is the same as that for HHL and Z-FHL and estimate the Kd,app to be 
~100mM.  Irrespective of this assertion, it can be seen that R522K and R522Q are reducing 
the affinity of chloride.  What is interesting is that R522K and R522Q are following the same 
Kd,app trend as tACE (AngI<Z-FHL<HHL), though proportionally higher than tACE for each.  
This would indicate that substrate interactions are somehow moderating access or binding 
of chloride.  Considering that chloride is present in the pocket of R522K, it can be surmised 
that the effect is on the coordination of chloride and not on access of chloride to the pocket.   
Another interaction to consider is whether the Lys or Gln in R522K and R522Q respectively 
are forming Pi-cation interactions with Y523 (see Figure 5.10).  Looking at the maximal 
kcat/Km values for HHL, Z-FHL and AngI (Figure 5.11A) confirmation of the varying levels of 
activity for the three substrates with tACE (Z-FHL>HHL>AngI) can be seen.  As would be 
expected with disruption of a key active site residue, the kcat/Km values for R522K and R522Q 














the kcat/Km values for R522K and R522Q are represented as a percentage of the kcat/Km 
values for tACE (Figure 5.11B).  Here the role that the nature of the substrate plays is clearly 
evident, where both R522K and R522Q see increases in activity with larger substrates that 
interact more tightly with the S1 and S2 active site pockets.  Whilst R522K shows only a 
marginal increase over HHL (AngI:15.6% >Z-FHL:9.3%>HHL:0.1%) relative to tACE, there is a 
marked increase for R522Q (AngI:87.7% >Z-FHL:27.5%>HHL:0.36%) to the point where 
R522Q activity is almost as high as tACE with AngI.  This would indicate at the very least that 
the bonding pattern is different between R522K and R522Q.  A further trend is in regard to 
the contributions of Km and kcat to kcat/Km for R522Q and R522K.  For HHL the mechanistic 
lack of activation is evidence by there being very little variation in Km but marked differences 
in the kcat , where values are very similar at 0mM chloride and only tACE shows an increase 
at 20mM (127.0 s-1 vs 4.8 s-1 and 2.08 s-1 for R522Q and R522K respectively; table 5.1).  
Interestingly, R522Q shows a 5-fold tighter Km for Z-FHL at 0mM NaCl than tACE (0.110mM 
and 0.580mM respectively), yet this trend is reversed at 20mM with R522Q being ~2-fold 
higher than tACE (0.20mM and 0.12mM respectively).  These data show that Km for R522Q 
with Z-FHL is higher at 20mM than 0mM, a reversal of the general trend for tACE with all 
substrates.  R522K hydrolysis of Z-FHL also shows a Km at 20mM (0.880mM) being higher 
than at 0mM (0.570mM), which shows that this is not a spurious result with R522Q.  Both 
R522Q and R522K show less than 2-fold increases in kcat from 0mM to 20mM NaCl, versus 
the >3-fold increase observed for tACE.  Thus the large decrease in activation for R522Q and 
R522K with Z-FHL is influenced by the increased Km as well as the reduced kcat associated 
with the presence of chloride, in contrast to HHL which is predominantly kcat influenced.  
Interestingly, a similar lack of variance is seen in Km values for R522Q and R522K with AngI 
(though they are 2-fold higher than tACE) and greater variation in kcat which is more similar 
to the HHL profile.  The increases in Km observed for all substrates with R522K and, to a 
lesser degree, R522Q indicates that coordination by chloride in this pocket affects substrate 
affinity as well as catalysis, suggesting some structural movement around helix α23.  What is 
most noticeable between R522K and R522Q is the greater kcat values for R522Q that 
increase with substrate length and are even higher than tACE for AngI.  Taking the Kd,app data 
already described for R522K and R522Q into account where it was ascertained that both 
residues were interacting with chloride via the hydration shell, it is most likely their ability to 














that the R522Q Gln is forming Pi-cation interactions with Y523 resulting in more efficient 
catalysis, and that the greater interactions of Z-FHL and AngI in the S1 and S2 pockets are 
compensating for the lack of direct chloride coordination, presumably via some structural 
effect.  This would also suggest that the R522K Lys does not form such an interaction as 
readily, where the structural interactions of Z-FHL and AngI don’t sufficiently stabilize Y523 
on its own.   
The next question would be whether chloride coordination induces R522 to form Pi-cation 
interactions with Y523, or whether this interaction is present already and chloride 
coordination merely stabilizes them.  This is addressed by referring to the kcat/Km values for 
HHL, Z-FHL and AngI at 0mM NaCl (Figure 5.11C) which are also represented as percentages 
of tACE activity for each substrate (Figure 5.11D).  The kcat/Km values for HHL with all 
constructs are all extremely low and comparable to each other, yet for Z-FHL and AngI 
considerable increases in activity are seen for R522Q over both tACE and R522K.  
Considering the hypothesis that the R522Q Gln doesn’t directly coordinate chloride yet Pi-
bonds with Y523, and that Z-FHL and AngI interactions in S1/S2 pockets affects their 
position, then this would indicate that a similar mechanism occurs in the absence of 
chloride.  That tACE activity at 0mM NaCl is substantially lower than R522Q suggests that 
the Arg does not Pi-bond with Y523 in the absence of chloride, which would indicate that 
chloride coordination is necessary for this to occur.  There were no substantial changes in 
activity for R522K at 0mM NaCl for any of the substrates indicating that the Lys doesn’t Pi-
bond with Y523.   
The change in thermodynamic profiles upon chloride addition for R522Q and R522K (Figure 
5.12), were evaluated.  For R522Q a reduced endothermic change in enthalpy is seen for 
HHL (0.165kcal/mol) and ZHFL (0.105 kcal/mol) relative to tACE (0.36 and 0.48 kcal/mol 
respectively), which would indicate the loss of an interaction. Presumably this would be loss 
of the salt bridge/hydrogen bonding interaction with chloride, essentially showing reduced 
variation with chloride present.  That the ΔΔH values don’t exceed the minimum hydrogen 
bonding energy (1kcal/mol) might be due to differing hydration effects associated with the 















For R522K there is a different pattern with the enthalpy changes, with HHL (-0.07kcal/mol)   
showing an exothermic shift relative to tACE (0.36kcal/mol), AngI (0.35kcal/mol) showing an 
endothermic shift relative to tACE (0.024kcal/mol), and Z-FHL relatively unchanged.  As with 
R522Q, an exothermic shift would suggest a bond breaking for HHL which would be 
expected with the lack of direct chloride coordination.  The lack of variation in enthalpy with 
Z-FHL for R522K is interesting seeing that there is no ΔΔG and the kcat/Km is lower than tACE 
and R522Q at both 0 and 20mM NaCl.  Given the assertions that Lys neither coordinates 
chloride nor Pi-cation bonds with Y523, the interactions of Z-FHL in the S1 and S2 pockets 
may be compensating via minor structural shifts.  The endothermic shift in enthalpy 
observed with AngI for R522K is accompanied by a relatively large shift in free energy (-
0.989kcal/mol) similar in magnitude to tACE (-1.087kcal/mol), which actually results in a 
larger –TΔΔS due to the more endothermic enthalpy shift.  As can be seen from table 5.1, 
there is a 5-fold increase in kcat/Km from 0mM to 20mM resulting in the observed ΔΔG, 
although these values are considerably lower than tACE.  The molecular docking of AngI into 
tACE (table 5.4) indicates that the P3 His of substrate protrudes into the chloride 2 pocket 
and interacts with the chloride ion itself.  This opens the possibility that the AngI P3 His may 
 
Figure 5.12  Change in thermodynamic parameters for R522Q and R522K.  The ΔΔG, ΔΔH and –
TΔΔS values for tACE, R522Q and R522K with HHL, Z-FHL and AngI are shown and represent the 














coordinate chloride via the Lys of R522K, which would account for the chloride mediated 
ΔΔG as well as the lower level of activity overall with AngI.  
In summary, chloride coordination is necessary to correctly orientate R522 to Pi-bond with 
Y523, thereby promoting catalysis of substrate.  Substrate interactions within the S1/S2 
pockets affect positioning of this complex, presumably via structural effects.  Furthermore, 
this provides a rationale whereby substrate binding modulates chloride affinity and hence 
its own catalysis, a feature that is explored further in the following sections. 
 
5.3.6  Chloride channel 
Thus far, evidence has been provided for a critical interaction between R522 and Y523 that 
is induced by chloride binding, however it has also been observed that chloride binding was 
affected by larger substrates which indicated a role for the S1, S2 and other non-prime 
pockets.   The E403R mutation was generated to investigate a proposed chloride channel, 
where the E403 that was postulated by Tzakos et al (2003) to act as an ionic gate mediating 
access of chloride to the chloride 2 pocket. The Glu was converted to an Arg, corresponding 
to R381 in the same position in the N-domain.  It was shown in section 3.3.2.2 that the 
E403R mutation significantly reduced Kd,app for chloride binding with HHL and Z-FHL relative 
to tACE, and that this effect was reversible in the N-domain when R381 was converted to a 
Glu.  It was also suggested that interactions of substrate in the S2 sub-pocket where E403 
resides would somehow disrupt its gating function, evidenced by the large discrepancy in 
Kd,app seen between HHL and Z-FHL for tACE which was largely abolished with E403R.   
However, not only are Kd,app  different with different substrates, which would suggest 
chloride coordination is affected,  but changes in overall activity and degrees of activation 
are also seen which begged further inquiry into whether E403 merely acts as a gate for entry 
of chloride.  Figure 5.13 shows the E403R kcat/Km relative to tACE (using values from table 
5.1) at maximal activity (A & B) and at 0mM NaCl (C &D) for HHL, Z-FHL and AngI.  The 
kcat/Km values for E403R with all substrates at maximal activity are generally lower relative 
to tACE, whereas at 0mM NaCl they are all higher.  This indicates that E403 affects activity 
as well as potentially mediating access of chloride to the chloride 2 pocket.   It was proposed 















chloride, where chloride binding would disrupt this interaction, coordinate R522 and allow 
Y523 to swing into the active site.  Furthermore, K118 residue was proposed to enhance the 
R522-E403 salt bridge by also forming a salt bridge with E403.  Mutation of the K118 
corresponding residues, K154 in rabbit testicular ACE (Sen et al., 1993), and K694 of rabbit 
lung ACE (Chen et al., 1990), drastically reduced chloride sensitivity, thus highlighting its 
critical role.  Looking at Figure 5.14, K118 is 5.13Å away from E403 in the lisinopril bound 
 
Figure 5.13  Minimal and maximal kcat/Km for E403R relative to tACE. Graphical representation 
of kcat/Km kinetic values obtained for tACE (black bar) and E403R (chequered bars) with HHL, Z-
FHL and AngI as substrates. A) The maximal kcat/Km values taken from table 5.1 for HHL, Z-FHL and 
AngI hydrolysis at 20mM NaCl (except for HHL with tACE which was at 300mM NaCl).  B) The 
kcat/Km values from A (indicated by blue arrow) taken as the percentage of the kcat/Km for tACE for 
each substrate. C) The minimal kcat/Km values taken from table 5.1 for HHL, Z-FHL and AngI 
hydrolysis at 0mM NaCl. D) The kcat/Km values from C (indicated by blue arrow) taken as the 














structure (PDB:1O86), whereas in the unbound structure (PDB:2IUL, not shown) these form 
a salt bridge (2.13Å).  Of interest, Tzakos et al (2003) claim that these mutations reduce a 
potent interaction of E403 with R522, suggesting that the E403-R522 salt bridge would still 
be present.  This does not correlate with the reduced chloride sensitivity observed by Sen et 
al (1993) and Chen et al (1990) for mutation of this residue.  Looking at the potential for an 
R522-E403 salt bridge in the absence of chloride, the distances of 7.9Å and 9.2Å are noted 
for the lisinopril-bound (PDB:1O86) and open structures (PDB:2UIL).  This would require a 
conformational change resulting in the protein backbone moving at least 5Å in order for a 
salt bridge to form.  This would have to be done either via movement of the 310 helix H5 
down towards α17 to bring E403 closer to R522 or from the movement of helix α23 up in 
order for R522 to move closer to E403 (Figure 5.14).  Helix α23 is already in close proximity 
to helix α17 and significant potential for this movement is not seen as it would affect the 
position of E411, which is critical to active site zinc coordination, as well as Y520 and Y523 
relative to the active site.  The H5 movement down also seems unlikely as this would require 
a shift of helix α15 (not shown) which contains the HEMGH zinc binding motif, also critical to 
active site zinc coordination.  Obviously these conformational changes can occur at the 
same time and would thus have to move less to bring both residues closer, however, all of 
these helices mentioned fall within the subdomain II of tACE, which has been shown to have 
a high degree of structural rigidity and showing little movement relative to neighbouring 
residues (Watermeyer et al., 2006).  Of interest in their work, they highlighted regions 
containing residues 400-409 (containing E403 and P407) and 98-125 (containing K118) as 
part of a proposed hinge-bending region mediating access of substrate to the active site 
(see Figure 5.15).  Region 98-125 was suggested to form part of the lid structure and 
showed a higher temperature factor (thus more flexible) than the 400-409 region that was 
suggested to be fairly rigid.  This also points to the unlikelihood of large structural 
movements that would be necessary for E403 and R522 to form a salt bridge.  Alternatively, 
the interaction between K118 and E403 could result in stabilization of the flexible 400-409 
region in tACE in such a way as to alter the structure of the chloride 2 pocket.  As can be 
seen in Figure 5.14, P407 is on the same flexible loop as E403 and forms Pi-Sigma 
interactions with Y224 which coordinates chloride within the pocket.  Thus movement of 
this loop would subtly affect the ability of Y224 to coordinate chloride, a potential 















likely occur in the presence or absence of chloride, and excludes the need for chloride 
disrupting what is a very strong interaction.  Whilst it is not observed in the lisinopril-bound 
structure of tACE (PDB:1O86), a compensatory interaction of K118 with the backbone 
carbonyl of Ala400 is seen, and the interaction is observed in both the unbound (PDB:2UIL) 
and RZPA380-bound (PDB:2OC2) tACE structures.   
 
Figure 5.14  Structural features, key residues and interactions in region of chloride 2 pocket and 
chloride channel. Representative depiction of the region between R522 and D465 in tACE-
Lisinopril (PDB:1o86).  All residues are shown as sticks, with the colouring indicating atom identity 
(carbon = grey, nitrogen=blue, oxygen=red), except for E403 residue is in green. Residues are 
labelled with tACE identity first and corresponding N-domain identity after, which those residues 
that differ in the N-domain being shown in red.  Cartoon depiction of protein backbone is shown, 
which includes α-helices 4, 9, 17 and 23 and 310 helices H9 and H16.  Chloride coordinated by 
R522 is shown as a purple sphere, zinc is shown as a grey sphere bonded to E411 and the 
lisinopril (yellow) in the active site.  Bonding interactions are: hydrogen bonding (dashed green 
lines), Pi-cation and Pi-Sigma bonds (solid orange lines). Images were created using Accelrys 















Relating this to observed data from section 3.3.2.2, both the E403R mutant and the N-
domain  would not have this stabilizing interaction, hence the chloride pocket would be in a 
conformation that more readily coordinates chloride and lower Kd,app values are observed 
for these constructs.  The R381E mutant resulted in weaker Kd,app values in the N-domain, 
however the polar charged Glu in position 381 won’t interact with the shorter non-polar  
 
Figure 5.15  Stabilizing interaction between E403 and K118 in tACE. Representative cartoon 
depiction of tACE-Lisinopril (PDB:1o86) with the high temperature, low sequence conservation 
region encompassing residues 98-125 (red) and low temperature, high sequence conservation 
region encompassing 400-409 (blue) highlighted (adapted from Watermeyer et al., 2006).  The 
E403 (blue) and K118 (red) residues are shown as sticks, with chloride (purple sphere) 
coordinated by R522 (grey stick) also shown to indicate relative position of chloride 2 pocket. A 
salt bridge interaction between E403 and K118 is shown as a solid green line. Images were 















hydrophobic A94, which is 8.9Å distant anyway (Figure 5.16).  Instead, it can be suggested 
that E381 instead interacts with R90 (2.97Å) which is 4 residues away from A94.  This would 
not be possible in tACE as the residue corresponding to S548 is F570, which has a large, 
bulky hydrophobic side-chain projecting directly between the 381 position and R90 (not 
shown).   
Further evidence of the stabilizing role of the E403-K118 interaction is seen in the change in 
thermodynamic parameters for E403R relative to tACE (Figure 5.17).  The ΔΔG values are 
reduced for all substrates relative to tACE, which is due to the observed increase in kcat/Km 
at 0mM NaCl and decrease at 20mM NaCl (Figure 5.13).  That the pattern and magnitude of  
 
Figure 5.16  Proposed stabilizing interaction between E381 and R90 in the N-domain_R381E 
mutant. Representative cartoon depiction in N-domain-Lisinopril structure(PDB:2C6N) with the 
tACE equivalent regions corresponding to residues 98-125 (red) and 400-409 (blue) highlighted in 
the same manner.  Relevant residues are shown as sticks. The R381 residue was mutated (*) 
using PyMOL to a Glu (E) which is shown in light blue.  The residue corresponding to K118 in tACE 
is A94 (red) and the residue proposed to interact with E381is R90 (light pink).  S548 is also 
indicated in green. Chloride (purple sphere) coordinated by R522 (grey stick) is shown to indicate 
relative position of chloride 2 pocket. A salt bridge interaction between E381* and R90 is shown 
















the enthalpies (ΔΔH) for the substrates correlates well with tACE indicates that there should 
be no major structural rearrangement proposed in the Tzakos et al (2003) model, which 
would presumably result in large structural shifts and hence enthalpy due to bond 
rearrangements.  The lack of significant enthalpy changes do not discount minor structural 
differences, which are evidenced by less favourable changes in entropy (-TΔΔS).   
These minor structural effects would help explain the Km and kcat data for E403R relative to 
tACE (table 5.1).  E403R shows increased kcat values at maximal activity for Z-FHL and AngI 
(929.34 s-1 and 9.08 s-1) relative to tACE (282.00 s-1 and 7.38 s-1), which is countered by 
higher Km values in the presence of chloride for E403R (0.530mM and 0.061mM) over tACE 
(0.120mM and 0.036mM). These result in lower maximal kcat/Km values with both substrates 
for E403R, but serve to confirm that some structural variation is present.  The HHL data are 
not included in this assessment as it doesn’t appear to interact strongly within the S2 region 
(Table 5.4) and it is likely that it’s affinity is predominantly affected by S1’/S2’ interactions. 
 
Figure 5.17  Change in thermodynamic parameters for E403R. The ΔΔG, ΔΔH and –TΔΔS values 
for tACE and E403R are shown and represent the difference in ΔG, ΔH, -TΔS between 0mM and 














In summary this section, for the first time, describes a stabilising role for E403 in tACE via its 
interaction with K118 within the hinge-bending region, which is contrary to the ion gated 
channel hypothesis of Tzakos et al (2003).  This serves to reduce the affinity of chloride 
within the chloride 2 pocket of tACE (C-domain) as well as affect the structural architecture 
of the S2 pocket.  Interactions of substrate within this pocket, exemplified by Z-FHL and to a 
greater extent AngI, appear to disrupt the E403-K118 interaction and allow for improved 
chloride binding.  The lack of this stabilizing interaction in the N-domain (R381 does not 
bond with A94) means that the chloride 2 pocket would have a higher affinity for chloride, 
even in the absence of any substrate interaction within the S2 pocket.  The size of the 
substrate, and more importantly how far it extends into the non-prime sub-sites, has been 
shown to be important where substrate interactions in the S2 pocket modulate chloride 
affinity directly in the C-domain of ACE.  These interactions are likely to be propagated via 
structural perturbations around the active site rather than any specific interaction, which is 
consistent with the high degree of variability in ACE substrate identity. 
 
5.3.7  Substrate mediated chloride dependence 
Thus far, key interactions and mechanisms within the chloride 1 pocket and chloride 2 
pocket have been described and related to substrate composition using structural, 
mutagenic and kinetic data.  In condensing these results, a rationale to account for the 
relative contributions of prime and non-prime substrate interactions to chloride 
dependence is suggested below. 
Figure 5.18 shows the C-terminal end of the α23 helix along with the variable loop up to 
part of the 310 H6 helix, but more importantly highlights the number of key residues 
contained within a 14 residue stretch.  As has already been proposed, R522/500 interacts 
with Y523/501 to position it for its role in stabilizing the enzyme-substrate transition-state 
intermediate (5.3.5.3).  Importantly, the affinity of chloride coordinating R522/500 is 
moderated by structural constraint via E403-K118 salt bridge in tACE, which is a point of 
major difference to the N-domain (5.3.6).  Two residues down from R522/R500 is Y520/498 
which has been suggested to stabilize the C-terminal carboxylate along with K511/489,  















Also on this variable loop are H513/491, which has also been proposed to stabilize the 
transition-state (Fernandez et al., 2001), and the S1 sub-site positioned V518/T496, for 
which the V518T mutant was generated and, whilst not found to significantly affect chloride 
binding did produce an increase in activity (3.3.2).  Thus, it is readily apparent that minor 
structural movement of this area can have a large effect on catalysis and chloride binding, 
yet more importantly that this can be heavily influenced by substrate interactions.  In order 
to understand the different contributions of various substrates and their role in modulating 
chloride binding and hence catalysis, a framework was developed that describes different 
binding modes based on the substrates that have been discussed.  Figure 5.19 shows a 
 
Figure 5.18  Relative orientation and proximity of critical residues to the active site of tACE and 
N-domain. Representative overlay of tACE-Lisinopril (PDB:1o86) and N-domain-Lisinopril 
(PDB:2C6N) showing the amino acid region spanning from Y523/501, which is positioned on the 
C-terminal end of helix α23 , via variable loop region to K511/489 which is on 310 helix H6. tACE 
residues are shown in light blue sticks and N-domain residues are shown in green sticks, with 
residue labels shown in the same colour for each domain. The labelled orange squares indicate 
the proximity to various regions in the active site; Y520/501 and K511/489 are in S2’ pocket, 
V518/T496 lines the S1 pocket, S2 shows position of S2 pocket, and TS* indicates that residues 
Y523/501 and H513/491 are proposed to be involved with stabilizing the transition-state 
intermediate. The active site zinc (grey sphere) and numbered chloride ions (purple spheres) 














schematic depiction of four different binding modes for tACE based on composition of 
substrate discussed in this chapter.   
Scheme A represents the binding mode for the tripeptide HHL, which show a highly chloride 
dependent profile exemplified by a high Kd,app.  The P1’ and P2’ residue interactions within 
their respective pockets have an unfavourable influence on chloride affinity, presumably via 
interaction or non-interaction with Y523.  These assertions are based on the S’ tetrapeptides 
described by Liu et al (2001) and discussed in 5.3.4, some of which are represented by 
Scheme B which have a similar binding mode.  HHL shares its P’ composition with AcAFHL, 
both of which induce poor chloride binding, thus we could extend the same rationale to the 
other tetrapeptides in Scheme B.  The suggestion of a non-interaction of the C-terminal 
carboxylate with Y523 is based on AcAFAG and AcAFGG where the P’ groups would be 
unlikely to interact with the sub-pockets probably resulting in increased flexibility of the 
carboxylate.  The P’ interactions of the remaining tetrapeptides would then result in poor 
orientation of the carboxylate as well, although it is still highly likely that K511 coordinates 
the C-terminal carboxylate and that lack of Y523 binding is the only difference.  A further 
implication of the interactions in the S’ pockets by peptides in Scheme A and B is the 
orientation of the peptide backbone around the scissile bond.  As was highlighted in 5.3.3, 
there was some variation in the pattern of interactions either side of the scissile bond for 
HHL, Z-FHL and AngI, likely a result of some rotation around the backbone, and some 
difference in the orientation of the P1 residue between HHL and Z-FHL (Figure 5.3).  Thus 
the P’ interactions would alter the binding pattern and potentially affect the positioning of 
the P1 residues, both of which could potentially account for the generally higher Km values 
observed for Scheme A and B peptides. Given that V518 is situated within the P1 pocket and 
is part of the variable loop the orientation of the P1 group may be of significance. 
Like Scheme B, the Scheme C tetrapeptides have the same P1 and P2 composition, but show 
much lower Kd,app for chloride binding and generally lower Km values than Scheme B peptides 
due entirely to their P’ composition.  This positive interaction with the S’ pockets would 
presumably orientate the C-terminal carboxylate for optimal interaction with Y523, which 
would affect positioning of helix α23 and hence chloride affinity within the chloride 2 
















Figure 5.19  Schematic representation of various substrate binding modes in tACE. Binding of 
substrate to the active site is shown using an adapted Schechter and Berger diagram (Schechter 
and Berger, 1967), with active site sub pockets (S2, S1, S1’ and S2’) shown as connect half-
spheres and peptides shown with labelled black spheres (P2, P1, P1’ and P2’, with P3+ indicating 
residues P3-P10 for AngI).  Position of tACE residues highlighted in Figure 5.18 shown (light blue) 
are shown above relevant sub-sites, with helix α23 containing R522, Y523 and Y520 shown as 
green triangle between them.  Chloride ions (numbered purple spheres) are shown, with chloride 
coordination to R522 indicated by dashed green line and influence of chloride on K511 by a green 
arrow.  Active site zinc (grey sphere) indicates position of catalytic mechanism between S1 and 
S1’, with yellow lightning showing position of scissile bond for each peptide.  Interactions that 
increase chloride affinity (green shaded semi-circles), those that do not increase chloride affinity 
(red shaded semi-circles) and interactions that may affect chloride affinity (orange shaded semi-
circles) are indicated above each peptide residue.  Rotation around the peptide backbone axis 
(circular arrows) and the potential effect of this rotation (red or green arrows that correspond to 
influence from P’ residues which is either red or green) are shown.  The peptides that are 














backbone resulting in a different pattern of interaction and potentially positioning the P1 
residue differently.  The tetrapeptides in Schemes B & C have an Acetyl-alanine in the P2 
position, however it is unlikely to interact significantly with the S2 pocket due to the smaller 
size of the alanine (where the larger P2 Cbz group of Z-FHL only just extends into the large 
S2 pocket) and the similarity in profiles of Scheme B to A which doesn’t have a P2 group 
(HHL).   
The peptides in Scheme D are distinguished by the fact that they interact with the S2 pocket 
(Z-FHL) and S3 and beyond (AngI).  What is key to notice here is that they both share the 
same His-Leu P’ composition as HHL (Scheme A) and AcAFHL (Scheme B), which have been 
shown not to affect chloride binding.  Given that both Z-FHL and AngI have much tighter 
Kd,app for chloride binding  shows that they moderate chloride affinity via interaction with 
the S2 pocket.  As has been discussed in 5.3.6, this would be mediated by disruption of the 
E403-K118 salt bridge either directly or via structural interaction.  How this affects 
orientation of the P1 groups is unclear as the peptide is constrained via interactions from S’ 
and S2 sides.  Docking simulations for Z-FHL and AngI (5.3.3) do indicate that the backbone 
rotation might differ which would go some way to explaining the vast differences in kcat 
between Z-FHL and AngI in presence of chloride (282 s-1 and 7.38 s-1 respectively).  We also 
showed in 5.3.4.3 that the greater length of AngI had a fairly large structural effect on the 
chloride pocket, which may also account for the relatively lower kcat values. 
The role of the chloride 1 pocket in tACE is less clear as we have no way of determining a 
Kd,app for it, where the measured Kd,app values relate to the chloride 2 pocket as confirmed by 
mutagenic data, and there is no stoichiometric data either.  Chloride within this pocket may 
be present in a structural role and there may not actually be any dynamic movement in this 
pocket.  The other possibility is that proposed by Moiseeva et al (2005) where they suggest 
chloride binding in this pocket would have an inhibitory role at high chloride concentrations.  
The latter proposal fits well with our framework, where it would affect C-terminal 
carboxylate coordination within the S2’ pocket and thereby moderate activity via those 
interactions.  This aspect though would require more investigation and was not part of the 
scope of this investigation.  Ultimately though, this framework presents a clear way of 














5.4  Summary 
The tACE mutants that showed marked effects on chloride dependence (R186H, E403R, 
R522Q and R522K) in Chapter 3 were evaluated further using kinetic and thermodynamic 
data determined for the hydrolysis of HHL, Z-FHL and AngI under various chloride 
conditions.  The interpretation was supplemented by molecular docking of HHL and Z-FHL, 
which provided insights into various interactions that these substrates might have with tACE 
and N-domain in relation to similar work done for AngI.  A model of interactions in the 
chloride 1 pocket was developed in the context of various mutants generated here and in 
the literature to explain how chloride binding might modulate K511 coordination, and 
potentially S2’ pocket conformation, in tACE.  A Pi-cation interaction between R522 and the 
transition-state stabilizing residue Y523 was observed in multiple crystal structures, the 
relevance of which was supported by interpretation of the kinetic and thermodynamic 
effects of the R522Q and R522K mutants.  This also suggested that chloride binding was 
most likely affected by subtle structural effects that could be modulated by differing 
substrate interactions.  Interpretation of the E403R mutant kinetics and thermodynamics 
allowed refinement of this concept and demonstrated that E403 in tACE plays a role in 
reducing chloride affinity in the chloride 2 pocket via a salt bridge with K118 through 
structural constraint, an interaction that is not present in the N-domain.  Finally, a 
framework that describes the different ways that substrate interactions can modulate 
chloride affinity, via the S’ or S2 pockets is presented.   The chloride modulation of other 




















Conclusions and Future Directions 
 
This study describes an investigation into the chloride dependence mechanisms of the C-domain of 
ACE using a mutational approach combined with kinetic, thermodynamic and structural analysis.  A 
series of tACE mutants was generated where specific residues in either the chloride 1 or chloride 2 
pockets were replaced with either their corresponding N-domain residues or a residues of differing 
functionality.  These constructs were subsequently characterized using the substrates HHL, Z-FHL 
and AngI, each of which has varying chloride dependence, activity and domain specificities. 
All tACE constructs were initially assessed using chloride titrations with HHL and Z-FHL to determine 
whether the mutations had an effect on chloride affinity.  The chloride 1 pocket R186H mutant 
showed no major change in chloride affinity (Kd,app), yet showed modest increases in overall activity 
for HHL and Z-FHL with no major loss of chloride activation.  Previous work by Rushworth et al 
(2008) showed mutation of R186 to a Gln reduced chloride activation with AngI, suggesting that it 
resulted in different interactions to those that would be expected with a His in that position.  The 
tACE E403R mutant, along with the R381E reversion in the N-domain, showed that a Glu in that 
position in either domain increased chloride dependence (Kd,app) for HHL and Z-FHL, an effect 
reversed by presence of an Arg. This provided the first clear evidence for the importance of this 
residue in chloride dependence in tACE.   The R522K and R522Q mutations produced large 
reductions in both chloride affinity and overall activity with HHL and Z-FHL, confirming the critical 
role of this residue.  With the other constructs not showing any appreciable alteration in chloride 
dependence, the R186H, E403R, R522K and R522Q constructs were chosen for further analysis. 
A novel Isothermal Titration Calorimetry-based approach was developed that could be applied to all 
substrates in order to determine enzyme kinetic constants of tACE constructs.  In the development 
of this methodology, it was established that considerable differences in tACE activity could be 
attributed to buffer composition, with the Tris and Phosphate buffers shown to disrupt chloride 
activation, an important consideration to be taken into account when assessing ACE kinetics in 
future studies.  The methodology provides a highly reproducible and efficient alternative to 
conventional fluorogenic assays, which rely on less than ideal modified substrates, and HPLC-based 
assays, which can be time consuming and inconsistent.  More importantly, it allows for potential 
evaluation of a wide variety of ACE substrates using the same technique, critical when looking at 














This technique also allows the determination of the enthalpy (ΔH) associated with substrate binding 
and hydrolysis, which, combined with the Gibbs free energy (ΔG) calculated from kcat/Km, permits 
determination of the temperature dependent entropy (-TΔS).  These values were determined for N-
domain and all tACE constructs in the presence and absence of chloride.  It was established that 
substrate binding and hydrolysis for both domains was entropically driven, presumably via substrate 
desolvation and structural movement of the enzyme which correlates well with the hinge bending 
hypothesis of Watermeyer et al., (2006).  The enthalpy for hydrolysis was also shown to be 
endothermic, further enforcing the structural movement hypothesis.  Critically, chloride binding did 
not produce any appreciable changes in enthalpy for either domain, suggesting that the chloride 
dependence mechanisms were not reliant on major salt bridge breakages. 
Chloride binding in the chloride 1 pocket of tACE was found to affect positioning of K511 and 
potentially alter the conformation of the active site.  Depending on substrate prime dipeptide 
identity, this was suggested to affect chloride 2 pocket ion affinity by coordinating Y520 and 
affecting peptide bond rotation and hence substrate interactions around the scissile bond and 
potentially in the non-prime sub-sites.  Furthermore, my data indicated that the lack of a chloride 
ion in the chloride 1 pocket in the N-domain was not due to the His residue (H162) instead of an 
arginine, but more likely to steric hindrances not present in the C-domain that prevented access of 
the ion.  
The R522Q and R522K mutations in the chloride 2 pocket showed kinetic parameters for AngI 
consistent with previous reports, confirming the critical role of this residue.  However, despite both 
vastly reducing chloride affinities in the chloride 2 pocket, the two mutants exhibited key differences 
in their overall activities seen with different substrates.  Both mutations largely abrogated any 
chloride activation for all substrates assessed, however, whilst R522K overall activity remained low 
for all substrates, R522Q showed increases in the overall activity relative to tACE in the order of 
AngI>Z-FHL>HHL.  This indicated that the number of interactions on the non-prime side of the active 
site was affecting positioning of these residues in the chloride 2 pocket.  These analyses, along with 
structural interpretations, confirmed a key R522-Y523 Pi-cation interaction that is stabilized via 
chloride coordination of R522.  Substrate interactions in the S2 sub-site were shown to affect 
positioning of this complex as well as chloride affinity in the chloride 2 pocket.   
Contrary to the chloride gated channel hypothesis of Tzakos et al (2003), the E403-K118 salt bridge 
in tACE, which is not present in the N-domain, was shown to stabilize the hinge-bending region and 














in Kd,app values reported here and in the literature, which can be destabilized via substrate 
interactions within the S2 pocket.  
This work showed that substrate composition to the C-terminal side of the scissile bond, as well as 
interactions of larger substrates in the S2 sub-site, moderate chloride affinity in the chloride 2 
pocket of the ACE C-domain.  The shorter the substrate, the greater the influence the prime 
dipeptide identity has on chloride dependence, a factor that can be largely overridden by larger 
substrates that interact with the S2 and other non-prime sub-sites.  This provides a rationale for the 
substrate selective nature of chloride dependence in ACE and how this varies between the N and C 
domains. 
Future aspects: 
The minimally glycosylated mutants were designed with a view to crystal structure studies and are 
the focus of ongoing structural studies.  Crystals have been obtained for 3 of these mutants using a 
Pheonix nano-drop robotic system. The structural work will be pursued in an iterative mode so we 
are able to provide empirical structural data to support the kin tic and thermodynamic findings in 
this study.  A structure for the E403R tACE mutant should reveal whether there is any structural shift 
in the S2 sub-site and chloride 2 pocket.  The R522Q and R522K mutants’ crystal structures should 
provide an indication of any rotation around the C-terminal end of helix α23 and the importance of 
the proposed Chloride-R522-Y523 Pi-cation interaction in stabilizing Y523 within the active site.  A 
crystal structure for the R186H would reveal whether the interactions in the chloride 1 pocket differ 
significantly from the N-domain and whether chloride is still being coordinated despite the presence 
of a His in place of an Arg.  The anticipated structural data for these mutants would significantly 
build on the findings presented in this study and go a long way towards a comprehensive 
understanding of the mechanism of variability between the C and N domains of ACE. 
Further understanding of the role of substrate composition and extension into the non-prime 
binding sub-sites would be greatly aided by systematically evaluating each residue position of the 
substrate.  This was attempted by Bersanetti et al (2004) where they used positional scanning 
combinatorial libraries of FRET peptides to determine substrate specificity.  However, the presence 
of large FRET acceptor and donor groups on the termini would no doubt influence substrate 
selectivity, especially at the C-terminus where large differences in activity and chloride dependencies 
for short peptides have been described.  A similar approach using non-labelled peptides  and  the 
ITC-based method described here would allow for a more accurate assessment of substrate 














larger, which would aid in delineating the specificity of interactions in the S1, S2 and more distal 
non-prime binding sites. 
It has been reported in the literature that there is a degree of cooperativity between the N and C-
domains within the context of somatic ACE (Binevski et al., 2003).  This is further evidenced by the 
findings reported here and by Liu et al (2001) where, individually, the N-domain cleaves AngI at a 
higher rate than the C-domain, but in vivo the C-domain is the main site of AngI hydrolysis (Fuchs et 
al., 2008).  This avenue of research could be furthered not only by the findings presented here, but 
also by the ITC-based methodology presented.  The importance of the α23 and α17 helices and the 
hinge-bending region in chloride dependence and activity presented here could be further explored 
using sACE and single domains, and a range of substrates of differing size and chloride dependence 
modes (Figure 5.19).  Using the ITC-based methodology would yield kinetic and thermodynamic data 
with which to interpret structural interactions between the domains.   
This work has provided unique insights into key interactions and mechanisms of chloride 
dependence and substrate selectivity in the C-domain of ACE, and has presented a new approach 

















Cloning and Mutagenesis 
Preparation of E. coli competent cells  
Competent cells were prepared using a slightly modified method described previously 
(Chung & Miller, 1988).  E.coli XL1 Blue cells from glycerol stocks were inoculated into 5ml of 
Luria-Bertani (LB) broth (10g/L tryptone, 5g/L yeast extract, 172mM NaCl) and shaken at 
37°C overnight.  1ml of this starter culture was inoculated into 100ml LB and shaken.  
Absorbance of the culture was monitored until cells reached early log phase (OD600 = 0.5 
[0.3-0.6]) and then the cells were collected by centrifugation at 4000 rpm, for 5-10 min at 
4°C.  Supernatant was removed, cells resuspended in 1/10 (10ml) ice-cold TSB (16g/L 
Peptone, 10g/L Yeast Extract, 86mM NaCl, 29.8mM PEG, 5% DMSO, 10mM MgCl2, 10mM 
MgSO4) and incubated for 20 min on ice.  Glycerol was added to final concentration of 15% 
and 100µl aliquots were flash frozen in liquid nitrogen and stored at -80°C.  To transform, 
approximately 100ng DNA was mixed with 100µl cells and incubated on ice for 30 min. 
900µl TSBG (TSB plus 20mM glucose) was added and mixture incubated for 4h at 37°C, 
shaking at 225 rpm.  Cells were plated out on LB agar plates containing 100µg/ml Ampicillin. 
Plasmid Mini-Preparation 
Protocol adapted from Sambrook & Russel (2001).  Transformed E.coli colonies were 
inoculated into 5ml of LB medium containing 100ug/ml ampicillin and shaken overnight at 
37°C.  1.5ml of the culture was harvested by centrifugation at 10000rpm for 2 min, the 
supernatant removed and the pellet resuspended in 250µl STET buffer (233mM sucrose, 
50mg/ml triton X-100, 50mM ethylenediaminetetraacetic acid (EDTA), 50mM Tris-HCl) 
containing 1mg/ml lysozyme.  The suspension was then boiled for exactly 1 min and then 
centrifuged at 10000rpm for 8 min, with the resultant pellet being removed via sterile 
toothpick.  250µl of room temperature isopropanol was added to the supernatant and then 
recentrifuged at 10000rpm for 8min.  The supernatant was then carefully discarded and the 













1/10 Tris-EDTA buffer (1mM Tris-HCL, 0.1mM EDTA) and incubation at 60°C for 15min.  One 
microlitre of minipreparation DNA was used in subsequent restriction digests. 
Restriction Digestion 
Reaction mixture for restriction endonuclease digestion consisted of:  2µl 10x restriction 
buffer, 0.5-2µl of 1ug/ml plasmid DNA and 5 units of restriction enzyme, made up to a 
volume of 20µl using sterile dH2O.  The mix was then incubated at 37°C for 1-3 hours.  In the 
case of double digestion reactions, some enzyme combinations required sequential 
incubation at different temperatures, whereby 2 hours at each temperature was employed.  
Reactions were stopped via addition of 3ul of STOP loading buffer (8 parts 6x loading buffer 
(0.25% Bromophenol Blue, 0.25% Xylene Cyanol, 30% glycerol) and 1 part 0.5M EDTA, pH 
8.0). 
Agarose Gel Electrophoresis 
Agarose gels were poured in a 6 x 10cm plate and consist d of 0.8-1.2% agarose in 1x Tris-
borate/EDTA (TBE) buffer (0.045M Tris-borate, 0.001M EDTA) containing 0.3ug/ml ethidium 
bromide. Samples containing 20µl of digestion reaction mixture and 3µl of STOP loading 
buffer were loaded into the agarose gel along with 7µl of lambda DNA digested with EcoRI 
and HindIII (40µl 553ug/ml lambda DNA, 16µl 10x restriction buffer, 50 units EcoRI, 50 units 
HindIII, made up to total volume of 160µl with sterile dH2Oand incubated for 4 hours at 
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